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Abstract: In Switzerland, cannabis has been illegal since 1951. Recently, decriminalizing cannabis has
been discussed in the Federal Assembly. Developments in other countries received increased attention
and stimulated further discussions on reforms. Regulatory approaches in other countries vary widely, but
firm scientific evidence on the effects of instruments is still scarce. Some Swiss cities launched initiatives
to conduct pilot trials with cannabis in order to find evidence-based alternatives to the status quo, which
is marked by various inconsistencies. An initial request by the city of Bern to the Federal Office of Public
Health (FOPH) was rejected in 2017 due to lack of legal basis, but contributed to the establishment of
an experimental article for pilot trials with cannabis in the following years. The Ordinance on pilot trials
in accordance with the Narcotics Act (BetmPV) allows cantons, municipalities, universities and other
organizations to conduct pilot trials to gain scientific knowledge about alternative approaches to regulate
the non-medical use of cannabis. The ordinance lists various conditions that must be met before an
application is approved by the FOPH. With a view to future pilot trials, the FOPH has mandated Prof.
Daniel Kübler and his team from the Department of Political Science at the University of Zurich (IPZ) to
develop a research agenda focusing on new legal approaches to cannabis regulation. This agenda aims to
serve as a guideline for the generation of scientific evidence related not only to the cannabis pilot trials,
but also with respect to additional questions related to cannabis regulation, and to reflect on research
coordination and funding.
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Executive summary 
Subject matter and mandate 
In Switzerland, cannabis has been illegal since 1951. Recently, decriminalizing cannabis has been 
discussed in the Federal Assembly. Developments in other countries received increased attention and 
stimulated further discussions on reforms. Regulatory approaches in other countries vary widely, but 
firm scientific evidence on the effects of instruments is still scarce. Some Swiss cities launched initiatives 
to conduct pilot trials with cannabis in order to find evidence-based alternatives to the status quo, which 
is marked by various inconsistencies. An initial request by the city of Bern to the Federal Office of Public 
Health (FOPH) was rejected in 2017 due to lack of legal basis, but contributed to the establishment of 
an experimental article for pilot trials with cannabis in the following years. The Ordinance on pilot trials 
in accordance with the Narcotics Act (BetmPV) allows cantons, municipalities, universities and other 
organizations to conduct pilot trials to gain scientific knowledge about alternative approaches to 
regulate the non-medical use of cannabis. The ordinance lists various conditions that must be met before 
an application is approved by the FOPH. With a view to future pilot trials, the FOPH has mandated 
Prof. Daniel Kübler and his team from the Department of Political Science at the University of Zurich 
(IPZ) to develop a research agenda focusing on new legal approaches to cannabis regulation. This 
agenda aims to serve as a guideline for the generation of scientific evidence related not only to the 
cannabis pilot trials, but also with respect to additional questions related to cannabis regulation, and to 
reflect on research coordination and funding.  
 
Methodology 
Four primary sources of information were used to elaborate this report. First, current English-language 
research and literature on the consequences of legalizing cannabis for recreational use was considered. 
A systematic literature search in the “Web of Science” for meta-analysis and systematic reviews yielded 
36 publications, all of which were reviewed. In addition, other recently published sources with reference 
to cannabis regulation in other countries or cannabis and drug policy in Switzerland were included. 
Secondly, a relatively broad-based advisory board was established. The members of the advisory board 
were in frequent exchange with the authors and provided feedback on earlier versions of this report. 
Third, a collaboration with the Canadian Center of Substance Use and Addiction (CCSA) was 
established. This collaboration resulted in an international workshop entitled "Cannabis research in 
times of legalization: What's on the agenda", held in February 2021. Fourth, we had conversations and 
exchanges with various experts in Switzerland and presented drafts of the present report to the Federal 
commission for questions on addiction and prevention of noncommunicable diseases (EKSN) and to 
interested members of the Swiss School of Public Health (SSPH+) network. 
 
Overarching question and research fields 
A wide spectrum of cannabis regulation models is theoretically conceivable, ranging from strict 
prohibition to a free commercial market. It is assumed that the social and health costs are particularly 
high at the poles of the spectrum, and an alternative in between should be sought. To work toward 
regulation options in this middle-ground, we are guided by the following overarching question: Under 
which regulatory conditions can the social and health costs of cannabis consumption be effectively minimized? 
Validated evidence from other jurisdictions is sparse, and difficulties of comparison include the context-
specific nature of the evidence as well as the lack of data on the status quo. Additional knowledge on 
how the social and health costs of cannabis consumption can be effectively minimized is therefore 
needed. It is especially relevant for Switzerland, where the political debate is strongly focused on public 
health aspects. Drawing on the current literature, we derived three partially overlapping key fields of 
research that are central to effective public health-oriented cannabis regulation, which are summarized 
in the following overarching logic model of cannabis regulation (see following page). 
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The first central field of research can be termed minimizing health and social harms of use. In this field, 
it is especially the fear of negative health consequences of cannabis legalization that has inspired various 
scientific publications. Current research comes to varied conclusions and there seems to be a need for 
further investigation. Existing evidence is mainly focused on prevention efforts and less on harm 
reduction. Important open research questions in this field include the following: 
 




Physical and mental health  
• How do the different regulatory models affect the physical and mental health of 
consumers? 
• How can the overall costs of and the demand for cannabis use be decreased? 
• How can individuals with at-risk and addictive consumption be detected through 
regulated access to cannabis? 
• What regulatory choices can be expected to have positive health effects for large parts of 
consumers? 
Consumption behavior:  
• What are the effects of different regulatory options on consumption behavior (intensity, 
prevalence, and incidence)? 
• How can regulatory measures (e.g. opening hours, locations) be designed in order to a) 
strengthen prevention efforts and b) facilitate low-risk consumption while minimizing 
harmful consumption? 
• What are the effects of different retail/sales models? 
Life quality & harm reduction: 
• How can regulatory measures support users’ strategies of consuming cannabis in non-
problematic ways and of integrating this use in their everyday life? 
• What structural measures encourage informed behavioral choice and enhance the 
consumption competences of users? What provisions regarding “safer use guidelines” 
are appropriate? 
• To what extent are harm reduction measures effectively implemented within the 
different regulatory frameworks?  
• How can a regulated cannabis market enhance health literacy of cannabis consumers 
and prevent problematic use (information through labelling, sales counselling, and 
public campaigns)? 
• How can the quality of life and social integration of addicted individuals be enhanced 





• What regulatory measures strengthen prevention efforts without pushing consumers 
into the illicit market?  
• What regulatory measures promote screening of and early intervention with vulnerable 
consumers (e.g. administrative measures for youth consumers)? 
• How can sex and gender related factors be integrated into regulatory frameworks? 
Protection 
of minors 
• What regulatory measures are important to effectively protect minors (including 
structural prevention measures) and therefore impede early initiation of use? 
• How should prevention campaigns be designed to reduce (especially high-risk) 
consumption among young people and possibly facilitate lower-risk consumption for 
young adults (e.g. graduated potency levels for different age groups)? 
• What are the effects of legalization on young people’s attitude towards cannabis, their 
perception of risks associated with cannabis use, and their probability to initiate use 
(early)? Does legal access foster normalization of cannabis use?  
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• What legal standards and quality controls regarding contaminants should be 
introduced (e.g. pesticides, contaminants)? 
• How can the supply chain be monitored to minimize health risks and social harms? 
• Can access to different cannabis products be regulated gradually according to the 




• Should the simultaneous sale and purchase of cannabis and alcohol be prohibited? 
• How can simultaneous use of cannabis and tobacco be reduced, and transition from 
cannabis to tobacco be prevented? 
• How should regulatory measures be designed in order to enable monitoring the 
production of cannabis and its quality, and ensuring its traceability? 
• How does regulated access to cannabis affect the co-use of other substances? 
 
The second field of research is improving public safety and order. Researchers in this area focus on the 
extent to which cannabis legalization affects law enforcement resources or to which regulatory options 
have an impact on drug-related crime and violence. A frequently studied topic are the consequences for 
road and occupational safety. As in the previous field, research results are inconclusive. Large-scale and 
long-term studies are needed, and sufficient information on the status quo is also necessary to assess 
the effect of regulations on the illegal market as a key issue. Central open research questions are: 
 




• What is the influence of different regulatory options on the illegal market? 
• To what extent is a legal market able to eliminate the illegal market? What conditions 
allow best to reach that goal? 
• What are the effects of decriminalization or legalization, respectively, on criminal 




• What measures should be taken to ensure road and workplace safety (definition of THC 
limits, fines, information, campaigns, controls etc.)? 
• What measures can be taken to prevent cannabis-related nuisances in public spaces (e.g. 
number and place of outlets, opening hours)?  
• How can adjustments to retail regulation lead to a reduction of cannabis-impaired 
driving and occupational safety risks? 
• What are the effects of different regulatory models on drug-related tourism? What are 







• What are effective approaches to prevent and detect cannabis-impaired driving (e.g. 
sanctions, enforcement, testing, and prevention)?  
• How do different regulatory frameworks affect the resources of the law enforcement 
system? 
• What approaches to policy coordination are the most promising (e.g., where various 
agencies are implicated in the policy delivery system such as police, justice, health, work 
inspectorate, etc.) 
 
The third field of research relates to the governance over a safe and responsible supply chain. The entire 
supply and value chain must be considered in order to effectively promote public health and safety. In 
this field, research is being done on production standards and regulations of self-cultivation, but even 
here the expected effects are by no means conclusive. The produced material needs to be processed and 
distributed in a safe and responsible manner. There are various regulations concerning the labeling of 
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products, packaging, and advertising. Furthermore, concerns regarding the structure for effective 
governance arise. Central unanswered questions in this field are: 
 




• What are the advantages of different licensing approaches regarding cultivation, 
processing, and selling cannabis? 
• How can future cannabis legislation and research be protected from corporate 
influence? 
Economic and equity aspects 
• What is the economic potential of an entirely or partially legalized cannabis market for 
Swiss producers and retailers compared to the status quo? 
• What can regulators learn from the experience of alcohol and tobacco to minimize 
industry manipulation of legal cannabis trade?  
• What regulatory options are effective in mitigating the risk of commercialization? 
• What are the advantages and disadvantages of completely banning a commercial 
market?  
• What consequences do different regulation approaches have on equity and social 
justice outcomes? 
• How can social equity be promoted from the very beginning? What kind of programs 
should be developed to support the inclusion of less advantaged and disproportionally 
affected groups in the industry? 
• What are the overall costs for society caused by the different regulatory choices 
(prohibition, decriminalization, legalization)? 
Policy implementation 
• What regulatory competences need to be situated on what state level (national, 
cantonal, municipal)? What are the risks and opportunities of a multi-level 
governance approach?  
• How can coordination between cantons be improved in order to facilitate 
harmonization of implementation? 
• How can regulations of medical and non-medical cannabis use be separated while still 
supporting and not hindering each other? 
• How should partnerships between the state and private actors in policy delivery 
(professional groups, producers, etc.) be established? 
Production • How should the regulation of cannabis production be designed to guarantee product 
safety and quality and ensure the security of production systems? 
• What are the effects of the legalization of home-growing and personal cultivation of 
cannabis? How is government oversight under such a model feasible?  




• What provisions should be taken for the processing and distribution of cannabis? 
• What kind of limitations should be implemented regarding promotion? 
• How should packaging and labelling be regulated in order to match local patterns of 
use and promote public health goals, thereby allowing a more efficient promotion of 
public health goals? 
Retail  • How should a retail system be regulated to accommodate public health and safety 
concerns?  
• Which sale setting is most likely to make users abandon their usual (illegal) sources of 
supply to promote the positive effects of a new regulation? 
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• What regulatory restrictions on sale and purchase are effective from a public health 
viewpoint (access and availability restrictions, rationing, purchases only up to a 
certain amount, etc.)? 
• What are the opportunities and risks of different retail/sales models (e.g. shops vs. 
online sales)? Are state-run cannabis outlets preferable to commercial outlets in terms 
of public health? 
Consumption • What is the evidence of the public health effectiveness of bans on cannabis use in 
public spaces? 
• What are advantages and disadvantages of different restrictions on the location of use 
from the perspective of public health and safety? 
• How should locations of allowed consumption be regulated and monitored? 
Pricing / 
Taxing 
• How do pricing and taxing influence consumption patterns (changes in patterns of 
use, local priorities, etc.)? 
• How can a balanced pricing and taxing structure be established that simultaneously 
ensures competitiveness with the illegal market and a sufficiently high price to restrict 
youth access and limit consumption? 
• How can revenues be allocated in order to promote social equity, protect public health 
and strengthen research? 
 
Prioritization in the Swiss context 
The cannabis debate in Switzerland mainly focuses on the regulatory approaches suitable to minimize 
risks and maximize benefits to public health. Within the political debate there are two viewpoints: the 
first emphasizes that cannabis use should be avoided altogether and therefore strictly prohibited, 
whereas the other welcomes the examination of alternative options, since cannabis use is a seen as a 
social reality. The so-called ‘experimental article’ for pilot trials was ultimately approved by the majority 
of parliament, aiming at the investigation of the central issues of cannabis regulation in an unbiased and 
open-ended manner. Four overarching priorities of future cannabis regulation can be derived from the 
debate in Switzerland as well as from international research evidence. These four priorities also form 
the impact dimensions in the logic model.  
 
The first priority, promotion of individual and public health, follows the aims set out in the Federal Act 
on Narcotics and Pychotropic Substances (NarcA) and the corresponding ordinance (BetmPV). Priority 
research questions in this field are the prevention of addictive disorders and high-risk consumption, the 
provision of necessary help and treatment for individuals at risk, the mitigation of damages to health 
and social harm, as well as the reduction of negative impacts on society. Firm evidence on this impact 
dimension is relatively scarce, as legalization in other countries is recent, transfer to the Swiss context is 
difficult, and measuring effects on individual and public health remains challenging. 
The second priority is the promotion of public order and the reduction of criminality. While it is not the 
primary motivation for rethinking current cannabis policy in Switzerland, displacing the illicit market 
is a recurring goal. In this context, special attention must be paid to the three priority areas of reducing 
criminal activities, improving public security and order, as well as policing, police organization and law 
enforcement. It seems to be of particular importance here that studies have a long-term focus and 
explore not only the period after an intervention, but also the status quo in order to make meaningful 
comparisons. 
 
The third priority is the protection of minors, since international studies do not provide clear evidence 
on the consequences of youth consumption, and cannabis use among Swiss adolescents is particularly 
high. Furthermore, the topic is virulent in political debates. The current Swiss approach to ensure 
effective protection of minors is based on the following three pillars: legal regulation to protect minors 
(“gesetzlicher Jugendschutz”), promotion of youth and prevention (“Jugendförderung”) and youth 
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support (“Jugendhilfe”). Future research on the consequences of different cannabis regulatory 
approaches for these three areas are important. 
 
The fourth and last priority is the establishment of an effective and equitable governance. Legalizing 
access to cannabis creates a new tax base and an opportunity for a new industry, and experience from 
other countries shows that profit-oriented actors quickly become influential and want to influence the 
regulatory framework in their favor. For this reason, it seems appropriate to explore middle ground 
alternatives to a commercial approach, despite Switzerland's liberal tradition. In addition, questions of 
social justice and equality as well as on monitoring the supply chain are of particular priority. 
 
Cannabis pilot trials 
The legal framework for future cannabis pilot trials is set out in the Ordinance on Pilot Trials under the 
Narcotics Act (BetmPV) of 2021. Pilot trials must provide evidence on the following topics: physical and 
mental health of consumers and their performance; consumption behavior; socio-economic aspects; the 
drug market in a specific area; protection of minors; public order and safety (Art. 2 Abs. 2 BetmPV). In 
addition, they must be limited in space and time and there are specifications regarding the substance to 
be dispensed as well as regarding participants. The FOPH is responsible for granting authorization and 
exercises a monitoring and control function. Several research teams in larger Swiss cities are currently 
giving extensive thought to research designs for future pilot trials. There are considerations about 
research coordination in the context of developing a common questionnaire for the participants. 
Research teams intend to work with different types of dispensaries (cannabis social clubs, pharmacies, 
kiosks, vaping stores) and partly to contrast them. Variation exists regarding how active the role of 
dispensaries should be during pilot trials. The considerations of the research teams are so far 
predominantly related to health aspects and focus on consumption. However, socioeconomic aspects 
and possible effects on public safety in the vicinity of dispensaries are also being addressed by some 
teams. Additionally, there are aspirations to investigate pricing, effects of different products and co-
consumption of other substances. 
 
Based on the considerations in connection with the logic model and the current reflections of the 
research teams, we developed possible research topics and questions for future pilot trials. Sales 
through online channels should be considered, to the extent legally possible, and their effects studied, 
as recent experience from other countries shows that this sales channel is on the rise. In order to study 
the drug market in a given area or the impact on public order and safety, similar cities could be 
compared and statistical methods could help estimate causal effects. Questions about co-use of other 
substances should be considered in interviews or surveys of participants. One approach to gain 
immediate evidence on the protection of minors would be to select study participants who live with 
minors and also interview them directly. Further questions for investigation include to what extent 
different product formats and variations have an impact on the health of the study participants, which 
product features particularly appeal to the participants, and which regulatory measures can promote 
lower risk consumption. 
 
Supplementary research and additional research needs 
Some important questions can hardly be investigated in pilot trials because of the legal requirements 
and are therefore better suited for supplementary research. Currently, the FOPH has awarded four 
mandates for this purpose and is financially supporting a fifth project together with other partners. A 
study by Sotomo is investigating the general acceptance of regulatory measures and the attitude of the 
voting population towards cannabis. On behalf of various institutions, the University of Geneva in 
collaboration with Rütter Soceco is investigating the economic effects of cannabis. The focus here is on 
questions regarding the economic consequences of various regulatory models, potential tax revenues 
and the economic potential of a legal cannabis market for Swiss producers and retailers. The recently 
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published study by IRM Basel aimed to analyze the literature on THC limits in road traffic and to 
develop possible scenarios for adapting road regulation. The ZHAW addressed the issues of cultivation, 
production, and product standards to best protect consumers. The mandate to Sucht Schweiz is about a 
comparative analysis of evaluations of different regulatory policies in other countries, as many policies 
are still insufficiently evaluated to date. 
 
Additional research in the area of processing and distribution is required on the effects of various 
product and packaging properties on consumer choice. In this context, research outside the framework 
of the pilot trials can deviate from the legally required specifications according to the BetmPV. Thus, 
additional knowledge might be gained. Relating to the theme of revenues and taxes, questions arise 
about the distribution of possible revenues, and about which pricing structure makes the most sense for 
regulation geared to promote public health. In the thematic block of public order and safety, we see a 
need to gain additional insights on the functioning of the illicit market, which it is hardly possible to 
comprehensively cover through the pilot trials. Moreover, additional research is needed on possible 
regulations of different types of products. In the context of youth protection, we see quasi-experimental 
designs on different product forms, prevention messages, and communication channels and their 
attractiveness to youth as a promising methodological approach. In addition, community or family-
based prevention campaigns, which have been found to be effective, should be investigated more 
closely to determine how they can be structurally strengthened. It is also important to investigate how 
appropriate state control, control bodies and control measures should be designed. It is not only a 
question of determining who should be the licensor, but also of whether a ban on simultaneous activity 
in the areas of production, supply and retail is conclusive. In addition, cross-thematic research on the 
status quo is necessary in order to be able to assess the effects of various regulations adopted in the 
future. Furthermore, research is needed in the area of policy implementation, as there is often a 
discrepancy between formal policies and their implementation. Comparative research is also needed on 
the advantages and disadvantages of the various regulatory options in the middle ground between 
decriminalization and legalization and on the extent to which structural measures can encourage 
informed behavioral choices and guide users towards less problematic ways of consumption. 
 
Research coordination and funding 
We distinguish three ideal-typical models of research funding and coordination, differing particularly 
in how strongly the content of the research is steered. The political funding scheme directly serves the 
interests of government and aims to answer practical questions and to develop implementable solutions. 
The science-based funding scheme starts from the research questions central to the disciplines, is often 
detached from policy-related debates and runs the risk of incoherent research efforts. The strategic 
funding scheme, as the third ideal type, pursues all promising research avenues in the relevant domains, 
addressing not only questions identified by academia, but also questions related to the policy-related 
perspective.  
 
Although the legal basis excludes a political funding scheme for the cannabis pilot trials, a look at 
experiences with coordination and funding regarding the medical prescription of heroin helps to 
identify success factors. In this case, the cantons, municipalities and private organizations were 
responsible for implementing the trials, and the federal government provided the financial resources 
for the scientific evaluation. A group of researchers was mandated to define and implement an overall 
research plan. Trials were not approved by the FOPH until a commitment was made to collect data 
using a common standardized questionnaire administered to study participants. 
 
For the cannabis pilot trials, the scenario of decentralized research funding and self-coordination is 
currently emerging as a more realistic viable path. The federal government evaluates and approves 
research projects and collects the results, but does not play an active role in research production or 
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funding. There are several possible donors in Switzerland for the financing of such a science-based 
funding scheme. The SNSF (Swiss National Science Foundation) is certainly the most important 
independent agency for research funding. Besides the possibility to submit individual applications for 
single projects, there are National Centres of Competence in Research (NCCRs) for established 
researchers with long-term research programs, Sinergia for interdisciplinary research of several 
research teams, and various instruments to enable international research collaborations. Several 
independent foundations also provide financial support for scientific projects. In addition, independent 
funds exist in the tobacco and alcohol sector that also support research in the field of substance use and 
addiction. The potential of conflicts of interest is a known problem in this area. Independence from 
possible industrial interests and preventing conflicts of interest is thus central for future cannabis 
research funding and can be strengthened by following some central principles. It is also conceivable 
that researcher-driven research coordination be oriented towards Open Science principles, which would 
guarantee transparency of the research process and public availability of data, among other benefits. 
 
Under the given conditions, we see a realistic chance for stronger coordination in the determination of 
a standard cannabis unit size, the development of a common core questionnaire for the participants and 
the creation of a common platform for data pooling and sharing, in which the raw data and results are 
made accessible. Coordination is strongly dependent on a well-connected research community and 
currently we do not see a multi-site or multi-center study as a realistic option, but stronger support from 
the FOPH including funding for research coordination could be helpful. The obvious instrument for a 
more strategically oriented funding scheme would be the SNSF’s National Research Programs (NRPs). 
NRPs are strategic funding schemes precisely in that they explicitly promote research in a specific problem 
area the government considers relevant. If expedient, the focus of such a NRP might be expanded to 
issues surrounding the use of other substances and addiction. 
 
Recommendations 
Development of a cross-project research methodology 
1. In international research, a standardized core questionnaire is sometimes used, to which modules can 
optionally be added to address the specific conditions in the relevant country or region. By analogy, we 
recommend the development of a core questionnaire for Switzerland with supplementary modules that 
take greater account of the situation of the drug market in a particular area, for instance. 
 
2. While some pilot trials appear to be using similar questions and items, a common set of questions 
with core items does not exist so far. We recommend that the FOPH contributes to a cross-project 
research methodology by supporting researchers’ endeavors towards a common questionnaire or some 
agreed-upon core questions. 
 
3. We recommend the determination of a standard cannabis unit size, a common core questionnaire for 
study participants and a common platform for data pooling and sharing as steps towards a cross-project 
research methodology.  
 
Coordination of research projects (pilot trials) 
4. Public and media scrutiny for the cannabis pilot trials and research can be expected to be intense. We 
therefore recommend that researchers coordinate in developing a sound public and political 
communication strategy. 
 
5. Besides the commonly-discussed alternatives, prohibition and the standard commercial model, 
theoretically there are many middle-ground options of cannabis regulation, which are rarely 
implemented in practice. We therefore recommend that more research be conducted in Switzerland on 
Executive summary A Research Agenda for the Regulation of Non-Medical Cannabis Use in Switzerland 
Page 14 
these middle ground options, which are still little researched internationally. These seem to have the 
potential to significantly reduce health and social costs. 
 
6. Within the framework of the pilot trials, the FOPH performs various functions and is first and 
foremost an authorization and control body. Conflicts of interest are inevitable, and we therefore 
recommend a clarification of the FOPH's role in order to better support pilot trials in the future. 
 
Research funding 
7. A science-based funding scheme or a strategic funding scheme via SNSF grants might be viable 
options for research funding, while the legal basis precludes direct funding by the federal government. 
In order to increase the chances of funding applications, we recommend greater cooperation with 
international experts to identify relevant research gaps and ensure international relevance. 
 
8. The Alcohol and Tobacco Prevention Funds, with their organizational and financial setups, represent 
interesting funding vehicles to which stakeholders interested in evidence-based research for the 
purpose of policy making should look. 
 
9. To ensure the independence of research and its credibility and to prevent undue industry influence 
on research activities, researchers should adhere to some guiding principles for avoiding conflicts of 
interest in cannabis-related research funding (e.g. no industry influence on funding decisions, freedom 
to publish research results). 
 
10. Independent foundations could play a critical role in funding pilot studies, provided the 
foundation's purpose is met. Coordination in this area (e.g. a central consulting office for the funding of 
cannabis research) could support the various research teams in seeking financial contributions from 
foundations and other actors. 
  




Gegenstand und Auftrag 
In der Schweiz ist Cannabis seit 1951 verboten. In letzter Zeit wurde die Entkriminalisierung in der 
Bundesversammlung diskutiert. Entwicklungen in anderen Ländern fanden erhöhte Aufmerksamkeit 
und regten weitere Diskussionen über Reformen an. In diesen Ländern kommen sehr unterschiedliche 
Regulierungsansätze zur Anwendung, wobei noch wenig gesicherte wissenschaftliche Erkenntnisse 
hinsichtlich der Auswirkungen der verschiedenen Ansätze vorliegen. Einige Schweizer Städte haben 
erste Initiativen zur Durchführung von wissenschaftlichen Pilotversuchen mit Cannabis lanciert, um 
evidenzbasierte Alternativen zum aktuellen Status quo zu finden, der von diversen Widersprüchen 
geprägt ist. Das erste Gesuch, das die Stadt Bern beim Bundesamt für Gesundheit (BAG) eingereicht 
hat, wurde im Jahr 2017 wegen fehlender Rechtsgrundlage abgelehnt. Jedoch trug es dazu bei, dass in 
den folgenden Jahren das Betäubungsmittelgesetz durch einen Experimentierartikel für Pilotversuche 
mit Cannabis ergänzt wurde. Die Verordnung über Pilotversuche nach dem Betäubungsmittelgesetz 
(BetmPV) erlaubt es Kantonen, Gemeinden, Universitäten und anderen Organisationen, Pilotversuche 
zur Zwecke der Gewinnung wissenschaftlicher Erkenntnisse über alternative Ansätze zur Regulierung 
der nicht-medizinischen Anwendung von Cannabis durchzuführen. In der Verordnung sind 
verschiedene Bedingungen aufgeführt, die für die Bewilligung des Gesuchs durch das BAG erfüllt sein 
müssen. Im Hinblick auf zukünftige Pilotversuche hat das BAG Prof. Daniel Kübler und sein Team vom 
Institut für Politikwissenschaft an der Universität Zürich (IPZ) mit der Entwicklung einer 
Forschungsagenda beauftragt, die sich auf neue rechtliche Ansätze der Cannabisregulierung fokussiert. 
Diese Agenda soll als Richtlinie für die Schaffung wissenschaftlicher Evidenz nicht nur in Bezug auf die 
Pilotversuche mit Cannabis, sondern auch hinsichtlich weiterer Fragen der Cannabisregulierung dienen 
und zur Reflexion über die Forschungskoordination und -finanzierung beitragen. 
 
Methodisches Vorgehen 
Bei der Ausarbeitung dieses Berichts wurden hauptsächlich vier Informationsquellen verwendet. 
Erstens wurden die aktuelle internationale Forschungsliteratur im Hinblick auf mögliche 
Konsequenzen der Legalisierung von Cannabis zu Genusszwecken herangezogen. Eine 
Literaturrecherche nach Meta-Analysen und systematischen Reviews im «Web of Science» brachte 
36 Publikationen hervor, die anschliessend allesamt gesichtet wurden. Zudem wurden weitere kürzlich 
erschienene Publikationen mit Bezug zur Cannabisregulierung in anderen Ländern oder zur Cannabis- 
und Drogenpolitik in der Schweiz einbezogen. Zweitens wurde eine relativ breit aufgestellte 
Begleitgruppe etabliert. Die Mitglieder der Begleitgruppe tauschten sich regelmässig mit den 
Autorinnen und Autoren aus und gaben Feedback zu früheren Versionen dieses Berichts. Drittens 
wurde eine Zusammenarbeit mit dem Canadian Center of Substance Use and Addiction (CCSA) 
etabliert. Im Rahmen dieser Zusammenarbeit wurde im Februar 2021 ein Workshop mit dem Titel 
«Cannabis research in times of legalization: What's on the agenda» durchgeführt. Viertens haben wir 
uns mit verschiedenen Expertinnen und Experten in der Schweiz ausgetauscht und Entwürfe des 
vorliegenden Berichts der Eidgenössischen Kommission für Fragen zu Sucht und Prävention 
nichtübertragbarer Krankheiten (EKSN) sowie interessierten Mitgliedern des SSPH+-Netzwerks (Swiss 
School of Public Health) vorgelegt, um zusätzliche Rückmeldungen einzuholen. 
 
Übergeordnete Fragestellung und Forschungsfelder 
Theoretisch ist ein breites Spektrum an Modellen zur Cannabisregulierung vorstellbar, das von einer 
strikten Prohibition bis hin zu einem unregulierten freien Markt reicht. Es wird angenommen, dass die 
sozialen und gesundheitlichen Kosten an den Polen des Spektrums besonders hoch sind und daher eine 
dazwischenliegende Regulierungsoption angestrebt werden sollte. Bei der Erarbeitung gemässigter  
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Regulierungsoptionen lassen wir uns von der folgenden übergeordneten Frage leiten: Unter welchen 
regulatorischen Bedingungen können die sozialen und gesundheitlichen Kosten des Cannabiskonsums 
wirksam minimiert werden? Es liegt wenig validierte Evidenz aus anderen Ländern oder Regionen vor. 
Zudem wird der Vergleich durch den starken Kontexbezug der wissenschaftlichen Evidenz sowie das 
Fehlen von Daten zum Status quo erschwert. Es sind weitere Erkenntnisse darüber erforderlich, wie die 
sozialen und gesundheitlichen Kosten des Cannabiskonsums wirksam minimiert werden können. Für 
die Schweiz, wo in der politischen Debatte ein starker Fokus auf Aspekte der öffentlichen Gesundheit 
gerichtet ist, ist dies besonders wichtig. Bezugnehmend auf die aktuelle Literatur haben wir drei sich 
teilweise überschneidende zentrale Forschungsbereiche abgeleitet, die von entscheidender Bedeutung 
für eine wirksame, auf die öffentliche Gesundheit ausgerichtete Cannabisregulierung sind und im 
vorstehenden Wirkungsmodell der Cannabisregulierung zusammengefasst wurden. 
Das erste Forschungsfeld fokussiert auf die Verminderung gesundheitlicher und sozialer Schäden durch 
den Konsum. In diesem Feld ist es insbesondere die Angst vor negativen gesundheitlichen 
Auswirkungen der Legalisierung von Cannabis, die den Anlass zu verschiedenen wissenschaftlichen 
Arbeiten gab. Die aktuelle Forschung kommt zu unterschiedlichen Ergebnissen und es scheint Bedarf 
an weiteren Untersuchungen zu bestehen. Die vorliegende Evidenz fokussiert sich vornehmlich auf 
Präventionsbemühungen und weniger auf die Schadensminderung. Zu den wichtigen offenen 
Forschungsfragen in diesem Bereich gehören:  




Physische und psychische Gesundheit 
• Wie wirken sich die unterschiedlichen Regulierungsmodelle auf die 
physische und psychische Gesundheit der Konsumentinnen und 
Konsumenten aus? 
• Wie können die gesellschaftlichen Kosten des Cannabiskonsums und die 
Nachfrage nach Cannabis reduziert werden? 
• Wie können Personen mit risikoreichem Konsum oder Abhängigkeit durch 
einen regulierten Zugang zu Cannabis erreicht werden? 
• Bei welchen regulatorischen Entscheidungen sind positive 
Gesundheitseffekte für viele Konsumentinnen und Konsumenten zu 
erwarten? 
Konsumverhalten:  
• Welche Auswirkungen haben unterschiedliche Regulierungsoptionen auf 
das Konsumverhalten (Intensität, Prävalenz und Inzidenz)? 
• Wie können regulatorische Massnahmen (beispielsweise Öffnungszeiten, 
Örtlichkeiten) gestaltet werden, um a) die Präventionsbemühungen zu 
stärken und b) einen risikoarmen Konsum zu ermöglichen, während der 
schädliche Konsum minimiert wird? 
• Welche Auswirkungen haben verschiedene Handels-/Vertriebsmodelle? 
Lebensqualität und Schadensminderung: 
• Wie können regulatorische Massnahmen die Strategien der 
Konsumentinnen und Konsumenten unterstützen, Cannabis auf 
unproblematische Weise zu konsumieren und diesen Konsum in ihren 
Alltag zu integrieren? 
• Welche strukturellen Massnahmen fördern informierte 
Konsumentscheidungen und stärken die Konsumkompetenzen der 
Konsumentinnen und Konsumenten? Welche Auflagen betreffend «Safer-
Use-Regeln» sind angemessen? 
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• Inwieweit werden Massnahmen zur Schadensminderung innerhalb der 
verschiedenen Regulierungsmodelle effektiv umgesetzt? 
• Wie kann ein regulierter Cannabismarkt die Gesundheitskompetenz der 
Cannabiskonsumentinnen und -konsumenten verbessern und einen 
problematischen Konsum verhindern (Information durch Kennzeichnung, 
Verkaufsberatung und öffentliche Kampagnen)? 
• Wie kann eine Verbesserung der Lebensqualität und der sozialen Integration 
von süchtigen Personen durch einen gesetzlich geregelten Zugang zu 
Cannabis erreicht werden? 
Wirksame Prävention 
und Intervention 
• Welche regulatorischen Massnahmen stärken die Präventionsbemühungen, 
ohne die Konsumierenden in den Schwarzmarkt zu drängen? 
• Welche regulatorischen Massnahmen fördern das Screening von und die 
frühzeitige Intervention bei besonders gefährdeten Konsumentinnen und 
Konsumenten (beispielsweise administrative Massnahmen für jugendliche 
Konsumierende)? 
• Wie können geschlechts- und genderbezogene Faktoren in den 
regulatorischen Rahmen integriert werden? 
Jugendschutz • Welche regulatorischen Massnahmen sind für die Gewährleistung eines 
wirksamen Jugendschutzes und damit der Verhinderung eines frühen 
Einstieges in den Konsum wichtig (einschliesslich struktureller 
Präventionsmassnahmen)? 
• Wie sollten Präventionskampagnen gestaltet werden, um den (vor allem 
risikoreichen) Konsum unter Jugendlichen zu reduzieren und 
möglicherweise einen risikoarmen Konsum für junge Erwachsene zu 
erleichtern (beispielsweise abgestufte Potenzlevel für verschiedene 
Altersgruppen)? 
• Welche Auswirkungen hat die Legalisierung auf die Einstellung, die 
Jugendliche zu Cannabis haben, ihre Wahrnehmung der mit dem 
Cannabiskonsum verbundenen Risiken und die Wahrscheinlichkeit eines 
(frühen) Einstiegs in den Konsum? Begünstigt der legale Zugang die 
Normalisierung des Cannabiskonsums? 
• Welche regulatorischen Massnahmen können ergriffen werden, damit 
gefährdete minderjährige Konsumentinnen und Konsumenten effektiv 
erkannt und unterstützt werden? 
Verbrauchersicherheit • Welche gesetzlichen Standards und Qualitätskontrollen in Bezug auf 
Verunreinigungen sollten eingeführt werden (beispielsweise Pestizide, 
Schadstoffe)? 
• Wie kann die Lieferkette so überwacht werden, dass gesundheitliche Risiken 
und soziale Schäden minimiert werden? 
• Kann der Zugang zu verschiedenen Cannabisprodukten entsprechend ihrem 




• Sollte es ein Verbot des gleichzeitigen Verkaufs und Kaufs von Cannabis 
und Alkohol geben? 
• Wie kann der gleichzeitige Konsum von Cannabis und Tabak reduziert und 
der Wechsel von Cannabis zu Tabak verhindert werden? 
• Wie sollten regulatorische Massnahmen ausgestaltet sein, um die 
Überwachung der Cannabisproduktion und  -qualität zu ermöglichen und 
die Rückverfolgbarkeit zu gewährleisten? 
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• Wie wirkt sich der regulierte Zugang zu Cannabis auf den Ko-Konsum 
anderer Substanzen aus? 
 
Das zweite Forschungsfeld ist die Verbesserung der öffentlichen Ordnung und Sicherheit. Forscherinnen 
und Forscher, die in diesem Bereich tätig sind, fokussieren sich darauf, inwieweit sich die Legalisierung 
von Cannabis auf die Ressourcen der Strafverfolgungsbehörden auswirkt oder welche 
Regulierungsoptionen eine Auswirkung auf Drogenkriminalität und Gewalt haben. Ein häufig 
untersuchtes Thema sind auch die Folgen für die Sicherheit im Strassenverkehr und am Arbeitsplatz. 
Wie auch im zuvor beschriebenen Feld sind die Forschungsergebnisse nicht schlüssig. Grossangelegte 
Langzeitstudien sowie ausreichende Informationen zum Status quo sind zur Beurteilung der 
Schlüsselfrage der Auswirkung von Regulierungen auf den Schwarzmarkt erforderlich. Die zentralen 
offenen Forschungsfragen sind:  




• Welchen Einfluss haben verschiedene Regulierungsoptionen auf den 
Schwarzmarkt? 
• Inwiefern ist ein legaler Markt in der Lage, den Schwarzmarkt zu eliminieren? 
Welche Bedingungen sind am besten geeignet, um dieses Ziel zu erreichen? 
• Welche Auswirkungen haben eine Entkriminalisierung oder eine Legalisierung 




• Welche Massnahmen sollten ergriffen werden, um die Sicherheit im 
Strassenverkehr und am Arbeitsplatz zu gewährleisten (Definition von THC-
Grenzwerten, Bussen, Information, Kampagnen, Kontrollen etc.)? 
• Welche Massnahmen können ergriffen werden, um cannabisbedingte 
Störfaktoren im öffentlichen Raum zu verhindern (beispielsweise Anzahl und 
Ort der Abgabestellen, Öffnungszeiten)? 
• Wie können Anpassungen der Regulierungen betreffend Einzelhandel zu einer 
Verringerung der Risiken für das Autofahren unter Cannabiseinfluss und die 
Sicherheit am Arbeitsplatz führen? 
• Welche Auswirkungen haben die verschiedenen Regulierungsmodelle auf den 
Drogentourismus? Welche Strategien zeigen die beste Wirkung hinsichtlich der 




• Welche Ansätze zur Verhinderung und Erkennung von Cannabis-
beeinträchtigtem Fahren (beispielsweise Sanktionen, Strafverfolgung, Tests und 
Prävention) sind wirksam?  
• Wie wirken sich unterschiedliche rechtliche Rahmenbedingungen auf 
strafverfolgungsbehördliche Ressourcen aus? 
• Welche Ansätze zur Koordination von Policies sind am erfolgversprechendsten 
(beispielsweise wenn verschiedene Behörden in System der Implementierung 
von Policies mitwirken, wie Polizei, Justiz, Gesundheit, Arbeitsinspektion etc.)? 
 
Das dritte Forschungsfeld bezieht sich auf die wirksame Steuerung von Produktion und Vertrieb von 
Cannabisprodukten. Die gesamte Liefer- und Wertschöpfungskette muss berücksichtigt werden, um 
einen wirksamen Schutz der öffentlichen Gesundheit zu erreichen. In diesem Bereich wird an 
Produktionsstandards und Vorgaben für den Eigenanbau geforscht, jedoch sind auch hier die zu 
erwartenden Auswirkungen keineswegs eindeutig. Das produzierte Material muss auf sichere und 
verantwortungsvolle Art und Weise weiterverarbeitet und verteilt werden. Es gibt unterschiedliche 
Regulierungen betreffend die Kennzeichnung von Produkten, die Verpackung und die Werbung. 
Zentrale unbeantwortete Fragen in diesem Feld sind:  
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Wirksame Steuerung von Produktion und Vertrieb 
KontrollstrukturÜbergreifende Fragen 
• Welche Vorteile haben verschiedene Lizenzierungsansätze hinsichtlich des Anbaus, 
der Verarbeitung und des Verkaufs von Cannabis? 
• Wie kann die zukünftige Cannabisgesetzgebung und -forschung vor Einfluss seitens 
der Industrie geschützt werden? 
Wirtschaftliche Aspekte 
• Wie gross ist das wirtschaftliche Potenzial eines vollständig oder teilweise 
legalisierten Cannabismarktes für Schweizer Produzenten und Händler im Vergleich 
zum Status quo? 
• Welche Schlussfolgerungen können die Regulierungsbehörden aus den Erfahrungen 
mit Alkohol und Tabak ziehen, um die Manipulation des legalen Cannabishandels 
durch die Industrie zu minimieren? 
• Welche regulatorischen Optionen können das Risiko der Kommerzialisierung 
wirksam mindern? 
• Welche Vor- und Nachteile hätte ein vollständiges Verbot eines kommerziellen 
Marktes? 
• Was sind die Folgen verschiedener Regulierungsmodelle hinsichtlich 
Verteilungsgerechtigkeit? 
• Wie kann gesellschaftliche Gleichberechtigung von Beginn an gefördert werden? Wie 
können benachteiligte Gruppen von Produktion und Vertrieb von 
Cannabisprodukten profitieren? 
• Welches sind gesamtgesellschafltiche Kosten verschiedener Regulierungsmodelle? 
Umsetzungsmassnahmen 
• Welche regulatorischen Kompetenzen müssen auf welcher staatlichen Ebene 
(national, kantonal, kommunal) angesiedelt werden? Welche Risiken und Chancen 
gehen mit einem Multi-Level-Governance-Ansatz einher? 
• Wie kann die Koordination zwischen den Kantonen verbessert werden, um die 
Harmonisierung der Umsetzung zu erleichtern? 
• Wie können Regelungen zum medizinischen und nicht-medizinischen 
Cannabiskonsum getrennt werden, sodass sie sich gegenseitig begünstigen und nicht 
behindern? 
• Wie sollten Partnerschaften zwischen dem Staat und privaten Akteuren 
(Berufsgruppen, Produzenten etc.) bei der Umsetzung von Massnahmen 
ausgestaltet werden? 
Produktion • Wie sollte die Regulierung der Cannabisproduktion ausgestaltet sein, um 
Produktsicherheit und -qualität zu gewährleisten und die Sicherheit der 
Produktionssysteme zu gewährleisten? 
• Welche Auswirkungen hat die Legalisierung des Eigenanbauson Cannabis? Wie 
kann im Rahmen eines solchen Modells die staatliche Aufsicht erfolgen? 
• Welche regulatorischen Optionen bestehen in den Bereich der Produktprüfung, der 
Evaluierung und der Aufsicht über den Produktionsvorgang? 
Verarbeitung 
und Vertrieb 
• Welche Vorkehrungen sollten für die Verarbeitung und den Vertrieb von Cannabis 
getroffen werden? 
• Welche Einschränkungen sollten im Hinblick auf die Werbung eingeführt werden? 
• Wie sollten Verpackung und Kennzeichnung reguliert werden, um den lokalen 
Nutzungsmustern zu entsprechen und die Ziele der öffentlichen Gesundheit 
effizienter zu verwirklichen? 
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Handel  • Wie sollte ein Handelssystem reguliert werden, um den Belangen der öffentlichen 
Gesundheit und Sicherheit Rechnung zu tragen? 
• In welcher Verkaufssituation ist die Wahrscheinlichkeit am grössten, dass die 
Konsumentinnen und Konsumenten ihre üblichen (illegalen) Bezugsquellen 
aufgeben, sodass die positiven Effekte einer neuen Regelung gefördert werden? 
• Welche regulatorischen Einschränkungen für Verkauf und Kauf sind im Hinblick 
auf die öffentliche Gesundheit effektiv (Einschränkungen betreffend Zugänglichkeit 
und Verfügbarkeit, Rationierung, Kauf nur bis zu einer bestimmten Menge, etc.)? 
• Welche Chancen und Risiken bringen die unterschiedlichen Einzelhandels-und 
Verkaufsmodelle (beispielsweise Shops vs. Online-Verkauf) mit sich? Sind staatlich 
geführte Cannabis-Abgabestellen im Hinblick auf die öffentliche Gesundheit den 
kommerziellen Abgabestellen vorzuziehen? 
Konsum • Welche Belege für die gesundheitliche Wirksamkeit von Verboten des 
Cannabiskonsums im öffentlichen Raum liegen vor? 
• Welche Vor- und Nachteile haben die verschiedenen Einschränkungen hinsichtlich 
des Konsumorts für die öffentliche Gesundheit und Sicherheit? 




• Wie beeinflussen Preisgestaltung und Besteuerung den Konsum (Veränderungen 
der Konsummuster, lokale Prioritäten etc.)? 
• Wie kann eine ausgewogene Preis- und Besteuerungsstruktur geschaffen werden, die 
gleichzeitig gegenüber dem Schwarzmarkt wettbewerbsfähig ist und einen 
ausreichend hohen Preis sicherstellt, um den Zugang von Jugendlichen zu begrenzen 
und den Konsum einzuschränken? 
 
Priorisierung im Schweizer Kontext 
Die Cannabisdebatte in der Schweiz konzentriert sich vorwiegend auf regulatorische Ansätze, die das 
Potenzial haben, Risiken zu minimieren und den Nutzen für die öffentliche Gesundheit zu maximieren. 
In der politischen Debatte gibt es verschiedene Standpunkte: der erste betont, dass der Cannabiskonsum 
komplett vermieden werden und daher streng verboten sein sollte, während der zweite die Prüfung 
von Alternativen zur Prohibition begrüsst, da der Cannabiskonsum als eine gesellschaftliche Realität 
zu betrachten sei. Der so genannte «Experimentierartikel» für Pilotversuche wurde schliesslich von der 
Mehrheit des Parlaments gutgeheissen, mit dem Ziel, die zentralen Fragen der Cannabisregulierung 
unvoreingenommen und ergebnisoffen zu untersuchen. Aus der Debatte in der Schweiz sowie aus 
internationalen Forschungsergebnissen lassen sich vier übergreifende prioritäre Fragestellungen zur 
zukünftigen Cannabisregulierung ableiten. Diese vier Themenfelder bilden auch die Grundlage des 
erstellten Wirkungsmodells.  
 
Die erste Priorität, die Förderung der individuellen und öffentlichen Gesundheit, folgt den im 
Bundesgesetz über die Betäubungsmittel und die psychotropen Stoffe (BetmG) und der entsprechenden 
Verordnung (BetmPV) festgelegten Zielen. Zentrale Forschungsfragen in diesem Bereich sind die 
Prävention von Suchterkrankungen und risikoreichem Konsum, die Bereitstellung notwendiger Hilfe 
und Behandlungsmöglichkeiten für gefährdete Personen, die Minderung gesundheitlicher und sozialer 
Schäden sowie die Reduktion negativer Auswirkungen auf die Gesellschaft. Belastbare Erkenntnisse zu 
dieser Wirkungsdimension sind relativ rar, da Cannabis in anderen Ländern erst kürzlich legalisiert 
wurde, die Übertragung auf den Schweizer Kontext schwierig ist und die Bestimmung der 
Auswirkungen auf die individuelle und öffentliche Gesundheit anspruchsvoll bleibt. 
 
Die zweite Priorität ist der Schutz der öffentlichen Ordnung und die Reduzierung der Kriminalität. 
Während die Verdrängung des Schwarzmarktes nicht die vordergründige Motivation für das 
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Überdenken der aktuellen Cannabispolitik darstellt, handelt es sich hierbei um ein Ziel, das wiederholt 
thematisiert wird. In diesem Kontext muss besonderes Augenmerk auf die drei Schwerpunktbereiche 
Verminderung krimineller Aktivitäten, Verbesserung der öffentlichen Sicherheit und Ordnung, sowie 
Polizeiarbeit, Polizeiorganisation und Strafverfolgung gelegt werden. Hierbei scheint es von besonderer 
Bedeutung zu sein, dass Studien einen langfristigen Fokus haben und nicht nur die Zeit nach einer 
Intervention, sondern auch den Status quo betrachten, um sinnvolle Vergleiche zu ermöglichen. 
 
Die dritte Priorität ist der Jugendschutz, da internationale Studien keine eindeutigen Erkenntnisse 
hinsichtlich der Auswirkungen verschiedener Regulierungsmodelle auf den Cannabiskonsum von 
Jugendlichen liefern und der Cannabiskonsum unter Schweizer Jugendlichen besonders verbreitet ist. 
Zudem spielt dieses Thema auch eine wesentliche Rolle in politischen Debatten. In der Schweiz basiert 
der aktuelle Ansatz zur Gewährleistung eines wirksamen Jugendschutzes auf den folgenden drei 
Säulen: gesetzlicher Jugendschutz, Jugendförderung sowie Jugendhilfe. Zukünftiger Forschung zu den 
Folgen unterschiedlicher Cannabis-Regulierungsansätze für diese drei Bereiche kommt eine grosse 
Bedeutung zu. 
 
Die vierte und letzte Priorität ist die Steigerung von Wohlstand und sozialer Gerechtigkeit. Die 
Legalisierung des Zugangs zu Cannabis ebnet den Weg für neue Steuereinnahmen sowie für den 
Aufbau einer neuen Industrie, und die Erfahrung aus anderen Ländern zeigt, dass profitorientierte 
Akteure schnell Einfluss gewinnen und den regulatorischen Rahmen zu ihren Gunsten beeinflussen 
wollen. Daher scheint es trotz der liberalen Tradition der Schweiz angebracht, gemässigte Alternativen 
zu einem kommerziellen Ansatz zu erkunden. Zudem kommt Fragen der sozialen Gerechtigkeit und 
Gleichberechtigung sowie der Überwachung der Lieferkette eine besondere Bedeutung zu. 
 
Pilotversuche mit Cannabis 
Die Verordnung über Pilotversuche nach dem Betäubungsmittelgesetz (BetmPV) von 2021 definiert den 
rechtlichen Rahmen für zukünftige Pilotversuche mit Cannabis. Pilotversuche müssen insbesondere 
Erkenntnisse liefern zu den Auswirkungen auf die physische und psychische Gesundheit der 
Konsumentinnen und Konsumenten sowie auf deren Leistungsfähigkeit, das Konsumverhalten, 
sozioökonomische Aspekte, den Drogenmarkt eines bestimmten Gebiets, den Jugendschutz oder die 
öffentliche Ordnung und Sicherheit (Art. 2 Abs. 2 BetmPV). Sie müssen örtlich und zeitlich begrenzt 
sein. Zudem gibt es Vorgaben zur abzugebenden Substanz sowie zu den Teilnehmerinnen und 
Teilnehmern. Das BAG ist zuständig für die Erteilung der Bewilligung und übt eine Überwachungs- 
und Kontrollfunktion aus. Mehrere Forschungsteams in grösseren Schweizer Städten arbeiten derzeit 
intensiv an Forschungsdesigns für zukünftige Pilotversuche. Es gibt Überlegungen zur 
Forschungskoordination im Zusammenhang mit der Entwicklung eines gemeinsamen Fragebogens für 
die Teilnehmerinnen und Teilnehmer. Forschungsteams beabsichtigen, mit verschiedenen 
Abgabestellen (beispielsweise in Cannabis Social Clubs, in Apotheken, Kiosken, Vaping-Stores) zu 
arbeiten und diese teilweise zu vergleichen. Es bestehen unterschiedliche Auffassungen darüber, wie 
aktiv die Rolle der Abgabestellen im Rahmen der Pilotversuche sein sollte. Die bisherigen 
Überlegungen der Forschungsteams befassten sich vorwiegend mit gesundheitlichen Aspekten und 
fokussieren sich auf den Konsum. Einige Teams beschäftigen sich auch mit sozioökonomischen 
Aspekten sowie mit möglichen Auswirkungen auf die öffentliche Sicherheit in der Umgebung von 
Abgabestellen. Zudem gibt es Bestrebungen, die Preisgestaltung, die Auswirkungen verschiedener 
Produkte und den Ko-Konsum anderer Substanzen zu untersuchen. 
 
Ausgehend von den Erwägungen, die im Zusammenhang mit dem Wirkungsmodell stehen, sowie den 
aktuellen Überlegungen der Forschungsteams, haben wir mögliche Forschungsthemen und -fragen für 
zukünftige Pilotversuche entwickelt. Verkäufe über Onlinekanäle sollten, soweit gesetzlich möglich, 
ebenfalls berücksichtigt und ihre Auswirkungen untersucht werden, da aktuelle Erfahrungen aus 
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anderen Ländern zeigen, dass dieser Vertriebskanal auf dem Vormarsch ist. Zur Untersuchung des 
Drogenmarktes eines bestimmten Gebiets oder der Auswirkungen auf die öffentliche Ordnung und 
Sicherheit könnten Vergleiche zwischen ähnlichen Städten angestellt und die kausalen Auswirkungen 
mit Hilfe statistischer Methoden geschätzt werden. Fragen zum Ko-Konsum anderer Substanzen sollten 
in Interviews oder Befragungen der Teilnehmerinnen und Teilnehmer berücksichtigt werden. Ein 
Ansatz zur direkten Erkenntnisgewinnung betreffend Jugendschutz besteht darin, 
Studienteilnehmerinnen und Studienteilnehmer auszuwählen, die mit Minderjährigen zusammenleben, 
und diese auch direkt zu befragen. Weitere zu untersuchende Fragestellungen sind, inwiefern 
verschiedene Produktformate und -variationen sich auf die Gesundheit der Studienteilnehmerinnen 
und Studienteilnehmer auswirken, welche Produktmerkmale die Teilnehmerinnen und Teilnehmer 
besonders ansprechen und welche regulatorischen Massnahmen zur Förderung eines risikoärmeren 
Konsums beitragen können. 
 
Weiterer Forschungsbedarf im Rahmen von Ressortforschung 
Einige wichtige Fragen können im Rahmen von Pilotversuchen aufgrund gesetzlicher Anforderungen 
kaum untersucht werden und eignen sich daher besser für Ressortforschungsprojekte. Aktuell hat das 
BAG vier Mandate vergeben und es beteiligt sich gemeinsam mit anderen Partnern an der finanziellen 
Unterstützung eines fünften Projekts. Eine Studie von Sotomo untersucht die allgemeine Akzeptanz von 
Regulierungsmassnahmen sowie die Haltung der Stimmbevölkerung zu Cannabis. Die Universität Genf 
befasst sich zusammen mit Rütter Soceco im Auftrag verschiedener Institutionen mit den wirtschaftlichen 
Auswirkungen von Cannabis. Fragen nach den wirtschaftlichen Folgen verschiedener 
Regulierungsmodelle, möglichen Steuereinnahmen, und das wirtschaftliche Potenzial eines legalen 
Cannabismarktes für Schweizer Produzenten und Händler stehen hierbei im Fokus. Die jüngst 
veröffentlichte Studie des IRM Basel zielte darauf, die Literatur hinsichtlich der THC-Grenzwerte im 
Strassenverkehr zu analysieren und mögliche Szenarien für die Anpassung der 
Strassenverkehrsordnung zu entwickeln. Die ZHAW befasste sich mit dem Anbau, der Produktion und 
den Produktionsstandards zur Gewährleistung des optimalen Verbraucherschutzes. Ein Auftrag an 
Sucht Schweiz umfasst eine vergleichende Analyse von Evaluationen verschiedener 
Regulierungsmassnahmen in anderen Ländern, da für viele Massnahmen derzeit noch keine 
ausreichende Beurteilung vorliegt. 
 
Weiterer Forschungsbedarf im Bereich der Verarbeitung und des Vertriebs von Cannabis betrifft die 
Auswirkungen unterschiedlicher Produkt- und Verpackungseigenschaften auf die Verbraucherwahl. 
In diesem Kontext kann Forschung, die jenseits des Rahmens von Pilotversuchen stattfindet, von den 
gesetzlich festgelegten Bestimmungen der BetmPV abweichen. Dadurch könnten zusätzliche 
Erkenntnisse gewonnen werden. Bezüglich der Thematik Einnahmen und Steuern stellt sich die Frage 
nach der Verteilung möglicher Einnahmen und danach, welche Preisstruktur im Rahmen einer 
gesundheitsfördernden Regulierung am sinnvollsten ist. Im Bereich Öffentliche Ordnung und 
Sicherheit sehen wir eine Notwendigkeit zur Gewinnung zusätzlicher Erkenntnisse über die 
Funktionsweise des Schwarzmarktes, was durch die Pilotversuche kaum umfassend abgedeckt werden 
kann. Zudem müssen die möglichen Regulierungen für verschiedene Produkttypen erforscht werden. 
Betreffend Jugendschutz sind wir der Ansicht, dass quasi-experimentelle Designs zu unterschiedlichen 
Produktformen, Präventionsbotschaften und Kommunikationskanälen sowie deren Attraktivität für 
Jugendliche einen vielversprechenden methodischen Ansatz darstellen. Ferner sollten gemeinschafts-- 
oder familienbasierte Präventionskampagnen, die sich als wirksam erwiesen haben, genauer untersucht 
werden, um zu bestimmen, wie sie strukturell gestärkt werden können. Es wäre zudem wichtig zu 
untersuchen, wie angemessene staatliche Kontrolle, Kontrollorgane und Kontrollmassnahmen 
ausgestaltet werden sollten. Dabei geht nicht nur um die Frage, wer Lizenzgeber sein sollte, sondern 
auch darum, ob ein Verbot der gleichzeitigen Tätigkeit in den Bereichen Produktion, Lieferung und 
Handel angezeigt ist. Darüber hinaus ist eine themenübergreifende Untersuchung des Status quo 
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erforderlich, um die Auswirkungen verschiedener zukünftiger Regelungen beurteilen zu können. 
Weiter besteht Forschungsbedarf im Bereich der Implementation, da oft eine Diskrepanz zwischen 
formalen Richtlinien und deren Umsetzung besteht. Auch zu den Vor- und Nachteilen der 
unterschiedlichen Regulierungsoptionen, die eine mittlere Position zwischen Entkriminalisierung und 
Legalisierung einnehmen, sowie dazu, inwiefern strukturelle Massnahmen informierte 
Verhaltensentscheidungen fördern und Konsumentinnen und Konsumenten zu weniger 
problematischem Konsumverhalten hinführen können, sind vergleichende Untersuchungen 
erforderlich.  
 
Forschungskoordination und -finanzierung 
Wir unterscheiden drei idealtypische Modelle der Forschungsfinanzierung und -koordination, die sich 
insbesondere dahingehend unterscheiden, wie stark die Forschungsinhalte gesteuert werden. Das 
politische Finanzierungssystem steht im direkten Dienst der Interessen der Politik und zielt auf die 
Beantwortung praktischer Fragen und die Entwicklung umsetzbarer Lösungen ab. Das 
wissenschaftsbasierte Finanzierungssystem geht von den aus wissenschaftlicher Sicht wichtigsten 
Forschungsfragen aus, ist oftmals losgelöst von politikbezogenen Debatten und geht mit der Gefahr 
von disparaten und inkohärenten Forschungsaktivitäten einher. Das strategische Finanzierungssystem 
verfolgt als dritter Idealtypus alle vielversprechenden Forschungsansätze in den relevanten Bereichen 
und adressiert nicht nur Fragen, die von der Wissenschaft identifiziert wurden, sondern auch solche, 
die sich aus ein politikbezogenen Perspektive ergeben.  
 
Obwohl die gesetzlichen Grundlagen ein politisches Finanzierungssystem für die Pilotversuche mit 
Cannabis ausschliessen, können aus Erfahrungen, die mit der Koordination und Förderung von 
Forschung bei der Etablierung der Heroingestützten Behandlung (HegeBe) gemacht wurden, 
Erfolgsfaktoren abgeleitet werden. In diesem Fall waren Kantone, Gemeinden und private 
Organisationen dafür verantwortlich, die Versuche durchzuführen, während der Bund die finanziellen 
Mittel für die wissenschaftliche Evaluation bereitstellte. Eine Gruppe von Forscherinnen und Forschern 
wurde damit beauftragt, einen Forschungsplanzu definieren und umzusetzen. Das BAG genehmigte 
Versuche nur, wenn sie mit der Verpflichtung einhergingen, mitttelseines gemeinsamen 
standardisierten Fragebogens für die Studienteilnehmerinnen und Studienteilnehmer Daten zu erheben. 
Für die Pilotversuche mit Cannabis zeichnet sich derzeit das Szenario einer dezentralen, 
wissenschaftsbasierten Forschungsfinanzierung und Selbstkoordination ab. Der Bund evaluiert und 
genehmigt Forschungsprojekte und sammelt die Ergebnisse, spielt aber keine aktive Rolle bei der 
Forschungsproduktion oder -finanzierung. In der Schweiz gibt es mehrere mögliche Geldgeber, die für 
die Finanzierung eines solchen wissenschaftsbasierten Finanzierungssystems in Frage kommen. Der SNF 
(Schweizerischer Nationalfonds zur Förderung der wissenschaftlichen Forschung) ist sicherlich die 
wichtigste unabhängige Agentur für Forschungsförderung. Neben der Möglichkeit, individuelle 
Gesuche für einzelne Projekte einzureichen, gibt es Nationale Forschungsschwerpunkte (NFS) für 
etablierte Forscherinnen und Forscher mit langfristigen Forschungsvorhaben, Sinergia für 
interdisziplinäre Forschung mehrerer Forschungsteams, und verschiedene Instrumente zur 
Ermöglichung internationaler Forschungskooperationen. Wissenschaftliche Projekte werden zudem 
von mehreren unabhängigen Stiftungen finanziell unterstützt. Darüber hinaus gibt es im Tabak- und 
Alkoholbereich unabhängige Fonds, die die Forschung betreffend Substanzgebrauch und Sucht 
ebenfalls unterstützen. Die Problematik potenzieller Interessenkonflikte ist ein bekanntes Problem in 
diesem Bereich. Die Unabhängigkeit gegenüber möglichen Interessen der Industrie sowie die 
Vermeidung von Interessenkonflikten ist für die zukünftige Förderung der Cannabisforschung 
ebenfalls von zentraler Bedeutung und kann durch die Einhaltung einiger Prinzipien gefestigt werden. 
Es ist auch denkbar, dass sich die wissenschaftsbasierte Forschungskoordination an den Grundsätzen 
der Offenen Wissenschaft (Open Science) orientiert. Diese würden neben anderen Vorzügen die 
Transparenz des Forschungsprozesses und die öffentliche Verfügbarkeit von Daten gewährleisten. 
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Unter den gegebenen Bedingungen sehen wir eine realistische Chance für eine stärkere Koordination 
in den drei Bereichen der Festlegung einer Cannabis-Standardeinheit, der Entwicklung eines 
gemeinsamen Basisfragebogens für die Teilnehmerinnen und Teilnehmer sowie der Schaffung einer 
gemeinsamen Plattform für das Pooling und den Austausch von Daten, in der die Rohdaten und 
Ergebnisse zugänglich gemacht werden. Die Koordination ist im erheblichen Masse von einer gut 
vernetzten Forschungsgemeinschaft abhängig, und aktuell würde unserer Ansicht nach eine an 
mehreren Orten stattfindende Studie (Multi-Site oder Multi-Center Study) keine realistische Option 
darstellen. Eine stärkere Unterstützung seitens des BAG einschliesslich der Finanzierung von 
Aktivitäten der Forschungskoordination könnte sich dabei allerdings als hilfreich erweisen. Das 
naheliegende Instrument für eine stärkere strategische Ausrichtung der Finanzierung wären die 
Nationalen Forschungsprogramme (NFP) des SNF. Bei den NFP handelt es sich gerade deshalb um 
strategische Finanzierungsinstrumente, weil sie explizit die Forschung in einem bestimmten 
Problembereich, den der Bund als relevant betrachtet, unterstützen. Gegebenenfalls könnte der Fokus 




Ausarbeitung einer projektübergreifenden Forschungsmethodik  
1. In der internationalen Forschung kommen oft standardisierte Basisfragebögen zur Anwendung, 
welche optional um Module erweitert werden können, die auf spezifische Bedingungen des jeweiligen 
Landes oder der Region eingehen. Entsprechend empfehlen wir für die Pilotversuche die Entwicklung 
eines gesamtschweizerischen Basisfragebogens mit ergänzenden Modulen, die beispielsweise die 
Situation des Drogenmarktes in einem bestimmten Gebiet stärker berücksichtigen.  
2. Während einige Pilotversuche ähnliche Fragen und Items anzuwenden scheinen, liegt derzeit kein 
einheitlicher Fragensatz mit Basis-Items vor. Wir empfehlen, dass das BAG sich an der Ausarbeitung 
einer projektübergreifenden Forschungsmethodik beteiligt, indem es die Anstrengungen der 
Forscherinnen und Forscher zur Erarbeitung eines einheitlichen Fragebogen oder einige vereinbarte 
Basis-Fragen unterstützt. 
3. Als Schritte auf dem Weg zu einer projektübergreifenden Forschungsmethodik empfehlen wir die 
Festlegung einer Cannabis-Standar-Konsumeinheit, eines gemeinsamen Basisfragebogens für die 
Studienteilnehmerinnen und Studienteilnehmer sowie einer gemeinsamen Plattform für das Pooling 
und den Austausch von Daten. 
 
Koordination von Forschungsprojekten (Pilotversuche) 
4. Es ist davon auszugehen, dass die Pilotversuche mit Cannabis sowie die damit zusammenhängende 
Forschung von einer intensiven öffentlichen und medialen Aufmerksamkeit begleitet werden. Aus 
diesem Grund empfehlen wir, dass Forscherinnen und Forscher bei der Entwicklung einer stimmigen 
öffentlichen und politischen Kommunikationsstrategie koordiniert vorgehen. 
5. Abgesehen von den häufig diskutierten Alternativen der Cannabisregulierung -  der Prohibition und 
dem kommerziellen Standardmodell -  gibt es theoretisch zahlreiche andere Optionen, die sich zwischen 
diesen Polen ansiedeln. Diese werden in der Praxis jedoch selten umgesetzt. Daher empfehlen wir, dass 
in der Schweiz mehr Forschung zu diesen international noch wenig untersuchten Mittelweg-Optionen 
betrieben wird. Diese scheinen das Potenzial zu haben, die gesundheitlichen und sozialen Kosten 
erheblich zu senken. 
6. Im Rahmen der Pilotversuche mit Cannabis nimmt das BAG verschiedene Funktionen wahr und ist 
in erster Linie als Genehmigungs- und Kontrollorgan tätig. Interessenkonflikte sind unvermeidlich. 
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7. Ein wissenschaftsbasiertes oder ein strategisches Finanzierungssystem mittels SNF-
Förderungsbeiträgen können einen gangbaren Weg für die Forschungsfinanzierung darstellen, 
während die direkte Finanzierung durch den Bund von den gesetzlichen Grundlagen ausgeschlossen 
wird. Um die Chancen der Förderungsgesuche zu erhöhen, empfehlen wir eine stärkere 
Zusammenarbeit mit internationalen Experten. So können relevante Forschungslücken identifiziert und 
die internationale Relevanz sichergestellt werden. 
8. Akteure, die an evidenzbasierter Forschung zum Zwecke der Politikgestaltung interessiert sind, 
sollten zudem die Alkohol- und Tabakpräventionsfonds im Auge behalten, da diese mit ihren 
organisatorischen und finanziellen Strukturen interessante Finanzierungsinstrumente darstellen. 
9. Um die Unabhängigkeit der Forschung sowie ihre Glaubwürdigkeit sicherzustellen und eine 
unzulässige Beeinflussung der Forschungsaktivitäten durch die Industrie zu verhindern, sollten sich 
Forscher an einige grundlegende Prinzipien zur Vermeidung von Interessenkonflikten bei der 
Cannabis-bezogenen Forschungsförderung halten (zum Beispiel keine Beeinflussung von 
Finanzierungsentscheidungen durch die Industrie, Freiheit hinsichtlich der Publikation von 
Forschungsergebnissen). 
10. Sofern der Stiftungszweck erfüllt ist, können unabhängige Stiftungen eine massgebliche Rolle bei 
der Förderung von Pilotstudien spielen. In diesem Bereich könnte die Koordination (zum Beispiel eine 
zentrale Beratungsstelle für die Finanzierung der Cannabisforschung) die unterschiedlichen 
Forschungsteams bei der Suche nach Zuwendungen von Stiftungen und anderen Akteuren unterstützt. 
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Résumé 
Sujet et Mandat 
En Suisse, le cannabis est illégal depuis 1951. Récemment, sa décriminalisation a fait l’objet de débats 
au sein de l’Assemblée fédérale. Les évolutions observées dans d’autres pays ont été davantage suivies 
et ont alimenté les discussions au sujet des réformes de la réglementation. Les approches en la matière 
sont très variées, mais il y a encore peu de données scientifiques solides sur les effets des instruments 
mis en place. De premières initiatives d’essais pilotes portant sur le cannabis ont été lancées par des 
villes suisses afin de trouver de nouvelles solutions fondées sur des données probantes pour remplacer 
les dispositifs actuels, marqués par un certain nombre d’incohérences. Une requête initiale de la ville de 
Berne déposée auprès de l’Office fédéral de la santé publique (OFSP) a été rejetée en 2017 faute de base 
légale mais a contribué à l’établissement d’un article de loi provisoire pour les essais pilotes sur le 
cannabis au cours des années suivantes. L’ordonnance sur les essais pilotes au sens de la loi sur les 
stupéfiants (OEPStup) permet ainsi aux cantons, aux communes, aux universités et à d’autres 
organisations de mener des essais pilotes visant à renforcer les connaissances scientifiques concernant 
la réglementation de la consommation de cannabis à des fins non médicales. Elle fixe plusieurs 
conditions nécessaires à l’approbation d’une demande d’essai par l’OFSP. En vue de ces futurs essais, 
l’OFSP a mandaté le professeur Daniel Kübler et son équipe de l’Institut de science politique de 
l’Université de Zurich (IPZ) pour élaborer un agenda de recherche concernant les nouvelles approches 
de la réglementation du cannabis. Celui-ci doit servir de guide pour la production de données 
scientifiques non seulement sur les essais pilotes concernant le cannabis mais aussi sur les questions 
plus larges relatives à la réglementation du cannabis, et permettre une réflexion sur la coordination et 
le financement de la recherche.  
 
Méthodologie 
Quatre sources d’information principales ont été utilisées pour élaborer le présent rapport. 
Premièrement, la recherche en langue anglaise sur les conséquences de la légalisation du cannabis à 
usage récréatif a été étudiée. Une recherche de méta-analyses et des revues systématiques dans le « Web 
of Science » a permis d’identifier 36 études qui ont toutes été examinées par la suite. Par ailleurs, d’autres 
publications récentes sur la réglementation du cannabis à l’étranger ou sur celle des stupéfiants en 
Suisse ont été prises en compte. Deuxièmement, un conseil consultatif a été constitué pour accompagner 
ce projet. Des échanges ont eu lieu avec celui-ci, et ses membres ont été appelés à faire des retours sur 
les versions précédentes de ce rapport. Troisièmement, une collaboration a été établie avec le Centre 
canadien sur les dépendances et l’usage de substances (CCDUS) et a donné lieu en février 2021 à la 
tenue d’un atelier international conjoint intitulé « Cannabis research in times of legalization: What’s on 
the agenda » (La recherche sur le cannabis à l’ère de la légalisation : ce qui est au programme). 
Quatrièmement, nous avons mené des discussions et des échanges avec divers spécialistes en Suisse, et 
avons transmis des versions de travail du présent rapport à la Commission fédérale pour les questions 
liées aux addictions et à la prévention des maladies non transmissibles (CFANT) et aux membres de la 
Swiss School of Public Health (SSPH+) intéressés. 
 
Question centrale et domaines de recherche 
De nombreux modèles de réglementation du cannabis sont concevables en théorie, allant de la 
prohibition stricte à un marché commercial libre. On peut supposer que les coûts sociaux et sanitaires 
sont particulièrement élevés aux deux extrémités de ce spectre et qu’il serait donc judicieux de trouver 
une solution intermédiaire. Pour ce faire, nous avons été guidés par une question centrale : quel cadre 
réglementaire permettrait de réduire efficacement les coûts sociaux et sanitaires de la consommation de cannabis ? 
Les preuves scientifiques concernant ce qui se fait dans d’autres contextes règlementaires sont rares. De 
plus, la nature contextuelle des preuves et le manque de données sur la situation actuelle, entre autres, 
rendent les comparaisons difficiles. Il est donc nécessaire de recueillir davantage de connaissances  
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concernant les moyens de réduire efficacement les coûts sanitaires et sociaux de la consommation de 
cannabis. Cela est particulièrement important en Suisse, où le débat est fortement axé sur la santé 
publique. Une analyse de la littérature récente a permis d’établir trois domaines de recherche 
fondamentaux pour réglementer efficacement le cannabis du point de vue de la santé publique se 
recoupant en partie et s’inscrivant dans un modèle logique général de réglementation (voir page 
précédente) 
 
Le premier domaine est la réduction des dangers d’utilisation sur les plans sanitaire et social. Dans ce 
domaine, c’est en particulier la crainte des conséquences négatives sur la santé de la légalisation du 
cannabis qui a inspiré de nombreuses publications scientifiques. Il n’y a actuellement pas de consensus 
et il semble donc que des recherches complémentaires soient nécessaires. Les données existantes portent 
essentiellement sur les efforts de prévention et concernent peu la réduction des dangers. Les principales 
questions en suspens dans la recherche ont trait aux aspects suivants :  
Réduire les dangers d’utilisation du Cannabis sur les plans sanitaire et social 
Réduction des 
risques pour la 
santé 
Santé physique et mentale  
• Comment les différents modèles réglementaires influent-ils sur la santé physique 
et mentale des consommateurs ? 
• Comment réduire le coût social global et la demande en cannabis ? 
• Comment les individus dépendants et ayant une consommation à risques 
peuvent-ils être détectés par le biais d’un accès réglementé au cannabis ? 
• Quelles réglementations sont susceptibles d’avoir des effets positifs sur une 
grande partie des consommateurs ? 
Comportements de consommation :  
• Quelles sont les répercussions des différentes options réglementaires sur les 
comportements de consommation (intensité, prévalence et incidence) ? 
• Comment élaborer des dispositions réglementaires (horaires d’ouverture, 
emplacements, etc.) permettant d’une part de renforcer les efforts de prévention 
et d’autre part de faciliter une consommation peu risquée tout en réduisant la 
consommation dangereuse ? 
• Quels sont les effets des différents modèles de vente du cannabis ? 
Qualité de vie et réduction des dangers : 
• Comment les dispositions réglementaires peuvent-elles soutenir les démarches de 
consommation non problématiques et les intégrer à la vie quotidienne des 
consommateurs ? 
• Quelles mesures structurelles encouragent les choix comportementaux éclairés et 
améliorent les connaissances des consommateurs sur leur consommation ? 
Quelles dispositions sont pertinentes dans le cadre de « directives pour une 
consommation plus sûre » ? 
• Dans quelle mesure les dispositifs de réduction des dangers sont-ils effectivement 
mis en œuvre au sein des différents cadres réglementaires ?  
• Comment un marché du cannabis réglementé peut-il renforcer les connaissances 
en matière de santé des consommateurs de cannabis et prévenir les usages 
problématiques (étiquetage, conseils de vente, campagnes de prévention) ? 
• Comment un accès légal réglementé au cannabis peut-il améliorer la qualité de 
vie et l’intégration sociale des personnes dépendantes ? 
Prévention et 
actions efficaces 
• Quelles dispositions réglementaires permettent de renforcer les efforts de 
prévention sans pousser les consommateurs à recourir au marché illégal ?  
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• Quelles dispositions réglementaires favorisent la détection des consommateurs 
vulnérables et la mise en œuvre d’actions auprès de ces derniers (mesures 
administratives pour les jeunes consommateurs p. ex.) ? 




• Quelles dispositions réglementaires (y compris mesures structurelles de 
prévention) sont importantes pour protéger efficacement les mineurs et empêcher 
une consommation précoce ? 
• Comment élaborer des campagnes de prévention permettant de réduire la 
consommation des jeunes (en particulier lorsqu’elle comprend des risques élevés) 
et éventuellement de faciliter une consommation peu risquée chez les jeunes 
adultes (p. ex. avec des teneurs en THC progressives en fonction de l’âge) ? 
• Quels sont les effets de la légalisation sur l’attitude des jeunes à l’égard du 
cannabis, sur leur perception des risques associés à la consommation et sur la 
probabilité qu’ils commencent (tôt) à en consommer ? Un accès légal favorise-t-il 
la normalisation de la consommation de cannabis ?  
• Quelles dispositions réglementaires peuvent être prises pour détecter et aider 
efficacement les consommateurs mineurs à risques ? 
Sécurité des 
consommateurs 
• Quelles normes juridiques et quels contrôles de qualité doivent être mis en place 
concernant d’éventuels contaminants (pesticides, p. ex.) ? 
• Comment contrôler la chaîne d’approvisionnement de manière à réduire les 
risques sanitaires et sociaux ? 
• L’accès aux différents produits du cannabis peut-il faire l’objet d’une 
réglementation progressive en fonction du potentiel danger qu’ils représentent 
pour leur public cible ? 
Polyconsommation • La vente et l’achat simultanés de cannabis et d’alcool doivent-ils être interdit ? 
• Comment diminuer la consommation simultanée de tabac et de cannabis et 
prévenir le passage du cannabis au tabac ? 
• Comment élaborer des dispositions réglementaires permettant de surveiller la 
production de cannabis et sa qualité, et d’assurer sa traçabilité ? 
• Quelles sont les répercussions d’un accès réglementé sur la polyconsommation ? 
 
 
Le deuxième domaine de recherche est l’amélioration de la sécurité et de l’ordre public. Les scientifiques 
cherchent ici à déterminer dans quelle mesure la légalisation du cannabis influe sur les moyens mis en 
œuvre aux fins d’application de la loi ou quelles solutions réglementaires ont une incidence sur la 
criminalité et la violence liées aux drogues. Les conséquences sur la sécurité routière et au travail font 
fréquemment l’objet de recherches, mais là aussi, les résultats ne sont pas concluants. Des études de 
grande ampleur et au long cours sont nécessaires. De même, il faudrait davantage d’informations sur 
le statu quo afin de déterminer les effets de nouvelles réglementations sur le marché illégal, qui sont un 
enjeu central. Les grandes questions ouvertes concernent les points suivants : 
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• Quelle est l’influence des différentes solutions de réglementation sur le marché illégal ? 
• Dans quelle mesure un marché légal peut-il éliminer le marché illégal ? Quelles 
modalités permettraient au mieux d’atteindre cet objectif ? 
• Quels sont les effets respectifs de la décriminalisation et de la légalisation sur les 




• Quelles mesures faudrait-il prendre pour que la sécurité routière et au travail soient 
assurées (définitions de taux limites de THC, amendes, information, campagnes de 
prévention, contrôles, etc.) ? 
• Quelles mesures peuvent être prises pour prévenir les nuisances liées au cannabis dans 
les espaces publics (p. ex. nombre et emplacement des points de vente, horaires 
d’ouverture) ?  
• Comment réduire les risques sur la route et au travail liés au cannabis en ajustant la 
réglementation sur la vente au détail ? 
• Quelles sont les répercussions des différents modèles de réglementation sur le tourisme 
associé à la drogue ? Quelles sont les stratégies les plus efficaces pour diminuer les 






de la loi 
• Quelles approches sont efficaces pour prévenir et détecter la conduite sous l’emprise du 
cannabis (p. ex. sanctions, maintien de l’ordre, tests, prévention) ?  
• Quelles sont les répercussions des différents cadres réglementaires sur les moyens 
nécessaires à l’application de la loi ? 
• Quelles approches de coordination des politiques sont les plus prometteuses (p. ex. 
lorsque plusieurs instances – police, justice, santé, inspection du travail – sont 
impliquées dans le système de mise en œuvre de la loi) ? 
 
Le troisième domaine de recherche porte sur la gouvernance de la production et de la vente du cannabis. 
L’ensemble de la chaîne d’approvisionnement et de valeur doit être prise en compte afin d’assurer une 
protection efficace de la santé publique. Des recherches sont menées sur les normes de production et la 
réglementation de la culture personnelle, mais là encore, les résultats sur les effets attendus ne sont pas 
probants. La production doit être transformée et distribuée d’manière sûre et responsable et de façon à 
promouvoir l’équité économique et sociale. Diverses réglementations existent en matière d’étiquetage, 
de conditionnement et de publicité. Les principales interrogations à ce sujet sont : 
 




• Quels sont les avantages des différents systèmes de licence possibles concernant la 
culture, la transformation et la vente du cannabis ? 
• Comment protéger la future législation sur le cannabis et la recherche contre 
l’influence du secteur privé à but lucratif ? 
Aspects socio-économiques 
• Quel est le potentiel économique d’un marché du cannabis totalement ou partiellement 
légalisé pour les producteurs et les vendeurs suisses par rapport à un statu quo ? 
• Que peuvent apprendre les législateurs de l’expérience de l’alcool et du tabac pour 
limiter les manipulations de l’industrie sur la vente du cannabis légal ?  
• Quelles solutions réglementaires sont efficaces pour atténuer les risques de 
commercialisation ? 
• Quels sont les avantages et les inconvénients d’une interdiction totale du marché 
commercial ?  
• Quels sont les effets de divers systèmes de réglementation en termes sociaux et 
d’équité ?  
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• Comment les aspects d’équité peuvent-ils être promus dès le départ ? Quels 
programmes devraient être développés pour améliorer la situation de groupes 
désavantagés ? 
• Quels sont les coûts sociaux globaux de différentes approches de réglementation 
(prohibition, décriminalisation, légalisation) ? 
Mise en œuvre des politiques 
• Quelles compétences réglementaires doivent être attribuées aux différents niveaux de 
l’État (national, cantonal, communal) ? Quels sont les risques et les avantages 
potentiels d’un modèle de gouvernance sur plusieurs niveaux ?  
• Comment améliorer la coordination entre cantons pour faciliter l’harmonisation de la 
mise en œuvre ? 
• Comment les réglementations relatives au cannabis médical et non médical peuvent-
elles être dissociées sans s’entraver, voire en s’étayant les unes les autres ? 
• De quelle manière les partenariats entre l’État et les acteurs privés (groupes 
professionnels, producteurs, etc.) devraient-ils être établis afin d’appliquer les 
politiques adoptées ? 
Production • Comment élaborer une réglementation concernant la production de cannabis 
garantissant la sécurité et la qualité des produits ainsi que la sécurité des systèmes de 
production ? 
• Quels sont les effets de la légalisation du cannabis sur les cultures personnelles et à 
domicile de cannabis ? Comment une supervision gouvernementale est-elle possible 
dans un tel modèle ?  
• Quelles sont les différentes options possibles en matière de test des produits, 
d’évaluation et de supervision du processus de production ? 
Transformation 
et distribution 
• Quelles dispositions doivent être prises pour la transformation et la distribution du 
cannabis ? 
• Quel type de restrictions doit être mis en œuvre concernant la promotion ? 
• Quelle réglementation appliquer au conditionnement et à l’étiquetage afin de 
correspondre aux habitudes locales de consommation et d’assurer la promotion des 
objectifs de santé publique pour que celle-ci soit plus efficace ? 
Vente au détail • Quelle réglementation appliquer au système de vente au détail pour répondre aux 
préoccupations en matière de santé publique et de sécurité ?  
• Quelle configuration de vente est la plus à même de pousser les consommateurs à 
abandonner leurs fournisseurs habituels (illégaux) pour promouvoir les effets positifs 
d’une nouvelle réglementation ? 
• Quelles restrictions sur les ventes et l’achat sont efficaces du point de vue de la santé 
publique (restrictions d’accès et de disponibilité, rationnement, achats limités à une 
certaine quantité, etc.) ? 
• Quels sont les avantages potentiels et les risques liés aux différents modèles de vente 
(p. ex. vente en boutique ou en ligne) ? Est-il préférable d’avoir des points de vente de 
cannabis étatiques plutôt que commerciaux du point de vue de la santé publique ? 
Consommation • Quelles sont les preuves de l’efficacité de l’interdiction de la consommation dans les 
lieux publics en matière de santé publique ? 
• Quels sont les avantages et les inconvénients des différentes options de restriction 
concernant le lieu de consommation du point de vue de la santé publique et de la 
sécurité ? 
• Comment réglementer et surveiller les lieux de consommation autorisés ? 
Prix / taxation • Comment le prix et la taxation influencent-ils les habitudes de consommation 
(changement d’habitudes, priorités locales, etc.) ? 
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• Comment établir une structure tarifaire et fiscale permettant de faire concurrence au 
marché illégal mais dont les prix soient suffisamment élevés pour limiter l’accès des 
jeunes au cannabis et la consommation ? 
• Comment les revenus du cannabis peuvent-ils être redistribués afin de promouvoir 
l’équité et la santé publique, ainsi que la recherche ? 
 
Priorités dans le contexte suisse 
En Suisse, le débat sur le cannabis se concentre principalement sur les approches réglementaires qui 
permettraient de réduire les risques et de maximiser les bénéfices sur la santé publique. Les avis 
divergent à ce sujet, les uns estimant que le cannabis est un produit à éviter en toutes circonstances et 
prônant par conséquent une interdiction totale, les autres avançant qu’il s’agit d’une réalité sociale et 
approuvant l’examen d’autres options. L’article dit d’« expérimentation » autorisant les essais pilotes a 
finalement été approuvé par la majorité du Parlement afin d’étudier les problématiques centrales de la 
réglementation du cannabis de manière ouverte et non biaisée. Les discussions menées en Suisse et les 
conclusions de la recherche internationale permettent d’établir quatre grandes priorités relatives à la 
réglementation future du cannabis, qui constituent la partie « conséquences » du modèle logique 
développé.  
 
La première d’entre elles est la promotion de la santé individuelle et publique et poursuit les objectifs 
fixés par la loi sur les stupéfiants (LStup) et l’ordonnance correspondante (OEPStup). Dans ce domaine, 
la recherche s’intéresse avant tout à la prévention des troubles addictifs et de la consommation à risques, 
à l’aide et au traitement des personnes à risques, à l’atténuation des nuisances sanitaires et sociales ainsi 
qu’à la réduction des retombées négatives sur la société. Les preuves solides sur les répercussions sont 
relativement rares car la légalisation dans les autres pays est récente, la transposition au système suisse 
est difficile et la mesure des effets sur la santé individuelle et publique reste complexe. 
 
La promotion de l’ordre public et la réduction de la criminalité constituent la deuxième priorité. Bien 
qu’il ne s’agisse pas de la principale raison de la réflexion entamée sur la législation actuelle en matière 
de cannabis en Suisse, le fait de remplacer le marché illégal est un objectif régulièrement évoqué. Dans 
ce contexte, il convient de prêter une attention particulière aux trois secteurs prioritaires que sont la 
réduction des activités criminelles, l’amélioration de la sécurité et de l’ordre public ainsi que le maintien 
de l’ordre, l’organisation de la police et l’application de la loi. Il semble très important ici que les études 
soient menées sur le long terme et ne se concentrent pas uniquement sur la période qui suit la mise en 
œuvre d’une mesure, mais également sur le statu quo afin de pouvoir effectuer des comparaisons 
intéressantes. 
 
La troisième priorité est la protection des mineurs. En effet, les études internationales ne fournissent pas 
de données claires sur les conséquences d’une consommation précoce et les adolescents suisses sont de 
grands consommateurs. De plus, le sujet est particulièrement sensible dans les débats politiques. 
L’approche suisse actuelle pour protéger efficacement les mineurs repose sur trois piliers : la protection 
légale de la jeunesse, la promotion de la jeunesse et l’aide à la jeunesse. Les recherches futures sur les 
conséquences des différentes approches réglementaires dans ces trois domaines sont essentielles. 
La quatrième et dernière priorité est le renforcement de la prospérité et de l’équité. La légalisation du 
cannabis fournit une nouvelle base d’imposition et offre la possibilité de créer une nouvelle industrie. 
L’expérience des autres pays montre que les acteurs à but lucratif de ce domaine gagnent rapidement 
en influence et cherchent à l’exercer pour que le cadre légal soit plus avantageux pour eux. Il semble 
donc judicieux de se pencher sur des solutions intermédiaires plutôt que sur une approche commerciale, 
malgré la tradition libérale de la Suisse. Par ailleurs, les questions concernant la justice sociale, l’égalité 
et le contrôle de la chaîne d’approvisionnement sont particulièrement importantes. 
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Essais pilotes sur le cannabis 
Le cadre légal pour les futurs essais pilotes sur le cannabis est fixé par l’ordonnance sur les essais pilotes 
au sens de la loi sur les stupéfiants (OEPStup) de 2021. Les essais pilotes doivent fournir des 
renseignements concernant les effets sur : la santé physique et psychique des consommateurs et leur 
performance, le comportement lié à la consommation, les aspects socio-économiques, le marché de la 
drogue sur un territoire spécifique, la protection de la jeunesse et la sécurité et l’ordre publics (art. 2, 
al. 2, de l’OEPStup). Ils doivent par ailleurs être limités géographiquement et dans le temps, et des 
critères concernant les substances à utiliser et les participants ont été établis. Il incombe à l’OFSP de 
délivrer les autorisations et d’assurer un suivi et un contrôle des projets. Dans les grandes villes suisses, 
plusieurs équipes scientifiques réfléchissent à des modèles de recherche pour les futurs essais pilotes. 
La coordination de la recherche est prise en compte avec le développement d’un questionnaire commun 
pour les participants. Les équipes de recherche ont l’intention de travailler avec différents types de 
points de distribution (cannabis social clubs, pharmacies, kiosques, magasins de e-cigarettes) 
notamment à des fins de comparaison. Les points de distribution jouent un rôle plus ou moins actif en 
fonction des projets. Jusqu’à présent, les équipes de recherche travaillent principalement sur des 
questions de santé et se concentrent sur la consommation. Toutefois, les considérations socio-
économiques et les répercussions possibles sur la santé publique à proximité des points de distribution 
sont aussi abordées par certaines équipes. L’étude des prix, des effets de différents produits et de la 
polyconsommation est envisagée. 
 
En fonction de ces aspects, du modèle logique et des réflexions actuelles des équipes de recherche, nous 
avons déterminé des sujets de recherche possibles et des questions pour les futurs essais pilotes. 
L’expérience récente des autres pays montrant que ce canal de distribution gagne en importance, la 
vente en ligne doit être envisagée dans la mesure de ce qu’il est légalement possible de faire, et ses effets 
doivent être examinés. Afin d’étudier le marché de la drogue dans une zone géographique donnée ou 
bien ses répercussions sur la sécurité et l’ordre publics, des villes similaires pourraient être comparées 
et des méthodes statistiques pourraient aider à évaluer les liens de causalité. Il convient en outre de 
prendre en compte la polyconsommation dans les enquêtes ou les entretiens menés avec les participants. 
Sélectionner des participants habitant avec des mineurs ou interviewer des mineurs directement 
pourrait permettre de collecter des données immédiates sur la protection de ces derniers. Parmi les 
autres sujets méritant également être d’étudiés figurent les répercussions des différents formats et des 
variations entre produits sur la santé des participants, les caractéristiques de produit qui attirent le plus 
les participants ou encore les dispositions réglementaires susceptibles d’encourager une consommation 
moins risquée. 
 
Recherches complémentaires et autres recherches nécessaires 
Certaines questions peuvent difficilement être traitées dans le cadre d’essais pilotes en raison des 
prescriptions légales et se prêtent donc davantage à des recherches complémentaires. Actuellement, 
l’OFSP a attribué quatre mandats de recherche à cet effet et cofinance un cinquième projet avec des 
partenaires. Une étude de Sotomo s’intéresse à l’acceptation générale des mesures réglementaires et à 
l’attitude des électeurs à l’égard du cannabis. En collaboration avec Rütter Soceco, l’Université de Genève 
enquête sur les effets économiques du cannabis pour le compte de plusieurs institutions. L’accent est ici 
mis sur les conséquences économiques de différents modèles réglementaires, les éventuelles recettes 
fiscales et le potentiel économique d’un marché du cannabis légal pour les producteurs et vendeurs 
suisses. Une étude récemment publiée par l’IRM de Bâle avait pour objectif d’analyser la littérature sur 
la limitation des taux de THC sur la route et d’imaginer des scénarios possibles pour adapter la 
législation routière. La ZHAW s’est intéressée au problème de la culture et de la production du cannabis 
et aux normes de produit qui permettraient de protéger au mieux les consommateurs. Addiction Suisse 
a quant à elle été mandatée pour réaliser une analyse comparative des évaluations des différentes 
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politiques réglementaires en vigueur à l’étranger, bon nombre d’entre elles n’étant en effet pas 
suffisamment étudiées. 
 
Des recherches complémentaires sont par ailleurs nécessaires dans le domaine du traitement et de la 
distribution concernant les effets des différents produits et de leur conditionnement sur le choix du 
consommateur. Les recherches réalisées en dehors du cadre des essais pilotes n’ont pas à satisfaire aux 
critères fixés par l’OEPStup, et devraient donc fournir des connaissances supplémentaires. S’agissant 
des recettes et des taxes, des questions se posent concernant leur redistribution ainsi que sur la 
tarification la plus judicieuse dans le cadre d’une législation visant la promotion de la santé publique. 
En matière d’ordre public et de sécurité, les auteurs du présent rapport estiment nécessaire de collecter 
davantage d’informations sur le fonctionnement du marché illicite. Ce sujet peut toutefois difficilement 
être traité par les essais pilotes. Des recherches concernant les réglementations potentiellement 
applicables à différents types de produits doivent également être menées. Dans le contexte de la 
protection de la jeunesse, les études quasi-expérimentales sur différentes formes de produits, les 
messages de prévention, les canaux de communication et l’intérêt que les jeunes leur portent constituent 
des approches méthodologiques prometteuses. Par ailleurs, les campagnes de prévention effectuées au 
sein des familles ou des communautés s’étant avérées efficaces, il convient de les examiner de plus près 
et de déterminer comment les renforcer du point de vue structurel. Il faut en outre mener une réflexion 
sur la forme que doivent prendre le contrôle par l’État ainsi que les organismes et dispositifs de contrôle 
pour être pertinents. Il s’agit non seulement de définir qui pourra octroyer les licences, mais aussi s’il 
est intéressant d’interdire aux acteurs du domaine d’exercer des activités à la fois dans la production, 
l’approvisionnement et la vente. Des recherches transversales sur le statu quo sont également 
nécessaires pour évaluer les effets des différentes législations qui seront adoptées. Au vu des différences 
souvent observées entre les politiques officielles et leur mise en œuvre, l’application des politiques doit 
faire l’objet de recherches. Les avantages et les inconvénients des diverses options réglementaires 
existantes entre décriminalisation et légalisation doivent aussi faire l’objet de recherches comparatives. 
Il en va de même pour les répercussions des mesures structurelles susceptibles d’encourager des choix 
comportementaux éclairés et de guider les consommateurs vers des manières de consommer moins 
problématiques. 
 
Coordination et financement de la recherche 
Trois modèles idéaux-typiques de financement et de coordination de la recherche sont à distinguer. Le 
modèle de financement politique sert directement les intérêts du gouvernement et vise à répondre à des 
questions pratiques ainsi qu’à développer des solutions qu’il sera possible de mettre en œuvre. Le modèle 
de financement axé sur la science prend appui sur les questions de recherche qui sont fondamentales pour 
une discipline. Souvent détaché du débat politique, il comporte un risque de dispersion des efforts de 
recherche. Le modèle de financement stratégique s’intéresse à toutes les pistes de recherche dans les 
domaines concernés et traite aussi bien les questions mises en avant par le monde académique que celles 
liées à la politique.  
 
Bien que le modèle de financement politique ne soit légalement pas applicable dans le cadre des essais 
pilotes sur le cannabis, l’expérience en matière de coordination et de financement de la recherche 
concernant la prescription d’héroïne peut permettre d’identifier des facteurs de réussite. Les cantons, 
les communes ainsi que des organisations privées étaient responsables de la mise en œuvre des essais 
et c’est le gouvernement fédéral qui finançait l’évaluation scientifique du projet. Un groupe de 
chercheurs avait été mandaté pour définir et appliquer un plan général de recherche. Les essais n’étaient 
pas approuvés par l’OFSP jusqu’à ce que les acteurs ne s’engagent à utiliser un questionnaire commun 
normalisé avec les participants pour collecter leurs données. 
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Concernant les essais pilotes sur le cannabis, le scénario d’un financement de la recherche décentralisé 
et auto-coordonné semble actuellement se dessiner. Le gouvernement fédéral évalue et approuve les 
projets et collecte les résultats, mais ne joue pas un rôle actif ni dans la production ni dans le financement 
de la recherche. Il existe plusieurs bailleurs de fonds en Suisse susceptibles de soutenir un tel modèle de 
financement axé sur la science. Le Fonds national suisse (FNS) est certainement la principale institution 
indépendante d’encouragement de la recherche. Outre la possibilité de déposer des demandes 
individuelles pour des projets spécifiques, le FNS connaît les Pôles de recherche nationaux (PRN) 
s’adressant aux scientifiques établis en Suisse qui souhaitent réaliser des projets de recherche sur le long 
terme, le programme Sinergia pour la recherche interdisciplinaire collaborative et divers instruments 
pour encourager les coopérations dans la recherche internationale. Plusieurs fondations indépendantes 
offrent également un soutien financier aux projets scientifiques. D’autres fonds existent dans le secteur 
du tabac et de l’alcool et promeuvent la recherche en matière de consommation de substances et 
d’addiction. Les conflits d’intérêts potentiels sont un problème connu dans ce domaine. L’indépendance 
par rapport à d’éventuels intérêts industriels et la prévention des conflits d’intérêts sont donc des 
questions centrales pour le financement des futures recherches sur le cannabis et peuvent être renforcées 
par certains principes clés. Ainsi, la coordination de la recherche portée par les chercheurs pourrait 
s’appuyer sur les principes de la science ouverte, ce qui garantirait entre autres la transparence du 
processus de recherche et l’accessibilité des données au public. 
 
Au vu des conditions actuelles, la coordination pourrait réalistement être renforcée avec la définition 
d’une taille unitaire standard pour le cannabis, le développement d’un questionnaire de base commun 
pour les participants et la création d’une plateforme commune pour la centralisation et l’échange des 
données où les données brutes et les résultats seront rendus accessibles. La coordination exige une 
communauté de recherche entretenant des liens forts. Une étude sur plusieurs sites ou centres ne semble 
aujourd’hui pas être une option réaliste, mais un soutien plus important de l’OFSP incluant un 
financement de la coordination de la recherche pourrait être utile. Les Programmes nationaux de 
recherche (PNR) du FNS constituent une solution évidente pour s’orienter vers un modèle de 
financement plus stratégique. En effet, ils promeuvent explicitement la recherche dans un domaine que 
le gouvernement estime pertinent. Si cela est jugé opportun, un PNR pourrait être étendu à des 
problèmes liés à la consommation d’autres substances et à l’addiction. 
 
Recommandations 
Développement d’une méthodologie de recherche transversale 
1. La recherche internationale utilise parfois des questionnaires de base normalisés qui peuvent être 
complétés par des modules additionnels pour tenir compte du contexte spécifique du pays ou de la 
région. Par analogie, nous recommandons de développer un questionnaire de base pour la Suisse avec 
des modules supplémentaires qui permettront de mieux prendre en considération les spécificités du 
marché de la drogue dans un espace donné, par exemple. 
2. Bien que certains essais pilotes semblent utiliser des questions et des notions similaires, il n’existe 
pour l’instant pas de questionnaire commun s’appuyant sur des notions clés. Nous recommandons que 
l’OFSP contribue à établir une méthodologie de recherche transversale en soutenant les initiatives de 
questionnaire commun ou de liste de questions essentielles des chercheurs. 
3. Nous recommandons de définir une taille unitaire standard pour le cannabis et de développer un 
questionnaire de base commun pour les participants ainsi qu’une plateforme commune pour la 
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Coordination des projets de recherche (essais pilotes) 
4. Il faut s’attendre à ce que le public et les médias prêtent une attention toute particulière aux essais 
pilotes et à la recherche sur le cannabis. Nous recommandons par conséquent que les chercheurs se 
coordonnent pour développer une stratégie de communication politique et publique solide. 
5. Outre la prohibition et le modèle commercial standard qui sont des options communément évoquées, 
il existe un grand nombre de solutions intermédiaires de réglementation du cannabis rarement mises 
en œuvre. Nous recommandons donc que davantage de recherches soient réalisées en Suisse sur ces 
solutions intermédiaires peu étudiées au niveau international. Il semble y avoir là un fort potentiel de 
réduction des coûts sanitaires et sociaux. 
6. Dans le cadre des essais pilotes, l’OFSP exerce différentes fonctions et est avant tout une instance 
d’approbation et de contrôle. Les conflits d’intérêts sont inévitables et nous recommandons donc de 
clarifier le rôle de l’OFSP pour mieux soutenir les essais pilotes à l’avenir. 
 
Financement de la recherche 
7. La recherche semble pouvoir s’appuyer sur un modèle de financement stratégique ou bien axé sur la 
science par le biais des subventions du FNS, mais le cadre légal exclut un financement direct par le 
gouvernement fédéral. Pour augmenter les chances de voir les demandes de financement aboutir, nous 
recommandons une plus grande coopération avec des experts étrangers afin d’identifier les lacunes de 
la recherche et de garantir la pertinence du projet au niveau international. 
8. Avec leurs structures organisationnelles et financières, les fonds de prévention du tabagisme et de 
l’alcoolisme sont de potentiels bailleurs de fonds intéressants pour les acteurs souhaitant mener des 
recherches pour établir une législation fondée sur des faits. 
9. Pour garantir l’indépendance et la crédibilité de la recherche et empêcher l’industrie d’exercer une 
influence abusive, les scientifiques doivent veiller à adhérer aux principes directeurs visant à éviter les 
conflits d’intérêts dans le financement de la recherche sur le cannabis (p. ex. pas d’influence de 
l’industrie sur les décisions de financement, liberté de publier les résultats de recherche). 
10. Les fondations indépendantes pourraient jouer un rôle crucial dans le financement des essais pilotes 
si leurs objectifs se recoupent. La coordination dans ce domaine (p. ex. avec une structure de conseil 
centrale pour le financement de la recherche sur le cannabis) pourrait aider les différentes équipes 
scientifiques dans leurs recherches de financements auprès des fondations ou des autres bailleurs. 
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Sintesi 
Oggetto e mandato 
In Svizzera la canapa è illegale dal 1951. Di recente la decriminalizzazione della canapa è stata discussa 
nell’Assemblea federale. Gli sviluppi in altri Paesi hanno ricevuto un’attenzione accresciuta e hanno 
stimolato ulteriori discussioni su possibili riforme. Gli approcci normativi in altri Paesi variano molto, 
ma le evidenze scientifiche solide sugli effetti degli strumenti sono ancora scarse. Alcune città svizzere 
hanno lanciato iniziative per condurre sperimentazioni pilota con la canapa al fine di trovare alternative 
basate su prove scientifiche allo stato attuale, segnato da varie incongruenze. Una richiesta iniziale 
presentata dalla città di Berna all’Ufficio federale della sanità pubblica (UFSP) fu rifiutata nel 2017 a 
causa della mancanza di una base legale, ma contribuì alla stesura di un «articolo sperimentale» per le 
sperimentazioni pilota con la canapa negli anni seguenti. L’ordinanza sulle sperimentazioni pilota 
secondo la legge federale sugli stupefacenti (OSPStup) consente a cantoni, comuni, università e altre 
organizzazioni di condurre sperimentazioni pilota per acquisire conoscenze scientifiche su approcci 
alternativi al disciplinamento dell’uso ricreativo della canapa. L’ordinanza elenca le varie condizioni 
che devono essere soddisfatte affinché una richiesta possa essere autorizzata dall’UFSP. In vista di 
future sperimentazioni pilota, l’UFSP ha incaricato il professor Daniel Kübler e il suo team del 
Dipartimento di scienze politiche dell’Università di Zurigo (IPZ) di sviluppare un’agenda di ricerca 
focalizzata su nuovi approcci giuridici alla regolamentazione della canapa. L’obiettivo di tale agenda è 
di servire da linea guida per la produzione di evidenze scientifiche legate non solo alle sperimentazioni 
pilota con la canapa, ma anche a ulteriori questioni relative alla regolamentazione della canapa, e di 
riflettere sul coordinamento e il finanziamento della ricerca.  
 
Metodologia 
Per elaborare la presente relazione sono state usate quattro principali fonti di informazioni. In primo 
luogo è stata considerata la ricerca e la letteratura in lingua inglese sulle conseguenze della 
legalizzazione della canapa ad uso ricreativo. Una ricerca sistematica della letteratura nel “Web of 
Science” per la meta-analisi e la revisione metodica ha consentito di identificare 36 pubblicazioni, le 
quali sono state esaminate. Inoltre sono state incluse ulteriori fonti di recente pubblicazione relative alla 
regolamentazione della canapa in altri Paesi o alla canapa e alla politica in materia di droghe in Svizzera. 
In secondo luogo è stato istituito un comitato consultivo con una base relativamente ampia. Gli autori 
si sono consultati frequentemente con i membri del comitato, che hanno fornito un feedback sulle 
versioni precedenti della presente relazione. In terzo luogo è stata instaurata una collaborazione con il 
Canadian Center of Substance Use and Addiction (CCSA), da cui è conseguito il seminario 
internazionale intitolato «Cannabis research in times of legalization: What’s on the agenda» (Ricerca 
sulla canapa in tempi di legalizzazione: cosa c’è in agenda), tenutosi a febbraio del 2021. In quarto luogo 
vi è stato un confronto con diversi esperti in Svizzera e le prime stesure della presente relazione sono 
state presentate alla Commissione federale per le questioni relative alle dipendenze e alla prevenzione 
delle malattie non trasmissibili (CFDNT) e ai membri interessati della rete Swiss School of Public Health 
(SSPH+). 
 
Domanda principale e campi di ricerca 
Dal punto di vista teorico è concepibile un ampio ventaglio di modelli di regolamentazione della canapa, 
da un divieto assoluto a un libero mercato commerciale. Si presume che i costi sociali e di salute siano 
particolarmente elevati ai due estremi di tale ventaglio, e andrebbe cercata un’alternativa nel mezzo. 
Per lavorare in direzione di opzioni normative situate nel mezzo di questi due estremi, la seguente 
domanda principale funge da guida: in quali condizioni normative possono essere minimizzati in modo efficace 
i costi sociali e di salute del consumo di canapa? Le evidenze validate da altre giurisdizioni sono scarse e le 
difficoltà di confronto includono la natura specifica di tali evidenze, che sono legate a un determinato 
contesto, nonché la mancanza di dati relativi allo stato attuale. Sono quindi necessarie maggiori  
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conoscenze su come possono essere minimizzati in modo efficace i costi sociali e di salute del consumo 
di canapa. Ciò è particolarmente rilevante in Svizzera, dove il dibattito politico è fortemente concentrato 
sulla salute pubblica. In base alla letteratura attuale sono state identificate tre aree di ricerca principali, 
parzialmente sovrapposte, fondamentali per un’efficace regolamentazione della canapa orientata alla 
salute pubblica, le quali sono riassunte nel seguente modello logico generale del disciplinamento della 
canapa (cf pagina precedente). 
 
Il primo campo di ricerca può essere denominato minimizzazione dei danni per la salute e la società. 
In questo campo è in particolare la paura di conseguenze negative per la salute della legalizzazione 
della canapa ad aver ispirato varie pubblicazioni scientifiche. Le ricerche attuali giungono a una varietà 
di conclusioni diverse e sembra esservi la necessità di ulteriori studi. Le evidenze esistenti riguardano 
principalmente gli sforzi di prevenzione e non tanto la riduzione dei danni. Le domande di ricerca 




per la salute 
Salute fisica e mentale  
• In che modo i diversi modelli di regolamentazione influiscono sulla salute fisica e 
mentale dei consumatori?  
• Come possono essere diminuiti i costi complessivi e la domanda dell’uso di canapa? 
• Come possono essere rilevate le persone con un consumo problematico e a rischio 
attraverso un accesso regolamentato alla canapa? 
• Quali scelte normative potrebbero presumibilmente avere effetti positivi sulla salute per 
un’ampia parte dei consumatori? 
Comportamento di consumo  
• Quali sono gli effetti di diverse opzioni normative sul comportamento di consumo 
(intensità, diffusione, frequenza)? 
• Come possono essere concepite le misure normative (ad es. orari di apertura, 
ubicazione) al fine di a) rafforzare gli sforzi di prevenzione e b) facilitare un consumo a 
rischio più basso minimizzando nel contempo il consumo dannoso? 
• Quali sono gli effetti dei diversi modelli di commercio/vendita? 
Qualità della vita e riduzione dei danni 
• In che modo le misure normative possono sostenere le strategie dei consumatori per un 
uso non problematico della canapa e per l’integrazione di tale uso nella loro vita 
quotidiana? 
• Quali misure strutturali incoraggiano una scelta comportamentale informata e 
aumentano le competenze dei consumatori relative all’uso? Quali disposizioni in 
rapporto alle «linee guida per un consumo sicuro» sono appropriate? 
• In che misura i provvedimenti per la riduzione dei danni sono implementati 
efficacemente nei diversi quadri normativi?  
• In che modo un mercato della canapa regolamentato può aumentare le competenze nel 
campo della salute dei consumatori di canapa e prevenire un uso problematico 
(informazione attraverso etichette, consulenza di vendita e campagne pubbliche)?  
• Come può essere migliorata la qualità di vita e l’integrazione sociale delle persone 




• Quali misure normative rafforzano gli sforzi di prevenzione senza spingere i 
consumatori verso il mercato illegale?  
• Quali misure normative promuovono il rilevamento e l’intervento precoci in rapporto 
ai consumatori vulnerabili (ad es. misure amministrative per i consumatori giovani)? 
• Come possono essere integrati nei quadri normativi i fattori relativi al sesso e al 
genere? 




• Quali misure normative sono importanti per proteggere i minori in modo efficace 
(incluse le misure di protezione strutturali) e di conseguenza impedire un inizio 
precoce del consumo? 
• Come dovrebbero essere concepite le campagne di prevenzione per ridurre il consumo 
(in particolare ad alto rischio) tra i giovani e possibilmente facilitare un consumo a 
rischio più basso per i giovani adulti (ad es. livelli di potenza graduati per diversi 
gruppi di età)? 
• Quali sono gli effetti della legalizzazione sull'atteggiamento dei giovani verso la 
canapa, la loro percezione dei rischi associati al consumo di canapa e la probabilità di 
iniziare a usarla (precocemente)? L’accesso legale favorisce una normalizzazione del 
consumo di canapa?  
• Quali misure normative possono essere prese per rilevare e sostenere i consumatori 




• Quali standard legali e quali controlli di qualità dovrebbero essere introdotti (ad es. 
pesticidi, sostanze contaminanti)? 
• Come può essere monitorata la catena di fornitura in modo tale da minimizzare i rischi 
per la salute e i danni alla società? 
• L’accesso ai vari prodotti della canapa può essere regolamentato in modo graduale 




• Dovrebbero essere vietati la vendita e l'acquisto simultanei di canapa e alcol? 
• Come si può ridurre l’uso simultaneo di canapa e tabacco e prevenire una transizione 
dalla canapa al tabacco? 
• Come dovrebbero essere concepite le misure normative al fine di consentire il 
monitoraggio della produzione di canapa e della sua qualità e di assicurarne la 
tracciabilità? 
• In che modo un accesso regolamentato alla canapa influisce sul policonsumo di altre 
sostanze? 
Il secondo campo di ricerca è l’aumento dell’ordine e della sicurezza pubblici. In questo ambito i 
ricercatori concentrano l’attenzione sulla misura in cui la legalizzazione della canapa ha un’influenza 
sulle risorse di polizia o su quali opzioni normative hanno un impatto sul crimine e la violenza legati 
alla droga. Un tema studiato spesso sono le conseguenze sulla sicurezza stradale e del lavoro. Come nel 
campo precedente, i risultati di ricerca sono inconcludenti. Sono necessari studi su larga scala e nel 
lungo termine, oltre a informazioni sufficienti sullo stato attuale per poter valutare la questione 
fondamentale dell’effetto delle regolamentazioni sul mercato illegale. Le principali domande di ricerca 
aperte sono le seguenti. 





• Qual è l’influenza di diverse opzioni normative sul mercato illegale? 
• In che misura un mercato legale è in grado di eliminare il mercato illegale? Quali 
condizioni consentono di raggiungere meglio tale obiettivo? 
• Quali sono gli effetti della decriminalizzazione, rispettivamente della legalizzazione, 




• Quali misure dovrebbero essere prese per garantire la sicurezza stradale e la 
sicurezza sul posto di lavoro (definizione dei limiti di THC, multe, informazione, 
campagne, controlli, ecc.)? 
• Quali misure possono essere prese per prevenire disturbi legati alla canapa negli 
spazi pubblici (ad es. numero e ubicazione dei punti vendita, orari di apertura)?  
• In che modo l’adeguamento della regolamentazione del commercio può condurre a 
una riduzione della guida sotto l’effetto di canapa e dei rischi di sicurezza sul lavoro? 
• Quali sono gli effetti di diversi modelli normativi sul turismo legato alle droghe? 
Quali sono le strategie più efficaci per minimizzare le conseguenze negative del 




della polizia e 
applicazione 
della legge 
• Quali approcci sono efficaci per prevenire e rilevare la guida sotto l’effetto di canapa 
(ad es. sanzioni, esecuzione, test e prevenzione)?  
• Come influiscono i diversi quadri normativi sulle risorse del sistema di applicazione 
della legge? 
• Quali approcci al coordinamento dell’attuazione sono i più promettenti (ad es. dove 
diverse agenzie sono coinvolte nel sistema di attuazione delle politiche, come le 
autorità di polizia, giustizia, salute, l’ispettorato del lavoro, ecc.) 
 
Il terzo campo di ricerca concerne la gestione di una catena di fornitura sicura e responsabile. Deve 
essere considerata l’intera catena di fornitura e di valore aggiunto al fine di conseguire una protezione 
della salute pubblica efficace. In questo campo si sta facendo ricerca sugli standard di produzione e 
sulla regolamentazione della coltivazione in proprio, ma anche qui gli effetti prevedibili non sono 
assolutamente concludenti. La materia prodotta deve essere lavorata e distribuita in modo sicuro e 
responsabile. Vi sono diversi disciplinamenti relativi all’etichettatura dei prodotti, le confezioni e la 





• Quali sono i vantaggi di diversi approcci all’autorizzazione riguardanti la coltivazione, 
la lavorazione e la vendita della canapa? 
• In che modo la legislazione e la ricerca future in materia di canapa possono essere 
protette dall’influenza delle imprese? 
Aspetti economici 
• Qual è il potenziale economico di un mercato della canapa interamente o parzialmente 
legalizzato per i produttori e i rivenditori svizzeri rispetto allo stato attuale? 
• Che cosa possono imparare le autorità di controllo dall’esperienza fatta con l’alcol e il 
tabacco per minimizzare la manipolazione del commercio legale di canapa da parte 
dell’industria?  
• Quali opzioni normative sono efficaci per ridurre il rischio della commercializzazione? 
• Quali sono i vantaggi e gli svantaggi di una proibizione assoluta di un mercato 
commerciale?  
• Quali conseguenze hanno i diversi approcci di regolamentazione sui risultati di equità 
e giustizia sociale? 
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• Come si può promuovere l'equità sociale fin dall'inizio? Che tipo di programmi 
dovrebbero essere sviluppati per sostenere l'inclusione di gruppi meno avvantaggiati e 
sproporzionatamente colpiti nell'industria? 
• Quali sono i costi globali per la società causati dalle diverse scelte di regolamentazione 
(proibizione, depenalizzazione, legalizzazione)? 
Implementazione delle politiche 
• Quali competenze normative devono essere situate a quale livello di autorità 
(nazionale, cantonale, municipale)? Quali sono i rischi e le opportunità di un 
approccio di governance a più livelli?  
• Come può essere migliorato il coordinamento tra cantoni al fine di facilitare 
l’armonizzazione dell’implementazione? 
• Come possono essere separati i disciplinamenti dell’uso di canapa medica e non medica 
in modo che siano di sostegno e non di ostacolo l’uno all’altro? 
• Come dovrebbero essere instaurati partenariati tra attori statali e privati 
nell’attuazione delle politiche (gruppi professionali, produttori, ecc.)? 
Produzione • Come dovrebbe essere concepita la regolamentazione della produzione di canapa per 
garantire la sicurezza e la qualità del prodotto e assicurare la sicurezza dei sistemi di 
produzione? 
• Quali sono gli effetti della legalizzazione della coltivazione in casa e in proprio di 
canapa? In che modo è praticabile la supervisione statale in un tale modello?  
• Quali sono le opzioni normative per testare i prodotti e valutare e supervisionare il 
processo di produzione? 
Lavorazione e 
distribuzione 
• Quali misure andrebbero prese per la lavorazione e la distribuzione di canapa? 
• Che tipo di limitazioni andrebbero implementate per quanto concerne la promozione? 
• Come dovrebbero essere regolamentati il confezionamento e l’etichettatura al fine di 
accordarsi con gli schemi di consumo locali e promuovere gli obiettivi di salute 
pubblica, così da consentire una promozione più efficiente degli obiettivi di salute 
pubblica? 
Commercio  • Come dovrebbe essere disciplinato un sistema di commercio in modo da soddisfare gli 
interessi della salute e della sicurezza pubbliche?  
• Quale impostazione della vendita farà più probabilmente abbandonare ai consumatori 
le loro consuete fonti (illegali) di rifornimento promuovendo gli effetti positivi di una 
nuova regolamentazione? 
• Quali restrizioni normative sulla vendita e l’acquisto sono efficaci dal punto di vista 
della salute pubblica (restrizioni di accesso e disponibilità, razionamento, acquisto solo 
fino a una determinata quantità, ecc.)? 
• Quali sono le opportunità e i rischi di diversi modelli di commercio/vendita (ad es. 
negozi vs online)? I punti vendita a gestione statale sono preferibili ai punti vendita 
commerciali in termini di salute pubblica? 
Consumo • Quali sono le evidenze relative all’efficacia, in termini di salute pubblica, del divieto di 
consumo di canapa negli spazi pubblici? 
• Quali sono i vantaggi e gli svantaggi di diverse restrizioni sul luogo del consumo 
dalla prospettiva della salute e della sicurezza pubbliche? 
• Come dovrebbero essere disciplinati e monitorati i luoghi in cui il consumo è 
ammesso? 
Determinazione
del prezzo / 
tassazione 
• In che modo la determinazione del prezzo e la tassazione influiscono sugli schemi di 
consumo (cambiamenti negli schemi di consumo, priorità locali, ecc.)? 
• Come può essere istituita una struttura equilibrata di determinazione del prezzo e di 
tassazione che assicuri la competitività rispetto al mercato illegale e nel contempo 
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garantisca un prezzo sufficientemente alto da limitare l'accesso dei giovani e ridurre il 
consumo? 
 
Priorizzazione nel contesto svizzero 
Il dibattito sulla canapa in Svizzera si concentra principalmente sugli approcci normativi adatti a 
minimizzare i rischi e massimizzare i benefici per la salute pubblica. All’interno del dibattito politico vi 
sono due punti di vista: il primo evidenzia che il consumo di canapa andrebbe evitato del tutto, e quindi 
sottoposto a un divieto assoluto, mentre il secondo accoglie con favore la valutazione di opzioni 
alternative, poiché il consumo di canapa è visto come una realtà sociale. Il cosiddetto «articolo 
sperimentale» per le sperimentazioni pilota alla fine è stato approvato dalla maggioranza del 
parlamento, con lo scopo di esaminare le questioni centrali della regolamentazione della canapa in 
modo obiettivo e aperto. Dal dibattito in Svizzera e dalle evidenze della ricerca internazionale si possono 
evincere quattro priorità generali per il futuro disciplinamento della canapa. Queste quattro priorità 
costituiscono anche le dimensioni di impatto nel modello logico.  
 
La prima priorità, la promozione della salute individuale e pubblica, si attiene agli obiettivi prefissati 
dalla legge federale sugli stupefacenti e sulle sostanze psicotrope (Lstup) e dalla relativa ordinanza 
(OSPStup). Le questioni prioritarie per la ricerca in questo campo riguardano la prevenzione delle 
dipendenze e del consumo ad alto rischio, la messa a disposizione dell’aiuto e del trattamento necessari 
alle persone a rischio, la riduzione dei danni per la salute e la società nonché la riduzione delle 
ripercussioni negative sulla società. Le evidenze solide su questa dimensione di impatto sono 
relativamente scarse poiché la legalizzazione in altri Paesi è recente, la trasposizione al contesto svizzero 
è difficile e la misurazione degli effetti sulla salute individuale e pubblica resta ardua. 
 
La seconda priorità è la promozione dell’ordine pubblico e la riduzione della criminalità. Benché non 
sia la motivazione primaria per riconsiderare l’attuale politica in materia di canapa in Svizzera, 
rimuovere l’attuale mercato illegale è un obiettivo ricorrente. In questo contesto, va prestata particolare 
attenzione a tre ambiti prioritari: la riduzione delle attività criminali, l’aumento dell’ordine e della 
sicurezza pubblici, nonché la sorveglianza, l’organizzazione della polizia e l’applicazione della legge. 
Parrebbe particolarmente importante che gli studi siano focalizzati sul lungo termine ed esplorino non 
solo il periodo che segue un intervento, ma anche lo stato attuale, al fine di poter fare paragoni 
significativi. 
 
La terza priorità è la protezione dei minori, poiché gli studi internazionali non forniscono prove chiare 
sulle conseguenze del consumo da parte di giovani e il consumo di canapa tra gli adolescenti svizzeri è 
particolarmente elevato. Inoltre il tema è al centro di discussioni accese nel dibattito politico. In Svizzera 
l’approccio attuale per assicurare una protezione efficace dei minori si basa sui tre pilastri seguenti: 
legislazione a protezione dei minori; promozione della salute dei giovani e prevenzione; aiuto alla 
gioventù. La futura ricerca sulle conseguenze di diversi approcci alla regolamentazione della canapa 
per queste tre aree tematiche è importante. 
 
La quarta e ultima priorità è l’aumento della prosperità e dell'equità. La legalizzazione dell’accesso alla 
canapa crea una nuova entrata fiscale e un’opportunità per una nuova industria, e l’esperienza fatta in 
altri Paesi dimostra che attori orientati al profitto diventano rapidamente influenti e vogliono esercitare 
un ascendente sul quadro normativo a proprio favore. Per questa ragione, sembrerebbe appropriato 
esplorare possibili alternative a un approccio commerciale, nonostante la tradizione liberale della 
Svizzera. Inoltre, hanno una particolare priorità le questioni della giustizia sociale e dell’equità, nonché 
del monitoraggio della catena di fornitura. 
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Sperimentazioni pilota con canapa 
La base legale per le future sperimentazioni pilota con la canapa è definita nell’OSPStup del 2021. Le 
sperimentazioni pilota devono fornire conoscenze in merito ai seguenti temi: la salute fisica e psichica 
dei consumatori nonché le prestazioni degli stessi; il comportamento legato al consumo; gli aspetti 
socioeconomici; il mercato della droga in un determinato territorio; la protezione della gioventù; 
l’ordine e la sicurezza pubblici (art. 2 cap. 2 OSPStup). Inoltre, le sperimentazioni pilota devono essere 
limitate sotto il profilo territoriale e temporale e vi sono indicazioni specifiche in merito alle sostanze da 
dispensare e ai partecipanti. L’UFSP è responsabile per l’autorizzazione ed esegue le funzioni di 
monitoraggio e controllo. Diversi team di ricerca nelle maggiori città svizzere stanno attualmente 
riflettendo approfonditamente sui design di ricerca per future sperimentazioni pilota. Vi sono 
considerazioni in merito al coordinamento della ricerca nel contesto dello sviluppo di un questionario 
comune per i partecipanti. I team di ricerca intendono lavorare con diversi tipi di dispensari (circoli 
sociali dedicati alla canapa, farmacie, chioschi, negozi di sigarette elettroniche) e in parte mostrarne le 
differenze. Vi è una certa variazione in relazione a quanto attivo dovrebbe essere il ruolo dei dispensari 
durante le sperimentazioni pilota. Le considerazioni dei team di ricerca finora riguardano 
prevalentemente gli aspetti della salute e sono incentrate sul consumo. Tuttavia, alcuni team affrontano 
anche gli aspetti socioeconomici e i possibili effetti sulla sicurezza pubblica nelle vicinanze dei 
dispensari. Inoltre esiste anche l’intenzione di investigare la determinazione del prezzo, gli effetti di 
diversi prodotti e il policonsumo di altre sostanze. 
 
Sulla base di considerazioni legate al modello logico e alle attuali riflessioni dei team di ricerca, sono 
stati elaborati possibili argomenti e domande di ricerca per future sperimentazioni pilota. Andrebbe 
considerata la vendita attraverso canali online, nel limite di quanto legalmente possibile, e studiato il 
suo effetto, poiché le esperienze fatte di recente in altri Paesi dimostrano che questo canale di vendita è 
in crescita. Al fine di studiare il mercato della droga in una determinata area o l’impatto sull’ordine e la 
sicurezza pubblici, città simili potrebbero essere paragonate e metodi statistici potrebbero aiutare a 
stimare gli effetti causali. Domande sul policonsumo di altre sostanze dovrebbero essere considerate 
nelle interviste o nei sondaggi rivolti ai partecipanti. Un metodo per ottenere evidenze immediate sulla 
protezione dei minori potrebbe essere quello di selezionare i partecipanti allo studio che convivono con 
minori e intervistare anch’essi direttamente. Ulteriori questioni da esaminare includono: in quale 
misura diversi formati e varianti dei prodotti hanno un impatto sulla salute dei partecipanti agli studi, 
quali caratteristiche dei prodotti sono particolarmente attrattive per i partecipanti e quali misure 
normative possono promuovere un consumo a rischio più basso. 
 
Ricerca supplementare e necessità di ricerche aggiuntive 
Alcune questioni importanti potranno difficilmente essere indagate nelle sperimentazioni pilota a causa 
dei requisiti legali e sono quindi più idonee per la ricerca supplementare. Attualmente, l’UFSP ha 
conferito quattro mandati a questo scopo e sta sostenendo finanziariamente un quinto progetto insieme 
ad altri partner. Uno studio di Sotomo sta analizzando l’accettazione generale delle misure normative e 
l’atteggiamento della popolazione votante nei confronti della canapa. Per conto di diverse istituzioni, 
l’Università di Ginevra sta esaminando in collaborazione con Rütter Soceco gli effetti economici della canapa. 
Al centro di questa ricerca vi sono questioni relative alle conseguenze economiche di diversi modelli di 
regolamentazione, al gettito fiscale potenziale e al potenziale economico di un mercato della canapa 
legale per produttori e rivenditori svizzeri. Lo studio recentemente pubblicato dall’Istituto di medicina 
legale (IRM) di Basilea mirava ad analizzare la letteratura sui limiti di THC nel traffico stradale e a 
sviluppare possibili scenari per l’adattamento delle norme stradali. La Scuola universitaria di scienze 
applicate di Zurigo (ZHAW) ha affrontato le questioni della coltivazione, della produzione e degli 
standard di prodotto che meglio proteggono i consumatori. Il mandato conferito a Dipendenze Svizzera 
riguarda un’analisi comparativa delle valutazioni delle diverse politiche di regolamentazione in altri 
Paesi, poiché molte di queste politiche attualmente sono ancora valutate in misura insufficiente. 
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Nel campo della lavorazione e della distribuzione sono necessarie ricerche aggiuntive sugli effetti delle 
diverse caratteristiche dei prodotti e delle confezioni sulle scelte dei consumatori. In questo contesto, la 
ricerca al di fuori del quadro delle sperimentazioni pilota può deviare dalle specifiche richieste per legge 
secondo la OSPStup. Ciò potrebbe permettere di acquisire ulteriori conoscenze. In rapporto al tema 
delle entrate e della tassazione, sorgono domande sulla distribuzione delle possibili entrate e su quale 
struttura di prezzo sia più sensata per una regolamentazione volta a promuovere la salute pubblica. 
Nell’area tematica dell’ordine e della sicurezza pubblici è stata identificata la necessità di ottenere 
conoscenze aggiuntive sul funzionamento del mercato illegale, che difficilmente potrà essere affrontato 
in modo esaustivo attraverso le sperimentazioni pilota. Inoltre sono necessarie ricerche aggiuntive sulle 
possibili regolamentazioni di diversi tipi di prodotto. Nel contesto della protezione dei giovani, si 
ravvisa un promettente approccio metodologico nei quasi-esperimenti relativi alle diverse forme di 
prodotto, ai messaggi di prevenzione, ai canali di comunicazione e la loro attrattività per i giovani. In 
aggiunta, le campagne di prevenzione basate sulle comunità o sulle famiglie, campagne che hanno 
dimostrato la loro efficacia, dovrebbero essere esaminate con maggiore attenzione in modo da 
determinare come possono essere rafforzate strutturalmente. È importante anche studiare come 
dovrebbero essere concepiti un controllo statale, enti di controllo e misure di controllo appropriati. La 
questione non è solo determinare chi dovrebbe concedere l’autorizzazione, ma anche se il divieto di 
un’attività simultanea nell’ambito della produzione, della fornitura e del commercio sia concludente. 
Oltre a ciò è necessaria la ricerca interdisciplinare sullo stato attuale al fine di poter valutare gli effetti 
delle diverse regolamentazioni che potrebbero essere adottate in futuro. Inoltre, vi è il bisogno di fare 
ricerca nell’area dell’implementazione delle politiche, poiché vi sono spesso discrepanze tra le politiche 
formali e la loro implementazione. È necessaria anche la ricerca comparativa sui vantaggi e gli svantaggi 
delle varie opzioni normative situabili tra la decriminalizzazione e la legalizzazione e sulla misura in 
cui provvedimenti strutturali possono incoraggiare scelte comportamentali informate e guidare i 
consumatori verso modalità d’uso meno problematiche. 
 
Coordinamento e finanziamento della ricerca 
Si possono distinguere tre modelli ideali di finanziamento e coordinamento della ricerca, che si 
differenziano in particolare nella misura in cui il contenuto della ricerca viene diretto. Il metodo di 
finanziamento politico è al servizio degli interessi del governo e mira a rispondere a questioni pratiche e 
a sviluppare soluzioni applicabili. Il metodo di finanziamento basato sulla scienza parte dalle domande di 
ricerca centrali per le varie discipline, è spesso distaccato dal dibattito legato alla legislazione e corre il 
rischio di sfociare in tentativi di ricerca incoerenti. Il metodo di finanziamento strategico, quale terzo 
modello ideale, persegue tutte le vie promettenti della ricerca negli ambiti rilevanti, affrontando non 
solo le questioni identificate dal mondo accademico, ma anche quelle relative alla prospettiva politica.  
Anche se la base legale esclude un metodo di finanziamento politico per le sperimentazioni pilota con 
la canapa, uno sguardo alle esperienze fatte con il coordinamento e il finanziamento in rapporto alla 
prescrizione medica di eroina aiuta a identificare i fattori di successo. In questo caso cantoni, comuni e 
organizzazioni private erano responsabili per l’implementazione delle sperimentazioni e il governo 
federale forniva le risorse finanziarie per la valutazione scientifica. Un gruppo di ricercatori fu incaricato 
di definire e implementare un piano di ricerca globale. Le sperimentazioni non furono approvate 
dall’UFSP finché non ci si impegnò a raccogliere dati utilizzando un questionario standardizzato 
comune distribuito ai partecipanti degli studi. 
 
Per le sperimentazioni pilota con la canapa, attualmente lo scenario del finanziamento della ricerca 
decentralizzato e dell’auto-coordinamento si sta delineando come una soluzione praticabile più 
realistica. Il governo federale valuta e approva progetti di ricerca e raccoglie i risultati, ma non svolge 
un ruolo attivo nella produzione o nel finanziamento della ricerca. In Svizzera vi sono diversi donatori 
possibili per finanziare un tale metodo di finanziamento basato sulla scienza. Il Fondo nazionale svizzero 
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per la ricerca scientifica (FNS) è certamente la più importante organizzazione indipendente per il 
finanziamento della ricerca. Oltre alla possibilità di presentare domande individuali per singoli progetti, 
vi sono i Poli di ricerca nazionali (PRN) per ricercatori affermati con programmi di ricerca a lungo 
termine, il programma Sinergia per la ricerca interdisciplinare da parte di diversi team di ricerca nonché 
vari strumenti per rendere possibile la collaborazione internazionale nella ricerca. Anche diverse 
fondazioni indipendenti forniscono un sostegno finanziario ai progetti scientifici. Inoltre, esistono fondi 
indipendenti nel settore del tabacco e dell’alcol che a loro volta sostengono la ricerca nel campo dell’uso 
di sostanze e delle dipendenze. Il potenziale conflitto di interessi è un problema noto in quest’area. 
L’indipendenza da possibili interessi industriali e la prevenzione dei conflitti d’interesse sono pertanto 
centrali per il futuro finanziamento della ricerca sulla canapa e possono essere rafforzate seguendo 
alcuni principi. È anche ipotizzabile un orientamento del coordinamento della ricerca ad opera dei 
ricercatori stessi verso i principi dell’Open Science, il che garantirebbe la trasparenza del processo di 
ricerca e la disponibilità pubblica dei dati, tra gli altri vantaggi. 
 
Alle condizioni date, è considerata realistica la possibilità di un maggiore coordinamento nella 
determinazione della dimensione di un’unità standard di canapa, nello sviluppo di un questionario di 
base comune per i partecipanti e nella creazione di una piattaforma comune per raggruppare e 
condividere i dati, sulla quale sono resi accessibili i dati e i risultati preliminari. Il coordinamento 
dipende fortemente da una comunità di ricerca strettamente connessa e al momento non si ritiene che 
uno studio multi-sito o multi-centro sia un’opzione realistica, ma un maggiore sostegno da parte 
dell’UFSP, che includa il finanziamento per il coordinamento della ricerca, potrebbe essere utile. Lo 
strumento più ovvio per un metodo di finanziamento strategico sarebbero i Programmi nazionali di 
ricerca (PNR) del FNS. I PNR sono un metodo di finanziamento strategico proprio in quanto promuovono 
esplicitamente la ricerca su una problematica specifica che il governo considera rilevante. Se opportuno, 




Sviluppo di una metodologia di ricerca condivisa 
1. Nella ricerca internazionale a volte viene usato un questionario di base standardizzato al quale 
possono essere aggiunti moduli facoltativi per prendere in esame le condizioni specifiche del Paese o 
della regione in questione. Analogamente, si raccomanda di sviluppare un questionario di base per la 
Svizzera con moduli supplementari che per esempio prendono maggiormente in considerazione la 
situazione del mercato della droga in una determinata area geografica. 
2. Anche se alcune sperimentazioni pilota sembrano usare domande e argomenti simili, una serie 
comune di domande con argomenti di base attualmente non esiste. Si raccomanda che l’UFSP 
contribuisca a una metodologia di ricerca condivisa sostenendo gli sforzi dei ricercatori volti a stilare 
un questionario comune o alcune domande di base concordate. 
3. Si raccomanda la determinazione della dimensione di un’unità standard di canapa, un questionario 
di base comune per i partecipanti agli studi e una piattaforma comune per raggruppare e condividere i 
dati come passi verso una metodologia di ricerca condivisa.  
 
Coordinamento dei progetti di ricerca (sperimentazioni pilota) 
4. Le sperimentazioni pilota con canapa saranno con ogni probabilità esposte a un intenso scrutinio da 
parte dell’opinione pubblica e dei media. Si raccomanda quindi che i ricercatori si coordinino per 
sviluppare una valida strategia di comunicazione pubblica e politica. 
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5. Oltre alle alternative discusse normalmente, ovvero la proibizione e il modello commerciale standard, 
in teoria esistono numerose vie di mezzo per la regolamentazione della canapa, che sono raramente 
messe in pratica. Si raccomanda pertanto che in Svizzera si svolga più ricerca su queste possibili vie di 
mezzo, che sono ancora poco indagate a livello internazionale e sembrano avere il potenziale per ridurre 
significativamente i costi di salute e sociali. 
6. Nel quadro delle sperimentazioni pilota, l’UFSP svolge varie funzioni ed è innanzitutto un organo di 
autorizzazione e di controllo. I conflitti di interesse sono inevitabili e si raccomanda perciò di chiarire il 
ruolo dell’UFSP al fine di sostenere meglio le future sperimentazioni pilota. 
 
Finanziamento della ricerca 
7. Un metodo di finanziamento basato sulla scienza o un metodo di finanziamento strategico tramite 
contributi del FNS potrebbero essere opzioni praticabili per il finanziamento della ricerca, mentre la 
base legale preclude il finanziamento diretto da parte del governo federale. Al fine di aumentare la 
possibilità delle domande di finanziamento, si raccomanda una maggiore cooperazione con esperti 
internazionali per identificare le lacune importanti nella ricerca e assicurare una rilevanza 
internazionale. 
8. I Fondi per la prevenzione dell’alcolismo e del tabagismo, con la loro impostazione organizzativa e 
finanziaria, rappresentano interessanti veicoli di finanziamento ai quali dovrebbero guardare i portatori 
di interessi che seguono la ricerca empirica a scopi legislativi. 
9. Per assicurare l’indipendenza della ricerca e la sua credibilità e per prevenire un’influenza 
inappropriata da parte dell’industria sulle attività di ricerca, i ricercatori dovrebbero aderire ad alcuni 
principi guida per evitare i conflitti di interesse nel finanziamento della ricerca in materia di canapa (ad 
es. nessuna influenza dell’industria sulle decisioni di finanziamento, libertà di pubblicare i risultati delle 
ricerche). 
10. Le fondazioni indipendenti potrebbero svolgere un ruolo fondamentale nel finanziamento degli 
studi pilota, a condizione che essi rispondano agli scopi delle fondazioni. Il coordinamento in questo 
ambito (ad es. un ufficio consultivo centrale per il finanziamento della ricerca sulla canapa) potrebbe 
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1 Introduction 
1.1 Background: Cannabis policy in Switzerland 
Cannabis is by far the most commonly used illegal drug worldwide (UNODC, United Nations Office 
on Drug and Crime 2018) as well as in Switzerland (Obsan 2019). In alignment with the international 
drug control conventions, most countries implemented national prohibition laws concerning the 
production, supply and use of cannabis (Rehm and Fischer 2015). Cannabis has been illegal in 
Switzerland since 1951. Today, Switzerland’s drug policy is still influenced by the so-called “four-
pillars-model”, which was established as a consequence of the drug-related crisis in the 1980s and 1990s. 
This period was marked by the spread of intravenous heroin use and the closely linked transmissions 
of infectious diseases, most notably HIV/AIDS. In addition to prevention, treatment and repression, harm 
reduction became an essential pillar of the Swiss approach. In the late 1990s, two popular initiatives were 
rejected, one of which was aimed towards a more restrictive drug policy (“Youth without drugs”), the 
other towards the legalization of all drugs (“Droleg”). Taking into account these developments and the 
increased use of cannabis among young people as well as the negative impacts of repression, the Federal 
Council proposed a revision of the Federal Law on Drugs to Parliament in 2001, which was rejected. In 
a later revision, the parliament decided to institutionalize harm reduction into law, without relaxing the 
repressive approach to any drugs. In 2008, this decision was confirmed in a referendum, whilst the 
voters opposed a popular initiative aiming to legalize cannabis. 
 
However, because of the increasing numbers of denunciations for cannabis use, a decriminalization of 
cannabis was discussed in parliament (Wenger et al. 2014). Since October 2013 and based on Article 19b 
of the Law on Narcotics, possessing up to 10 grams of the substance for consumption purposes is not 
considered a criminal offense anymore. Nevertheless, consumption is still illegal and a fine of 100 CHF 
can be charged (“Ordnungsbusse”). The administrative fines have created confusion and contributed to 
new problems (Zobel et al. 2019). In addition, in 2008 the legal regulation was specified with a limit of 
one percent tetrahydrocannabinol (THC) (BetmVV-EDI SR 812.121.11). This led to the emergence of a 
new “legal” cannabis market since 2016, selling products with low doses of THC but high levels of 
cannabidiol (CBD). Even though the initially fast-growing trend around the new CBD market has 
levelled off again, it has put forward new commercial actors and fueled new discussions. Furthermore, 
the current situation of requiring a special permit by the Federal Office of Public Health (FOPH) for the 
medical use of cannabis has been criticized (Brunner and Kübler 2019). There is a broad political 
consensus that access to medical cannabis should be facilitated, and revisions have been passed by the 
parliament accordingly. 
 
Alternative cannabis regulation models to prohibition are discussed and have been introduced in different 
countries, thereby challenging the international treaties on drug enforcement. Many countries now allow 
not only the use of medicinal cannabis, some US-states (since 2012), Uruguay (2013), as well as Canada 
(2018) have also legalized cannabis for recreational use (Hall et al. 2019). Consequently, those 
developments have fueled the discussions about cannabis regulation in many other countries. Regulatory 
choices for non-medical cannabis use vary widely, and there are still many open questions with respect to 
the impact of cannabis legalization not only for individual users, but also for communities and the wider 
society. There is thus a need for scientific evidence on the existing policy options and their consequences. 
This need is not only felt internationally, but also in Switzerland, where the debate about how and what 
to learn from other experiences started in the last decade. Whereas some political actors have welcomed 
efforts to rethink the current policy and have pointed out the positive aspects of cannabis regulation, such 
as decriminalization of consumers, harm reduction, quality control of the substances as well as the 
collection of taxes, opponents have raised concerns regarding the protection of minors and the 
maintenance of public order. Consequently, several local initiatives, in particular in urban areas, started 
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to develop plans for local pilot trials for cannabis regulation, criticizing the limits and inconsistencies of 
the current situation. After the first project request by the City of Bern was rejected by the Federal Office 
of Public Health (FOPH) in 2017 due to lack of legal basis, political action by the parliament was sparked 
and a public consultation was launched. This process lead to the establishment of a so-called 
"experimentation article“ in the Federal Act on Narcotics and Psychotropic Substances (NarcA), allowing 
pilot trials with cannabis during a period of ten years after adoption of the article (Art. 8a) . The term “pilot” 
refers to the experimental legislation rather than the form of the trials.  
 
The regulation of cannabis in Switzerland would mean a change of paradigm. The recent amendment 
of the NarcA entails the possibility for third parties, e.g. cantons, municipalities or universities, to 
conduct pilot trials with cannabis in order to gather more evidence-based knowledge about the 
possibilities and limitations of a regularized cannabis market. In order to build a solid foundation for 
future decision-making, and eventually a reorientation of the Swiss cannabis policy, these projects need 
to be coordinated accordingly (BBI 2019: 2556). The current legal framework states that the pilot trials 
should focus on “non-medical” use of cannabis, and generate findings on the consequences of different 
measures, instruments and approaches in the field of cannabis. Further specifics were defined in the 
Federal Council’s ordinance on the pilot trials regarding the requirements (local and temporal 
restrictions, target groups and participation, cultivation standards, product quality and safety, etc.), the 
procedure (submission of requests, authorization, etc.) as well as the implementation. The pilot trials 
should build on prior international experience with the regulation of cannabis and should speak to the 
objectives formulated in the National Strategy on Addiction 2017-2024 1  (BBI 2019: 2534). The 
implementation of this strategy includes the priorities of early detection, needs-oriented treatment, 
counselling and harm reduction as well as coordination.  
1.2 Mandate and aim  
In parallel to the preparation of the legislative framework for the pilot trials for non-medical cannabis 
use, the FOPH started the development of a research agenda for the generation of scientific evidence, 
during the ten-year period defined by the experimentation article (2021-2031), needed for decision-
making on a potential re-orientation of cannabis legislation after the experimental period. On the 
14th of July 2020, the FOPH sent out invitations to a variety of scientists, and finally mandated Prof. 
Daniel Kübler and his team from the Department of Political Science at the University of Zurich (IPZ) 
to formulate a research agenda suitable to guide the elaboration of relevant scientific evidence on the 
topic of cannabis regulation. Coordination of the contents of the different pilot trials as well as the 
research methodology is considered necessary in order to obtain a clear picture of the possibilities and 
constraints of a regulated access to cannabis. As agreed with the FOPH, the specific aims 2 of this 
mandate were to elaborate a report that  
1. identifies the relevant research questions on the topic of cannabis regulation; 
2. suggests an order of priority for these questions according to their relevance for policy-making; 
3. clarifies which of these questions can be studied in the context of future pilot trials for non-
medical cannabis use; 
4. lists those questions that need to be studied through additional research;  
5. formulates recommendations regarding measures of overall research integration, coordination 
and funding.  
 
 
1 An overview document is available online under https://www.bag.admin.ch/bag/en/home/strategie-und-politik/nationale-
gesundheitsstrategien/strategie-sucht.html 
2 Cf. Bundesamt für Gesundheit (2020), Pflichtenheft: Forschungskonzept Cannbisregulierung und Pilotversuche mit Cannabis, Bern: 
Bundesamt für Gesundheit; D. Kübler (2020) Forschungskonzept Cannbisregulierung und Pilotversuche mit Cannabius. Offerte zur 
Ausschreibung des Bundesamtes für Gesundheit vom 14.7.2020, Zürich: Institut für Politikwissenschaft.  
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In view of the upcoming pilot trials in various Swiss cities, the aim of this report is to provide a 
systematic basis that can be used by the federal government or the FOPH for the coordination of the 
upcoming pilot trials, as well as the awarding of contracts within the framework of departmental 
research or any further research projects in the field of cannabis. Coordination of the contents of the 
different pilot trials as well as the research methodology is considered desirable in order to obtain a 
clear picture of the possibilities and constraints of a regulated access to cannabis. The interested parties 
(cities and cantons) already signaled that they would welcome coordinative support by the federal 
government. The federal government plans to coordinate the various research projects within the 
framework of the pilot phase in order to ensure that an appropriate scientific basis for decision-making 
is created for a possible reorientation of cannabis policy to be submitted to parliament. Coordinating 
the content and methodology of the research efforts is one aspect of this goal. 
 
1.3 Structure of this report 
The structure of this report follows our mandate. The next chapter shortly explains our methodological 
approach, which is based mainly on a structured search for relevant reviews in order to gain an 
understanding of existing research and relevant debates as well as on discussions with national and 
international experts. In the third chapter, the research agenda will be discussed by setting the 
framework and defining the overarching question. Based on the international literature the most 
important research fields to the particular topic of cannabis regulation will be determined, which will 
be summarized in a logic model. Chapter four is dedicated to a prioritization of relevant research 
questions in the Swiss context. In chapter five we discuss the legal framework of the pilot trials, present 
ongoing reflections by several research teams and point to questions to potentially be incorporated in 
future pilot trials. In chapter six, research questions for supplementary investigations are presented. 
Chapter seven focuses on questions regarding the coordination of the different research endeavors and 
funding. Lastly, we conclude by summarizing the main points and formulating recommendations. 
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2 Method 
For the development of the research agenda, we draw on four major sources of information.  
 
First, in order to gain an understanding of existing research and relevant debates to the particular topic 
of cannabis regulation, we take into account the most recent research and literature on the consequences 
of cannabis legalization in other countries as well as specific literature on cannabis policy in Switzerland. 
Because of the fast growing field, we rely primarily on meta-analyses such as systematic literature 
reviews, other reviews, and policy papers that address the implications of cannabis legalization from a 
public health perspective. More precisely, we searched the database “Web of Science” using search 
terms including ‘cannabis’ as well as ‘legalization’ or ‘regulation‘ and ‘public health’ (and synonyms). 
The search was limited to reviews published in the last 5 years (i.e. 2017-2021) to cover current research 
questions, and was restricted to English language publications. A total of 156 records were identified. 
After screening of the titles we removed 104 records not directly relevant for the purpose of this report 
(e.g. papers on medical cannabis etc.). While reading the abstract we also excluded papers examining 
only the medical consequences of cannabis consumption with no reference to policy choices. We finally 
included 36 reviews.  
 
Additionally, we consulted further studies such as the systematic literature review by Darnell (2020), 
produced on behalf of the French Monitoring Centre for Drugs and Drug Addiction (OFDT), as well as 
the recently published anthology on international experiences related to the legalization of cannabis 
(Decorte et al. 2020). Furthermore, we considered policy papers that highlight the design considerations 
and policy decisions surrounding the question of cannabis regulation. For instance, we consulted the 
final report of the Canadian Task Force on Cannabis Legalization and Regulation that recommended to 
take a public health approach (Canada. Task Force on Cannabis Legalization and Regulation 2016) as 
well as reports by the RAND corporation (Caulkins et al. 2015) and by the Canadian Centre on 
Substance Abuse (2015) summarizing the “lessons learned” from experience in US states. In addition, 
we take into account papers summarizing learnings and recommendations for cannabis regulation from 
alcohol and tobacco control (Haden & Emerson 2014; Ghosh et al. 2016). Lastly, we draw on recent 
publications on cannabis in Switzerland to identify the most relevant research questions for the Swiss 
context (Zobel et al. 2019; Herzig et al. 2019; Pütz 2016; Philbert et al. 2019; Brunner and Kübler 2019). 
 
Second, in order to avoid blind spots and missing important issues from only reviewing the literature, 
an advisory board was set up (see Table 1). Switzerland-based experts from various disciplinary 
backgrounds were invited in collaboration with the FOPH. More precisely, the advisory board included 
experts involved in the planning of cannabis pilot trials, as well as experts working in other functions 
related to cannabis policy in Switzerland. The advisory board convened in a virtual meeting in 
December 2020, which not only allowed an exchange of information on the current state of the pilot 
trials and their research agenda, but also to discuss research topics and questions that are of overarching 
interest and significance to researchers in Switzerland (see Appendix). Finally, all members of the 
advisory group were invited to comment on the first draft of this report in early March and the revised 
version in April 2021.  
 
Method A Research Agenda for the Regulation of Non-Medical Cannabis Use in Switzerland 
Page 53 
Table 1: Members of the Advisory Board 
Title Name Institution 
Prof. lic. phil. Irene Abderhalden FHNW School of Social Work, Institute for Social Work and Health 
Prof. Dr. Reto Auer  University of Bern, Institute of Primary Health Care (BIHAM) 
Prof. Dr. med. Barbara Broers University of Geneva, Swiss Society for Cannabis in Medicine 
Prof. Dr. Sandro Cattacin University of Geneva, Department of Sociology 
Dr. Florian Elliker University of St.Gallen, Seminar of Sociology 
Prof. Dr. Jean- François Etter University of Geneva, Institute of Global Health, Division of Cancer 
Epidemiology and Prevention  
Julia Joos City of Bern 
Dr. Céline Mavrot University of Bern, KPM Center for Public Management 
Dr. Carlos Nordt Psychiatric University Clinic Zurich (PUK) 
 Andres Oehler City of Zurich 
 Niklaus Reichle University of St.Gallen, Seminar of Sociology 
Prof. Dr. Michael Schaub University of Zurich, Swiss Research Institute of Public Health and 
Addiction 
Dr. Christian Schneider Independent expert 
Prof. Dr. Marc Walter University Psychiatric Clinics (UPK), Center for Addictive Disorders,  
Prof. Dr. Gerhard Wiesbeck University Psychiatric Clinics (UPK), Center for Addictive Disorders  
Frank Zobel Addiction Switzerland 
Prof. Dr. Daniele Zullino Geneva University Hospitals, Department of Psychiatry, Addiction 
Division 
 
Third, facilitated by the FOPH, we established a collaboration with the Canadian Centre on Substance Use 
and Addiction (CCSA) in order to gain insight on the state of the art in the international scientific debate 
on cannabis regulation. With Rebecca Jesseman from CCSA we co-convened a workshop with 
international experts in the field of cannabis research. Entitled "Cannabis research in times of 
legalization: What's on the agenda?", the workshop was held online on February 8, 2021 with the aim 
of compiling findings, identifying research gaps, and establishing an international cannabis research 
network (see Appendix). The workshop also led to the elaboration of a paper with the same title, which 
will be published in the CCSA series later this year. 
 
Finally, we had additional meetings and exchanges with individual experts in Switzerland. 
Supplementary interviews were conducted with those responsible for the planned pilot trials. In 
addition, we were able to participate in meetings of the interurban working group on cannabis on 
December 17, 2020, and to exchange information with Swiss cannabis experts in the context of meetings 
with the advisory board. Lastly, a first draft of this report was presented to and discussed with members 
of the Federal Commission for Questions on Addiction and Prevention of Noncommunicable Diseases 
(EKSN) at its meeting on March 4, 2021, as well as to interested members of the Swiss School of Public 
Health (SSPH+) network on March 19, 2021, in order to validate the content and the key messages of the 
report.  
 
We thank the members of our advisory board, as well as all other experts for their numerous and 
valuable comments and remarks we received during the exchanges and processes outlined above. While 
we have revised the final version of this report in light of all these comments, the final responsibility for 
the content of this report is ours.  
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3 Research Agenda 
3.1 Overarching question for a new approach to regulate non-medical use of cannabis 
Currently, different models of cannabis regulation exist ranging from strict prohibition to a commercial 
market with little regulation, each with its advantages and drawbacks (Fischer et al. 2020b). The 
available legal and political models of regulating the production, supply and use of cannabis can be 
described as a spectrum with differing levels of government intervention (see Figure 1). Under 
prohibition, cannabis is illegal, all activities from production to consumption are forbidden, and 
repressive measures are in place. Criminal law and enforcement by the police and justice system are 
essential within most cannabis policies. In many countries, the impact of being convicted for cannabis 
possession or consumption has ramifications such as the stigma of arrest. Therefore, the prohibitive 
model has been criticized to fail harm reduction goals. Furthermore, “experts have long argued that 
enforcement has not succeeded in deterring cannabis use, while the health and social harms that result 
from such a regulatory approach are disproportionately high relative to the health risks of cannabis use, 
especially given that cannabis use is common in industrialized countries” (Lake et al. 2019). In order to 
reduce the risk of individuals of having a criminal record, decriminalization refers to the removal of 
criminal sanctions for some offences, such as simple possession for personal use, and replacing them 
with sanctions such as fines, as currently it is the status-quo in Switzerland. Therefore, the illegality of 
cannabis remains in place, and criminal organizations continue to play a leading role. The Dutch model 
tolerates the sale and possession of cannabis in small amounts, without allowing for its production, and 
Spain’s model is characterized by non-profit cannabis social clubs. 
 
Figure 1: Spectrum of policy options available 
 
Source: Canada. Task Force on Cannabis Legalization and Regulation 2016: 12.3 
 
In contrast, within a legal regulation framework, profits should be kept out of the hands of criminals, 
eventually displacing the illegal market. A strictly regulated market aims at keeping control of the 
whole supply chain, and thus at regulating all aspects of cannabis production and the availability of 
products (Decorte 2018). This was the main objective in Uruguay, which was grappling with the 
problem of gangs and drug-related violence. The first country to introduce a nationally regulated 
 
 
3 First published in: lles, S. & Murkin, G. (2016) How To Regulate Cannabis: A Practical Guide. 2nd ed. Transform Drug Policy 
Foundation, page 28–29. Available from: www.tdpf.org.uk/resources/publications/how-regulate-cannabis-practical-guide. Adapted 
from an original concept by John Marks. [Marks, J. The Paradox of Prohibition in “Controlled Availability: Wisdom or Disaster?”; 
National Drug and Alcohol Research Centre, University of New South Wales; p. 7–10. 1990.] 
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market for non-medical use of cannabis offers consumers three methods of accessing cannabis: home 
growing, cannabis social clubs, and buying from pharmacies. In Canada the idea was important that 
public interest is best served if the regulatory regime is designed to maximize health and social welfare 
by facilitating lower-risk consumption and reducing illegal market activity. Finally, the various US-
states in which marijuana is legal are an example of a liberal commercial approach. 
 
According to the theoretical model displayed in Figure 1, at both extremes of the spectrum – prohibition 
with a thriving illicit market as well as a free market – social and health harms are the highest. Whereas 
unconditional commercial promotion is expected to increase consumption, an ultra-prohibition 
approach on the opposite causes harms for users by uncontrolled products and stigmatization. 
Therefore, the model theorizes that the costs on the prohibitive side can be decreased if consumption is 
decriminalized, and on the legal side if the market is strictly regulated. Thereby, the vast evidence from 
related policy areas, in particular tobacco and alcohol, offer inspiration and guidance for policy-makers 
to re-evaluate their cannabis policies (Decorte 2018). In some countries, tobacco and alcohol have 
traditionally been heavily marketed but are now increasingly restricted according to public health 
principles. At the same time, other countries moved from strictly controlling these popular, yet 
potentially harmful and addictive substances to making them widely available. Consequently, at the 
bottom of the curve lies the point where public policy goals are most likely to be achieved (Canada. 
Task Force on Cannabis Legalization and Regulation 2016: 11). Seeking a balance according to public 
health principles would allow to control and manage the individual as well as societal use of cannabis, 
which is not possible under the current prohibition. Furthermore, concerns over insecurity and public 
safety can be tackled by depriving organized crime groups of control of the cannabis market. Therefore, 
the supply- as well as the demand-side of cannabis use could be controlled. While clear in theory, in 
practice the following overarching question arises:  
 
Under which regulatory conditions can the social and health costs of cannabis consumption be 
effectively minimized? 
 
Even though scientific evidence has accumulated over the past years, we still lack comprehensive 
research in many areas and evidence is often incomplete or inconclusive (Fischer et al. 2020b). On the 
one hand, it is difficult to transfer experiences from one national context to another because of the 
different social, cultural and political circumstances, on the other, solid knowledge about the point of 
departure is often missing although it would be necessary in order to contrast different approaches. The 
main objective of research endeavors thus is to generate more knowledge about how different 
regulatory measures can minimize negative impacts on health and reduce consequential social costs. In 
Switzerland, a public health perspective has been at the forefront of the debate. Therefore, the regulatory 
models which occupy the middle ground on the spectrum, ranging from decriminalization to strict legal 
regulation, are of particular interest.  
 
3.2 Defining the most important research fields  
There are different regulatory options aiming at an effective cannabis policy by a) minimizing social 
and health harms of use, b) improving public safety and order; and c) establishing a safe and responsible 
supply chain. Regulation options based on those principles should enable cannabis to be regulated in a 
responsible and controlled way. Those three fields will be explained in more detail in the following 
sections, in which we review the current literature in order to determine the most important fields for 
research and to identify research gaps. Since our compilation is based on systematic reviews, it contains 
the best explored topics, and is far from complete. We are aware that it is not possible to make an 
absolutely clear distinction between the three research fields discussed below and the respective 
research questions in each field. Moreover, it is also in the eye of the beholder to what extent a research 
question can be classified under one or to the other research field. 
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Some overarching questions that play into all three research areas provide a rough guiding framework 
for further discussion in the sections that follow. These fundamental questions are: 
 
• What are the effects of legally regulating vs. decriminalizing the production, possession, sale 
and consumption of cannabis on public health and security? 
• To what extent do different gradations of cannabis legalization reduce the social costs of 
prohibition?  
• What are the advantages and disadvantages of small-scale decriminalization vs. large scale 
regulated market options? 
 
 Minimizing health and social harms of use 
The fear of health harms and negative social consequences of cannabis legalization, especially a 
potential increase in use and the impact on health, is at the forefront of not only the public debate, but 
also many scientific studies (Mokwena 2019). According to the research literature, cannabis use is 
considered a risk factor for many medical conditions and harms, including mental health, somatic harm 
and physical injury (Campeny et al. 2020), with specific communities at higher risk (Hasin et al. 2019). 
Studies in US states emphasize several health implications after legalization and find an increases in the 
number and rates of cannabis-related visits at emergency departments (Bahji and Stephenson 2019). 
While some users consume cannabis without harm, others experience adverse effects (Carliner et al. 
2017). Research about the question of how the legalization of cannabis affects consumption behavior is 
still new and studies have come to mixed results (Smart and Pacula 2019). Adult use appears to be 
increasing, however, there is no clear evidence on the impact on heavy users (Caulkins 2019). Especially 
in the long run, cannabis consumption is expected to increase after commercialization and as it becomes 
more socially acceptable (Carliner et al. 2017; Hall et al. 2019). Borodovsky and Budney (2018: 194) find 
“that those with mental disorders are negatively and disproportionately impacted by cannabis use, and 
are decidedly vulnerable to poorly regulated for-profit industries that market addictive substances such 
as cannabis”. Several studies examine thus the risks related to cannabis use, such as developing a 
cannabis use disorder, cannabis abuse or cannabis dependence (Leung et al. 2020). An expansion of 
treatment for problematic use, such as motivational, cognitive behavioral therapy, and contingency 
management (Sahlem et al. 2018) as well as computerized interventions (Olmos et al. 2018) to reduce 
the frequency of cannabis use is therefore essential. Furthermore, measures in the field of harm 
reduction could be applied and explored as well, for instance vaping cannabis instead of smoking 
(Zobel et al. 2019). However, research in this area is still in its early stages and more evidence is needed 
to guide policy-making. 
 
Sahlem et al. (2018) emphasize the increased need for effective prevention and intervention programs, 
particularly targeting adolescents, after legalization. Experience from other countries has shown that 
“legalization has created a cannabis industry with an interest in promoting regular cannabis use” (Hall 
et al. 2019: 1580). Because of the subsequent potentially undesirable effects, research on how to facilitate 
lower-risk consumption while minimizing harmful consumption is key from a public health 
perspective. Long-term objectives of cannabis policies often entail decreasing the prevalence of 
problematic cannabis consumption as well as the postponement of initial cannabis use (Decorte 2018). 
However, concrete measures and possible mechanisms on how to achieve these objectives are still 
unclear. What is more, as cannabis legalization is still quite young, long-term public health effects have 
yet to be assessed. Structural restrictions on access (locations, opening hours, etc.) or limiting the 
presence of cannabis and its advertising in public spaces have been implemented as form of prevention. 
Other approaches include regulating the different cannabis products, the weight of cannabis as well as 
THC potency (Borodovsky and Budney 2018). Shover and Humphreys (2019: 698) for instance find that 
“capping potency of cannabis products can reduce the harms of the drug, including addiction”. 
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However, research on the effectiveness of purchase restrictions or on how to nudge consumers to less 
harmful modes of use is still lacking. Here, the literature on tobacco and alcohol control (nudging 
towards e-cigarettes, ban on sales towards minors, etc.) could give valuable insights. However, it 
remains open to what extent the findings can be transferred4. 
 
Information about the risks linked to cannabis use, however, is a crucial aspect. According to the 
review by Hall et al. (2019), measures focusing on health education for cannabis users might reduce 
associated harms. Consequently, training salespeople regarding public health considerations becomes 
critical (see Lenton 2020), especially since the commercial sale of cannabis has led to increasing diversity 
and potency of cannabis products (Matheson and Le Foll 2020). Additionally, research on labeling 
including health warnings and harm reduction advice becomes important. Research evidence indicates 
that informed behavioral choices among users might reduce the risk of adverse health outcomes of 
cannabis use substantially, whereby “Lower-Risk Cannabis Use Guidelines” might offer a potentially 
valuable tool (Fischer et al. 2017). Our literature search did not yield any review focusing on large-scale 
and mass-reach public cannabis prevention campaigns. According to Ghosh et al. (2016: 24), Colorado 
has introduced prevention messaging campaigns since “they are one of the few evidence-based 
interventions shown to increase awareness of harms and reduce marijuana use at the population level 
when integrated with community-, school-, and family-based prevention efforts”, which still need to be 
evaluated. Furthermore, existing evidence suggests that disseminating anti-drug messages during 
public-service announcements may have a limited impact (Werb et al. 2011). Large anti-cannabis 
campaigns might even have the potential to unintentionally stimulate interest in cannabis (Haden & 
Emerson 2014). However, compared to other measures, the impact and efficacy of such large-scale 
campaigns is difficult to measure.  
 
To protect minors from the negative effects of cannabis use is seen as one of the most important 
objectives of drug policies. Particularly research evidence about the association of adolescent cannabis 
use and neurological changes (Blest-Hopley et al. 2020) warrants further considerations for regulatory 
choices. There is little and somewhat contradictory evidence on the effects of legalizing cannabis on 
youth use. It can be assumed that minors would profit indirectly5 from regulation even though they are 
being a priori excluded. The few available results indicate that there is no increase in cannabis use 
among adults younger than 21 years, although they report a lower perceived level of risk stemming 
from cannabis after legalization (Hasin 2018; Dilley et al. 2019). In contrast, results of another recently 
published meta-analysis suggest that legalization of cannabis for non-medical purposes leads to a small 
increase in use among adolescents (Melchior et al. 2019). Therefore, prevention campaigns (e.g. 
television, print media, social media, online games, etc.) have been introduced for instance in Canada 
as well as the US to educate consumers, especially the youth, and parents about the risks of cannabis 
use (Lancione et al. 2020). Depending on how prevention programs are designed, they can be more or 
less conducive to prevent use in minors. Campaigns that only increase participants' knowledge do not 
reduce consumption, while more targeted family prevention strategies and family-based prevention 
programs might be more effective (Faggiano et al. 2014). Additionally, peer interventions are found to 
be a useful approach in preventing substance use (Georgie et al. 2016). Enforcing minimum ages is seen 
as critical, especially because earlier cannabis use is generally associated with higher risk for mental 
illnesses (Hosseini and Oremus 2019). Also, experiences from alcohol and tobacco have found a 
minimum purchase age to be important (Haden & Emerson 2014). In the US states, legal age of cannabis 
possession is mostly consistent with legal drinking age (Lancione et al. 2020). In Canada, a minimum 
 
 
4 This would be in line with the demand that cannabis prevention should be carried out in conjunction with the prevention efforts on 
other substances (see also FOPH 2019). 
5 This would be similar to the experience with alcohol: minors are also not allowed to purchase it, but still get products from the legal 
market, where they are controlled, rather than from the illicit market, where quality standards might be low. 
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age of 18 was adopted, allowing provinces and territories to raise the age if desired (DeVillaer 2019). 
Furthermore, several measures should limit child exposure, such as the prohibition of cannabis use in 
indoor spaces or the sealing of cannabis containers (Lancione et al. 2020). However, the topic of 
protecting minors also include additional considerations on passive smoking, safe packaging, etc. 
 
According to available data, long-term effects of cannabis exposure during pregnancy are unclear. 
However, cannabis use in pregnant women is relatively persistent despite awareness about potential 
risks (Bahji and Stephenson 2019). Therefore, future research should focus on the efficacy of educational 
programs for pregnant women about cannabis use and appropriate recommendations for decision 
makers (Ahmed et al. 2019). Furthermore, sex and gender related factors (hormones, anatomy, roles, 
identity, etc.) need to be analyzed in the light of current trends (Hemsing and Greaves 2020). Since these 
factors influence recreational cannabis use, Greaves and Hemsing (2020) point out that gender 
principles should be integrated in prevention campaigns (Hemsing and Greaves 2020; Greaves and 
Hemsing 2020).  
 
As research shows, a huge variety of cannabis products are consumed in a legal market (e.g. dry flowers, 
extracts of cannabis resin, oils, edibles, etc.). Thus, the quality of cannabis has become a major concern 
for consumer safety, which is why standards and quality controls regarding contaminants (pesticides, 
pathogens, toxins, molds, etc.) need to be defined and controls need to be implemented. Areas of 
concern are possible restrictions on product types or formats, as well as levels of THC or other 
cannabinoids, especially regarding the potency and purity. Furthermore, questions of effective safety 
or security protocols arise. Based on their review, Matheson and Le Foll (2020) suggest to minimize 
acute harms implementing an early introduction of restrictions on edibles and high-potency products. 
Charlebois et al. (2020) show how Canadians have different concerns regarding edibles and carry doubts 
regarding the safety of cannabis-infused food products, especially towards children and pets. 
Preventative safety measures and best practices with regard to edible cannabis products are crucial to 
protect public health (Soroosh et al. 2020), especially when “edibles and beverages continue to win over 
market share from dried flower, which is the traditional form of cannabis consumed through smoking 
or vaporizing” (Blake and Nahtigal 2019: 25). Controlling the production of cannabis and its quality, 
and ensuring its traceability, is crucial to minimize harms.  
 
Lastly, according to Hall et al. (2019) the effect of cannabis legalization on alcohol use will be a major 
determinant of its public health impacts. Unfortunately, the current literature is still unclear on the 
outcome and thus on whether cannabis could substitute alcohol use or whether co-use becomes more 
prevalent (Hall et al. 2019: 1586). The same applies to the co-use of other substances such as tobacco, 
opioids, etc. (Schlienz and Lee 2018). Therefore, besides cannabis use trends, also other substance use 
trends need to be monitored. What is more, consumption patterns in European countries show that 
cannabis is often consumed with tobacco in a joint. Nevertheless, the synergistic effect of nicotine in the 
development and maintenance of cannabis dependence has been largely neglected in European research 
so far (Pirona et al. 2015). 
 
To sum up, there is hardly any area of research which does not demand further investigation. In general, 
it should be noted that current research evidence focuses mainly on prevention efforts and less on harm 
reduction and the question of how to maximize the potential benefits associated with the use of cannabis. 
Furthermore, future regulations need to take into account existing market structures and consumption 
patterns in order to be effective. There is a considerable number of users who consume cannabis in non-
problematic ways. Table 2 displays the most important open research questions in the field of 
minimizing health and social harms, which can be derived from the current state of scientific research 
and the experiences from other countries.  
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Physical and mental health  
• How do the different regulatory models affect the physical and mental health of 
consumers? 
• How can the overall costs of and the demand for cannabis use be decreased? 
• How can individuals with at-risk and addictive consumption be detected through 
regulated access to cannabis? 
• What regulatory choices can be expected to have positive health effects for large parts of 
consumers? 
Consumption behavior:  
• What are the effects of different regulatory options on consumption behavior (intensity, 
prevalence, and incidence)? 
• How can regulatory measures (e.g. opening hours, locations) be designed in order to a) 
strengthen prevention efforts and b) facilitate low-risk consumption while minimizing 
harmful consumption? 
• What are the effects of different retail/sales models? 
Life quality & harm reduction: 
• How can regulatory measures support users’ strategies of consuming cannabis in non-
problematic ways and of integrating this use in their everyday life? 
• What structural measures encourage informed behavioral choice and enhance the 
consumption competences of users? What provisions regarding “safer use guidelines” 
are appropriate? 
• To what extent are harm reduction measures effectively implemented within the 
different regulatory frameworks?  
• How can a regulated cannabis market enhance health literacy of cannabis consumers 
and prevent problematic use (information through labelling, sales counselling, and 
public campaigns)? 
• How can the quality of life and social integration of addicted individuals be enhanced 





• What regulatory measures strengthen prevention efforts without pushing consumers 
into the illicit market?  
• What regulatory measures promote screening of and early intervention with vulnerable 
consumers (e.g. administrative measures for youth consumers)? 
• How can sex and gender related factors be integrated into regulatory frameworks? 
Protection 
of minors 
• What regulatory measures are important to effectively protect minors (including 
structural prevention measures) and therefore impede early initiation of use? 
• How should prevention campaigns be designed to reduce (especially high-risk) 
consumption among young people and possibly facilitate low-risk consumption for 
young adults (e.g. graduated potency levels for different age groups)? 
• What are the effects of legalization on young people’s attitude towards cannabis, their 
perception of risks associated with cannabis use, and their probability to initiate use 
(early)? Does legal access foster normalization of cannabis use?  




• What legal standards and quality controls regarding contaminants should be 
introduced (e.g. pesticides, contaminants)? 
• How can the supply chain be monitored in ways that minimize health risks and social 
harms? 
• Can access to different cannabis products be regulated gradually according to the 
products’ potential for harm and/or their different target groups? 





• Should the simultaneous sale and purchase of cannabis and alcohol be prohibited? 
• How can simultaneous use of cannabis and tobacco be reduced, and transition from 
cannabis to tobacco be prevented? 
• How should regulatory measures be designed in order to enable monitoring the 
production of cannabis and its quality, and ensuring its traceability? 
• How does regulated access to cannabis affect the co-use of other substances? 
 
 
 Improving public safety and order 
There is widespread uncertainty regarding the potential benefits and harms of a non-prohibition-based 
regulatory framework for cannabis, whereas the improvement of public safety and order are important 
topics. The costs associated with controlling cannabis use and supply largely stem from high levels of 
recourse expenditures for police and the justice system, while the dissuasive effect of law enforcement 
is very limited. Therefore, the question arises how police activity can be incorporated into preventive, 
harm reducing and therapeutic measures. Future regulatory endeavors should minimize the negative 
consequences of criminalization or prohibition. Costs in this area include associated criminal activities 
and personal costs of a criminal conviction, risks of further criminal involvement as well as the 
opportunity for harder drug use provided by overlapping illegal markets.  
 
A decriminalization approach, for instance allowing self-supply and low-level acquisition, would entail 
fewer of these costs compared to the existing larger-scale illicit drug market. Regularization policies aim 
to enforce public order and eventually remove organized crime from cannabis supply and to protect 
public health by regulating the supply side. Even though a legal and accessible cannabis market should 
eventually eliminate the illegal market, illicit activities related to cannabis might still exist, such as 
selling cannabis to minors. Research evidence is still unclear as to the extent to which a regulated market 
can replace the illegal market, and what key policy and enforcement approaches are effective in 
reducing the illegal market. For instance, studies have shown that some Canadian consumers adhere to 
former channels of distribution, despite legalization (Charlebois et al. 2020). It has been crucial that legal 
cannabis can be purchased in an affordable and convenient way (Lancione et al. 2020). Furthermore, 
studies indicate that the effects on the illicit market in Uruguay might be smaller than in Canada or the 
USA because of Uruguay’s restrictive policy (Hall et al. 2019).  
 
It is often argued that legalization of cannabis would lead to more resources for law enforcement, but 
the effects of different regulatory options on drug-related crime needs to be researched. In certain US 
states where cannabis has been legalized, cannabis-related criminal activity has decreased (Bahji and 
Stephenson 2019). According to Dellazizzo et al. (2020) there is research evidence from meta-analyses 
that there is an association between violence and cannabis use, especially among more at-risk 
populations. The authors emphasize that the mechanism between cannabis use under recent policy 
changes and different forms of harm-to-others need to be analyzed more in detail in order to take 
measures to mitigate these risks. One open question moreover is how prior convictions for possession 
of cannabis should be addressed (e.g. pardons) (Shover and Humphreys 2019). Expungement of prior 
criminal records of cannabis-related convictions that are no longer illegal as well as consequences of 
cannabis-related offenses in a legalized environment are seen as crucial aspects for social justice 
(Adinoff and Reiman 2019), which has initially been neglected in many countries.  
 
Furthermore, road and workplace safety are an important issue as cannabis consumption is associated 
with significant cognitive and psychomotor effects and thus affects performance and productivity of 
consumers (Chow et al. 2019). The results of US studies on the effects of cannabis legalization on road 
safety are to date inconclusive. There seems to be no difference in the number of accidents in American 
states irrespective of whether they have or have not legalized cannabis (Aydelotte et al. 2017). With 
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respect to workplace safety and presence, US studies come to somewhat counter-intuitive results and 
show that workplace incidents tend to decrease, and absenteeism is reduced, which even leads to an 
increase in average hours worked (Darnell 2020: 23ff.). It is assumed that this can be explained by the 
positive health effects of cannabis use, reducing work absence due to illness and medical issues. 
The question arises how adjustments to retail regulation can lead to a reduction of cannabis-impaired 
driving and occupational safety risks and what are effective approaches (e.g. sanctions, enforcement, 
testing, and prevention). All jurisdictions with a legalized market have implemented laws against 
drugged driving (Lancione et al. 2020). However, questions arise such as how to handle frequent 
cannabis users’ partial tolerance to some of its impairing effects (Peng et al. 2020) Evidence indicates 
that blood levels of THC do not correlate strongly with the impairment level and there seems to be 
considerable individual variation, which makes it difficult to establish clear and reasonable thresholds 
(Chow et al. 2019). A literature analysis by IRM Basel summarizes the scientific evidence presenting 
three options regarding a possible threshold: A threshold of 2.2 nanograms of THC per milliliter in 
whole blood (including a 30 percent tolerance), above which level driving is forbidden, a threshold of 
4.3 nanograms per milliliter in whole blood (including a 30 percent tolerance), above which level there 
is an actually measurable impairment, or a multi-stage system with both of these thresholds, whereby 
administrative measures would be provided for the area between the two values (Bucher et al. 2020). 
Roadside behavioral testing to detect cannabis-related impairment still needs to be improved (Hall et 
al. 2019). Comparing two cannabis-impaired driving detection methods, Ginsburg (2019) argues that 
general strategies to detect and prevent impaired driving (e.g. independent assessment of driving 
behavior based on camera material) are the preferable option rather than establishing specific methods 
for every specific substance or situation.  
 
Finally, it is often debated if the legalization of cannabis contributes to drug tourism and what measures 
are appropriate to control public safety impacts of drug tourism (e.g. restrictions for foreign residents). 
However, experience of the Netherlands suggests that cannabis-related tourism, which is comparable 
to any other form of tourism, might even bring economic benefits and only few problems (Rolles & 
Murkin 2013). Nevertheless, there are ongoing political discussions about whether access to the so-
called coffee shops selling cannabis in Amsterdam should be limited to Dutch residents (Henley 2021). 
 
To sum up, in order to enforce public safety, public order should be promoted and criminality should 
be reduced. However, scientific evidence in this research area is scarce and large-scale studies would be 
necessary. Furthermore, in order to distinguish the effect of new regulations or approaches there needs 
to be a solid foundation about the status quo. Table 3 displays the most important open research 
questions in the field of public safety, which can be derived from the current state of scientific research 
and the experiences from other countries.  
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• What is the influence of different regulatory options on the illegal market? 
• To what extent is a legal market able to eliminate the illegal market? What conditions 
allow best to reach that goal? 
• What are the effects of decriminalization or legalization, respectively, on criminal 




• What measures should be taken to ensure road and workplace safety (definition of THC 
limits, fines, information, campaigns, controls etc.)? 
• What measures can be taken to prevent cannabis-related nuisances in public spaces (e.g. 
number and place of outlets, opening hours)?  
• How can adjustments to retail regulation lead to a reduction of cannabis-impaired 
driving and occupational safety risks? 
• What are the effects of different regulatory models on drug-related tourism? What are 







• What are effective approaches to prevent and detect cannabis-impaired driving (e.g. 
sanctions, enforcement, testing, and prevention)?  
• How do different regulatory frameworks affect the resources of the law enforcement 
system? 
• What approaches to policy coordination are the most promising (e.g., where various 




 Establishing governance over a safe and responsible supply chain 
The nature and level of cannabis-related costs will depend on the form of regulation in question. With 
a decriminalization approach, cannabis might be not de jure legal, but in practice the law would not be 
enforced, pursued, or administered when it comes to certain of those nominally prohibited offences (see 
Dutch model). As already discussed, there are different options in a partial prohibitionist approach 
banning some cannabis related activities (for instance, the cultivation for commercial use), but allowing 
others (like personal use, and cultivation of small quantities) without penalty.  
 
The main idea of legalization is that the control of the cannabis market through responsible and 
controlled governance mechanisms would allow protecting public health and safety. Thus, it is 
important to keep an eye on the whole supply chain as well as the question of how to make use of 
revenues. 
 
First, cannabis production begins with the cultivation and harvest of the plant material. Its subsequent 
preparation as well as the manufacturing of products using cannabis as a raw material, including 
concentrates and other derivatives, are an area in which regulations can further public health goals. This 
is especially important since the usability of cannabis differs much from alcohol and tobacco and there 
is thus great uncertainty regarding the social and health consequences of individual production steps. 
However, legal cannabis production can be conducted on a smaller scale, including home growing or 
cannabis social clubs, or on a larger scale, through government controlled or private enterprises. 
Consequently, apart from the commercial supply chain, it needs to be determined whether personal 
cultivation is allowed, and if yes, in what way. Home growing, as an important decriminalization 
approach, has been prohibited in some US states and the Canadian province of Quebec, but not in other 
subnational jurisdictions in Northern America. The effect of these different approaches is still not clear 
(Lancione et al. 2020). The literature reviewed clearly suggests that the regulation of production, 
however, should aim at guaranteeing product safety and quality, and at ensuring the security of 
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production systems (Rolles & Murkin 2013). Therefore, questions of effective safety or security protocols 
arise. Unfortunately, no standardized protocols for potentially harmful pesticides detection exist to this 
day (Taylor and Birkett 2020). The reflection on the production and processing dimensions, furthermore, 
might also build on the existing experience with the production system of cannabis for medical use, 
where despite a variety of objectives a certain know-how (e.g. regarding compliance with product safety 
standards) already exists (see for the Swiss context Mavrot et al. 2019). 
 
Second, processing and distribution are the next steps. A distribution system needs to control the chain 
of custody in order to guarantee high product quality. Furthermore, there is a plethora of regulatory 
options regarding labeling and packaging (warning labels, childproof, declarations, safety measures, 
etc.). Clear and consistent labelling that communicates important information (e.g. health risks) as well 
as key product information related to contents (e.g. dosage, potency, ingredients) to the consumer has 
been found to be critical in order to minimize harms of use (Matheson and Le Foll 2020). However, 
Rolles and Murkin (2013: 9) emphasize that regulatory models need to be designed according to local 
patterns of use “given that cannabis comes in many different preparations and can be consumed in a 
variety of ways”. Governments can adopt policies to mitigate the negative consequences, such as 
restrictions or bans on advertisement and promotion (Hall et al. 2019). In this respect, cannabis 
regulation can benefit from lessons learned from the regulation of alcohol and tobacco (Haden & 
Emerson 2014). 
 
Third, regarding retail and sales, a regulated system has the potential to provide consumers with safe 
access to cannabis. This fosters the minimization of potential risks to consumers and the involvement 
in the illicit market. There are different options ranging from a centralized government monopoly to 
non-profit organizations to specific cannabis shops and private enterprises. Past experience with alcohol 
indicates that public monopolization is generally a preferable option with regard to public health and 
welfare interests (Room and Cisneros Örnberg 2019). The aim of the Uruguayan model, for instance, is 
the close control of the market by the state, realized through different forms of access to recreational 
cannabis (individual self-production, as part of cannabis social clubs, or in pharmacies). In Canada, a 
mix of publicly and privately run retail structures, as well as online sales, have been introduced on a 
provincial and territorial level (Lancione et al. 2020). Online purchasing of cannabis is seen as vital to 
increase access in more rural areas for instance, but has also been more commonly used in times of the 
Covid-19 pandemic. However, research evidence in this field is missing to date. 
 
As displayed in Figure 2, there are several alternatives ranging from home-growing-only models to 
allowing profit-maximizing firms (Kilmer 2019). Besides of the commonly-discussed prohibition and 
standard commercial models, there are many middle-ground options such as co-operatives or non-
profits, in which for instance public health advocates are part of the board (DeVillaer 2019). This options 
could be situated in the middle of Figure 1, where health and social costs could theoretically be reduced 
the most. Therefore, more research on these middle-ground options is necessary which can be 
differentiated into decriminalization approaches (small scale middle ground options) and strictly 
regulated and controlled markets (large scale middle ground options).  
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Figure 2: Spectrum of different policy options available 
 
Source: Caulkins and Kilmer (2016: 111). 
 
To establish effective control, a commercial model with a licensing system is seen as another way to go. 
License categories for growing, processing, and selling cannabis as well as restrictions on horizontal or 
vertical integration are regulatory options here. Horizontal integration includes mergers and large-scale 
acquisitions which can reduce the operational costs, vertical integration refers to companies that control 
more than one aspect of the supply chain. An example here would be a company that owns everything 
from cultivation to retail locations for their products (see also Hall& Lynskey 2020). Restricting the 
number of licenses would make it easier for the state to control the number of businesses or could 
prevent an over-supply of cannabis potentially leading to a price collapse in the market. Scientific 
literature on the variety of rules and regulations regarding licensing tends to be descriptive and it seems 
to be too early to provide evidence on the various consequences of different licensing models. 
 
Fourth, another important aspect concerns pricing and taxing, where the goals of health protection and 
of displacing the illegal market need to be balanced. Low prices could encourage consumption, but high 
prices would make it difficult to compete with the illegal market. Experiences from alcohol show that 
taxes are highly effective as a means to influence price and thus reduce consumption and harm, however, 
this depends on the governmental control of the total supply side (Haden & Emerson 2014). Studies 
show greater preference of users for legal cannabis up to a certain price point and highlight the 
importance to study the demand side (Aston and Meshesha 2020). Minimum unit pricing or taxation by 
weight are thus seen as an important lesson to guide cannabis policy (Shover and Humphreys 2019). 
However, experience from the first US states to legalise cannabis has shown that cannabis prices have 
decreased by up to 50%, whereas the average potency of cannabis flower has increased (Hall et al. 2019). 
Consequently, policy papers also mention a THC potency-based minimum price or a linear/progressive 
taxation by THC-content (Canada. Task Force on Cannabis Legalization and Regulation 2016). Lastly, 
revenues gained through taxes could be used for prevention, research purposes and accompanying 
measures (Zobel et al. 2019). However, introducing adequate taxation in practice and into existing tax 
frameworks is seen as one of the main challenges (Ploeg and Baptista-Leite 2018). 
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Last but not least, there is significant interest in the economic potential and new revenues that the 
cannabis industry will bring (see also section 6.1). Promises of economic growth and prosperity by a 
future market especially for producers and farmers are at the forefront of many legalization debates 
(Caulkins and Kilborn 2019). Thus, decisions on production, distribution and retail have clear 
implications for businesses, including how to ensure diversity of participants and to restrict corporate 
influence (DeVillaer 2019). Evidence from alcohol and tobacco control show how commercial interests 
can trump public health priorities if the risk of over-commercialization is not well regulated. Experience 
from other countries, such as Canada, has shown how a cannabis industry grows quickly and becomes 
a powerful player with significant lobbying resources (Jesseman 2019). Decision-making in US-states 
was dominated by aspects of commercialization and tax revenue generation, putting the public health 
agenda on the sideline (Rehm and Fischer 2015: 451). Holding the industry accountable to regulatory 
provisions is therefore essential. Kilmer (2019) emphasizes that the type of agencies involved with 
enforcing new regulations could have major impacts for health outcomes. In particular, protecting 
science and public health from corporate interest is crucial and the funding of studies by lobbies might 
be prevented by respective restrictions (Shover and Humphreys 2019). The history of alcohol and 
tobacco control is littered with examples of commercial interests trumping public health priorities. 
Regulators should learn from this experience and ensure that the legal cannabis trade is not susceptible 
to similar industry manipulation 
 
Local businesses and products could constitute a preferable market model, compared to domination by 
multinational corporations, in order to establish an efficient, accountable and transparent system for 
regulatory oversight of the supply chain, emphasizing the protection of health and safety and reducing 
diversion to the illicit market. However, with high regulatory standards regarding production and 
products, it might be difficult to stay competitive. Experience from tobacco regulation indicates that it 
is an empirically open question whether a highly regulated market is a more promising option from a 
public health perspective compared to businesses and producers in strong competition to each other. 
Although social justice and equity goals were set, encouragement of diversity in the cannabis industry 
and funding of equity programs has been very limited to date (Adinoff and Reiman 2019). Regardless 
of the model chosen, research emphasises the role of well-trained employees to inform consumers 
about the risks of use and about different product types available (see Lenton 2020).  
 
To sum up, there are different regulatory options to mainly influence the supply side – legalizing 
cannabis and establishing a control structure over the whole supply chain, or decriminalizing some 
aspects. In the case of the former, research points out the importance of an oversight body in order to 
reduce the profit motive to promote sales and the potential influence of corporate interest which would 
benefit from relaxed regulations. Furthermore, even though regulations for recreational and medical 
cannabis use have been mostly separated, they are often conflated. Table 4 displays the most important 
open research questions in this field, which can be derived from the current state of scientific research 
and the experiences from other countries. 
 





• What are the advantages of different licensing approaches regarding cultivation, 
processing, and selling cannabis? 
• How can future cannabis legislation and research be protected from corporate 
influence? 
Economic and equity aspects 
• What is the economic potential of an entirely or partially legalized cannabis market for 
Swiss producers and retailers compared to the status quo? 
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• What can regulators learn from the experience of alcohol and tobacco to minimize 
industry manipulation of legal cannabis trade?  
• What regulatory options are effective in mitigating the risk of commercialization? 
• What are the advantages and disadvantages of completely banning a commercial 
market?  
• What consequences do different regulation approaches have on equity and social 
justice outcomes? 
• How can social equity be promoted from the very beginning? What kind of programs 
should be developed to support the inclusion of less advantaged and disproportionally 
affected groups in the industry? 
• What are the overall costs for society caused by the different regulatory choices 
(prohibition, decriminalization, legalization)? 
Policy implementation 
• What regulatory competences need to be situated on what state level (national, 
cantonal, municipal)? What are the risks and opportunities of a multi-level 
governance approach?  
• How can coordination between cantons be improved in order to facilitate 
harmonization of implementation? 
• How can regulations of medical and non-medical cannabis use be separated while still 
supporting and not hindering each other? 
• How should partnerships between the state and private actors in policy delivery 
(professional groups, producers, etc.) be established? 
Production • How should the regulation of cannabis production be designed to guarantee product 
safety and quality and ensure the security of production systems? 
• What are the effects of the legalization of home-growing and personal cultivation of 
cannabis? How is government oversight under such a model feasible?  




• What provisions should be taken for the processing and distribution of cannabis? 
• What kind of limitations should be implemented regarding promotion? 
• How should packaging and labelling be regulated in order to match local patterns of 
use and promote public health goals, thereby allowing a more efficient promotion of 
public health goals? 
Retail  • How should a retail system be regulated to accommodate public health and safety 
concerns?  
• Which sale setting is most likely to make users abandon their usual (illegal) sources of 
supply to promote the positive effects of a new regulation? 
• What regulatory restrictions on sale and purchase are effective from a public health 
viewpoint (access and availability restrictions, rationing, purchases only up to a 
certain amount, etc.)? 
• What are the opportunities and risks of different retail/sales models (e.g. shops vs. 
online sales)? Are state-run cannabis outlets preferable to commercial outlets in terms 
of public health? 
Consumption • What is the evidence of the public health effectiveness of bans on cannabis use in 
public spaces? 
• What are advantages and disadvantages of different restrictions on the location of use 
from the perspective of public health and safety? 
• How should locations of allowed consumption be regulated and monitored? 
Pricing / 
Taxing 
• How do pricing and taxing influence consumption patterns (changes in patterns of 
use, local priorities, etc.)? 
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• How can a balanced pricing and taxing structure be established that simultaneously 
ensures competitiveness with the illegal market and a sufficiently high price to restrict 
youth access and limit consumption? 




 Summary: logic model of cannabis regulation 
As discussed in chapter 3.1., the primary goal of sound cannabis legislation is to reduce cannabis related 
costs. This principle of cost minimization needs to be taken into account when comparing the success 
of differing approaches to cannabis. Therefore, a full and comprehensive array of costs associated with 
cannabis needs to be investigated. Even though research in this field is growing, more scientific evidence 
on the “impact of variations in regulatory policies on potential harms of legalization to inform future 
policy decisions“ is needed (Lancione et al. 2020: 7). We summarize the different aspects discussed in 
the previous sections in a logic model6, which was validated by the advisory group (see Figure 3).  
 
The left side displays various regulation options such as the supply architecture. Important regulatory 
questions concerning cannabis legalization and decriminalization arise: Who can produce which 
products? Where, when and which amount of cannabis can be sold? And where can those products be 
used? Different regulatory choices in the different subfields ranging from production, over distribution 
and processing, retail and consumption finally to pricing and taxing need to be defined. In order to 
realize and implement different regulation options, various public, private or other actors from different 
areas might be involved. For all possible actor constellations, cooperation plays a central role. We focus 
our inquiry on the so-called middle-ground options as already mentioned earlier – ranging from 
decriminalized self-cultivation over state monopoly to a strictly regulated commercial market. Those 
policy decisions will affect the consequences of any regulation endeavor as they have different 
advantages and disadvantages regarding the aims of minimizing the harms of use, enforcing public 
safety and order, as well as establishing a control structure over a safe and responsible supply chain. 
 
Following the international and national discussions about the underlying long-term goals of cannabis 
legislation and with reference to Art. 2 Abs. 2 BetmPV, the following four main objectives regarding 
impact can be formulated (see right side of the logic model): 
 
- Promotion of individual and public health 
- Protection of children and minors 
- Reduction of criminality 
- Effective and equitable governance 
Whereas the main emphasis in Uruguay was laid on the reduction of criminality, in Canada a public 
health perspective was essential when developing the regulatory framework. Identifying a clear 
purpose to drive the overall approach is seen as a key aspect to determine which legislative approach 
to cannabis would be the best, or most successful (Canadian Centre on Substance Abuse 2015).  
 
The different possibilities to intervene, such as restricting the influence of the industry or prohibiting 
sales to minors, are illustrated in the output row, where the different intervention components can 
 
 
6 According to Anderson et al. (2011: 34) a “logic model is a graphic description of a system and is designed to identify important 
elements and relationships within that system”. Therefore, it can be used not only in planning and evaluating public health 
programs, but also as an analytic framework for systematic reviews. Logic models help to identify the complex links between 
determinants and the different outcomes, thereby encouraging the translation of evidence into policy. 
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target social as well as market behavior. The different (desired) individual as well as societal effects such 
as the control of the drug market or the mental and physical health of consumers are summarized in the 
outcome row. We identified four different categories alongside to the four desired long-term impacts, 
whereby a significant amount of overlap and interdependencies exist as well.  
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Figure 3: Logic model of cannabis regulation 
  
Source: own illustration
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There are several tensions in the model between different goals such as between public health protection 
and a liberal revenue-driven market with potentially harmful products (DeVillaer 2019) having a 
“desire to maximize sales and profits” (Caulkins and Kilborn 2019: 689). Another tradeoff exists between 
the goal of keeping prizes low and minimizing taxes to reduce the illegal market on the one hand and 
imposing high prizes or taxes to discourage heavy use on the other (Canadian Centre on Substance 
Abuse 2015). There are not only conflicting objectives; tensions can also arise within one objective: from 
a public health perspective, the question arises whether to advocate indoor use, risking poor air quality 
and passive smoking, or outside use, even if that normalizes cannabis use (Caulkins and Kilborn 2019). 
Furthermore, restricting consumption to in-house use only could discriminate against marginalized 
groups such as homeless people. Another balancing act can be found regarding the different levels of 
government. Research emphasizes that authority for oversight should remain at higher levels of 
government endowed with more extensive resources and therefore potentially less vulnerable to 
industry pressure, while local government should still have the ability to adapt to its specific conditions 
(Caulkins and Kilborn 2019). 
 
Lastly, there are also other contextual factors of influence, such as the regulation of medical cannabis. 
As experience from other countries shows, recreational use of cannabis was mainly legalized after 
regulations were loosened with regard to medical use of cannabis. Shover and Humphreys (2019) 
identify in their narrative review lessons from other policy areas such as alcohol or tobacco, which are 
already more established, to guide legalization for recreational cannabis. However, in what ways 
similarities and differences exist is still an open debate. To what extent learning from tobacco and 
alcohol can be transferred to the regulation of cannabis is an important research inquiry. Other 
contextual factors include public opinion, political debates as well as the specific cultural context of a 
country, which influence the social acceptance of a policy. For instance, Switzerland has a very liberal 
tradition with substances compared to other countries. Not least, international developments also play 
an important role and might increase pressure for policy change (Brunner and Kübler 2019). 
 
To sum up, understanding effects of cannabis laws requires greater attention to differences in short-
term versus long-term effects of the laws, nuances of policies, and patterns of consumption. It is 
important to create a comprehensive public health monitoring and evaluation system for cannabis 
regulation, in which metrics about not only possible risks but also the potential benefits should be 
reported (Lake et al. 2019). Many researchers have noted that a concerted effort to create a cannabis data 
collection systems is necessary for creating effective regulation (Borodovsky and Budney 2018), while 
getting access to relevant governmental and corporate data has been seen as challenging. Despite the 
growing research field, there is still a paucity of literature on a variety of implications related to cannabis 
legalization. As we have seen, some available studies are fairly heterogeneous in their findings (Bahji 
and Stephenson 2019). As there are trade-offs between and within different objectives, it is important to 
distinguish those different fields and make clear what the goal of a specific measure is.  
 
Future research questions should directly speak to the overarching question formulated in section 3.1 
and thus offer more insights on how social and health costs of cannabis consumption can be reduced. 
An optimal protection of health can be ensured if the negative effects of an under regulated legal as well 
as an unregulated criminal market are minimized. In the next section, we will therefore prioritize the 
different research fields in the Swiss context, before we then discuss which questions can be analyzed 
within the framework of the Swiss pilot trials and which questions need to be addressed with different, 
complementary research. 
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4 Prioritization in the Swiss context 
As a consequence of international developments, the central question today according to the former 
Federal Commission on Addiction (“Eidgenössische Kommission für Suchtfragen” EKSF) is no longer 
whether regulation is needed instead of complete prohibition, but rather how cannabis should be 
regulated to minimize risks and increase public health benefits. The protection of the public and the 
control and regulation of the market are seen as fundamental axes of a potential cannabis regulation in 
Switzerland (Zobel et al. 2019: 26-29). In this chapter, we will take this principle as a starting point to 
identify research questions of priority for Switzerland. Even though we base our prioritization on 
objective criteria such as the political debate and current research evidence, priority order lies in the eye 
of the beholder at least to some extent. The central research fields presented below will subsequently be 
discussed in decreasing order of priority. 
 
 
Not only is the relationship between evidence and policy complex, but the concerns, priorities and 
values expressed by different stakeholders and the public are important for future steps. It is thus 
important to situate the potential pilot trials and possibilities of cannabis regulation into the political 
landscape. Therefore, we briefly discuss the characteristics of the current political debate on cannabis 
policy in Switzerland. The political debate is mainly characterized by two different viewpoints (Brunner 
and Kübler 2019; Wenger et al. 2014). Supporters of an approach focused on abstinence highlight the 
negative effects of cannabis use and push for repressive measures. This view holds that the aim of 
cannabis policy is to minimize the use of cannabis (and all drugs). Supporters of the harm reduction 
approach emphasize that prohibition not only failed, since many people still regularly use cannabis in 
Switzerland, but also has many serious negative consequences. After lengthy parliamentary debates, 
these different viewpoints were brought together in the so-called experimental article for pilot trials. A 
majority of members of parliament ultimately approved the corresponding amendment of NarcA, on 
the condition that future pilot trials investigate the central issues of cannabis regulation in an unbiased 
and open-ended manner.  
 
4.1 Promotion of individual and public health 
Despite different standpoints, the four-pillars-policy consisting of 1) health promotion, prevention, 
early detection, 2) treatment and counselling, 3) harm reduction and minimization of risks, and 4) 
regulation and enforcement, enjoys large support within the whole political spectrum (Brunner and 
Kübler 2019). It constitutes the basis of the government’s National Strategy on Addiction (2017 – 2024) 
which emphasizes the strengthening of health literacy, the creation of favorable conditions, the 
differentiation of risks, the assessment of consumption and behavior as well as early support as its core 
objectives (Swiss Confederation - The Federal Council 2017). This strategy also provides the overall 
framework for the cannabis pilot trials. Hence, priority research questions in the field of individual and 
public health should allow addressing the four overriding objectives of the strategy. In conjunction with 
the findings from international research, the following research fields can be formulated:  
• Prevent addictive disorders and high-risk consumption: In this context, the main question is 
what structural strategies are effective to strengthen prevention efforts and to facilitate low-risk 
consumption. Future research should therefore deliver more insights into the debate on 
whether a decriminalization approach or a strictly regulated cannabis market can enhance 
health literacy and competences of individuals. Furthermore, there are different regulatory 
options aiming at restricting access, promotion, etc. Another pivotal instrument is pricing and 
taxing (minimum pricing according to weight or potency, etc.).  
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• Provide individuals at risk with the necessary help and treatment: It is often argued that the 
prohibited status of cannabis deters individuals who are at risk, who show problematic 
consumption patterns or who are addicted from seeking out professional help. Therefore, the 
legal or decriminalized access to cannabis should facilitate early support and treatment. 
Whether the quality of life and social integration of addicted individuals can be enhanced 
through a legal/decriminalized access to cannabis remains a pivotal question. With regard to 
those who consume cannabis in a harmful manner, research emphasizes that problematic 
consumption is often caused by or co-occurring with circumstances in which individuals face 
difficulties or distress related to their environment. This should be considered in order to 
identify segments of users who are at a higher risk in terms of their socio-economic living 
conditions (and, potentially, other social factors that have not been identified yet).  
 
• Mitigate damage to health and social harm: A clear priority can be found in the question 
whether controlling the supply chain – partially or in its entirety – minimizes health risks and 
social harms. Therefore, quality and control standards should be introduced (e.g. pesticides, 
contaminants). Here, the physical and mental health of consumers should be at the forefront, 
including preventing problematic use by providing them with information. Therefore, the 
question arises as to what effect the different regulatory options have on consumption behavior 
(intensity, minimization of harmful consumption, prevalence and incidence of consumption, 
consumption of other substances). Additionally, in contrast to an ultra-prohibitionist approach, 
there is a wide range of harm reduction options that have not been fully researched to date (the 
risks of different modes of cannabis use, gradual regulation according to the products’ potential 
for harm and the different target groups, etc.). 
 
• Reduce negative impacts on society: Lastly, not only effects on the individual, but also the 
society as a whole need to be investigated in depth, and thus the overall costs of 
decriminalized/regulated access to cannabis (hospitalizations, disability/unemployment 
insurance, workplace performance, road safety, etc.). 
 
In conclusion, an analysis of how the various cannabis regulation options affect not only the individual 
person and their behavior, but also the societal framework including the overarching social, economic, 
and cultural context, the living and working conditions, as well as the social setting, is crucial in order 
to gain more knowledge about how to create a favorable environment. 
 
Firm evidence on the public health impact of various regulatory measures is relatively scarce. While 
there are several papers that look at the public health impact of legalization, the studies often come to 
different conclusions. In particular, two points prevent the production of conclusive results that are 
directly relevant for Switzerland. First, the time dimension needs to be mentioned. In their article on the 
effects of the legalization of recreational cannabis use in the United States, Hall and Lynskey (2020) 
stress that even Washington and Colorado, the first states that legalized recreational cannabis, can only 
look back on about six years of experience with their legal cannabis markets. This is considered too short 
a period to fully assess the effects of legalization. This is even truer for Canada and Uruguay, where 
legalization occurred more recently. It takes decades to reliably identify the public health effects of 
legalization. Second, the context-dependency of the currently available evidence needs to be mentioned. 
Transferring evidence from vastly different cultural and political contexts is not an easy undertaking 
(Fischer et al. 2020a). Behavioral insights from the handling of other psychoactive substances might help 
to design effective interventions in accordance with the different target groups (recreational/dependent 
users, vulnerable groups, parents, professionals, etc.). Finally, a lesson learned from our international 
workshop is that there are still many open questions regarding the measurement of individual and 
public health impacts of cannabis use and legalization. Further efforts should continue to be made to 
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develop standard instruments and questionnaires to monitor cannabis consumption behavior and 
health risks to produce the high-quality data needed to answer the important questions in this realm. 
 
In this context, experience from North America and Canada in particular shows that profit-oriented 
companies (e.g. alcohol or tobacco firms) develop into powerful players on the cannabis market 
relatively quickly after legalization and try to influence legislation in their favor (Transform Drug Policy 
Foundation 2020b; Jesseman 2019; Transform Drug Policy Foundation 2020a). They try to repeal 
regulatory measures or to circumvent them (e.g. by means of new products). These attempts to influence 
and/or avoid legislation make it impossible to consistently align policies with public health or the 
protection from negative impacts on society. With a look at Canada, it is even said that “despite the 
prohibition of direct cannabis advertisements and promotion, a vastly expansive cannabis industry […] 
is driving a commercialized environment in which the armory of public health may simply be too slow 
and weak for effective checks and protections” (Fischer et al. 2020a: 187). The dilemma of legalization is 
that meaningful information on its costs and benefits is not available for a well-informed decision-
making until after legalization. By then, a profitable industry that also generates substantial revenue for 
the government has usually already emerged, and it is too late to reverse this development (Hall et al. 
2019: 1587). Future research must therefore address the question of how regulatory measures in 
Switzerland must be specifically designed and introduced in order to prevent corporate capture as far 
as possible. This is especially important in Switzerland having a very liberal approach to other 
substances such as alcohol and tobacco. 
 
4.2 Promotion of public order and the reduction of criminality  
Whereas the reduction of criminality and the exposure to organized crime has been at the forefront of 
many legalization debates, such as in Uruguay, problems with organized crime or criminal activities 
are not the main motivation to overthink cannabis policy in Switzerland. While the potential 
replacement of the illegal market has been an argument for the introduction of a regulated legal market, 
the other main advantage highlighted is the issue of consumer safety by establishing and controlling 
the supply chain. The decriminalization of consumers has been widely discussed. In the administrative 
fines, a solution supported by a majority was found, even though many are not completely satisfied 
with it (Brunner and Kübler 2019). Research evidence on the effects of legalization on drug-related crime 
and the illegal market is still scarce. Insights from our international workshop and the literature suggest 
that long-term implications depend on how criminal organizations will react to a newly established 
legal market for non-medical cannabis. To date it is not clear whether they will switch to other (more 
potent) substances, which are still illegal, or if they might even target specific groups such as minors or 
addicted users. Experience from Canada has shown that the latter tend to still buy their products in the 
illegal market, as restrictions with respect to quantity or potency discourage them.  
Beside the effect on criminal activities, there are two other core areas which are relevant in the Swiss 
context. In the following, the three priority areas will be discussed shortly: 
 
• Criminal activities: The effects on the illegal market are clearly a research priority at the 
forefront of many political and public debates. Therefore, new insights could or should inform 
future regulations. Seeking to displace the illicit market over time requires the establishment of 
a competitive legal market (including safe and reasonable access, price, product choice, etc.) 
Therefore, excessive restrictions could lead to the re-entrenchment of the illicit market. 
Conversely, inadequate restrictions could lead to an unfettered and potentially harmful legal 
market. 
 
• Public security and order: Security and order in public spaces need to be maintained by 
controlling for cannabis-related disturbances. This also includes preventing and sanctioning 
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driving as well as certain professional activities when under the influence of cannabis as an 
important aspect to guide regulation models (Zobel et al. 2019). 
 
• Policing, police organization and law enforcement: Another priority research question 
includes the effects on policing and the resources of law enforcement, which are an often 
discussed area. The success of the four-pillars-approach is based on the good cooperation 
between different stakeholders and the necessity to work together in the implementation phase 
(see also section 6.2), which was evident in the wake of the drug crises in the 1990s. Therefore, 
the police play an important part, as also under decriminalized or legalized cannabis access, 
regulations need to be enforced and certain activities remain illegal (sharing/selling products 
with/to minors, etc.). 
 
Concluding, the different regulation options should be contrasted with the status-quo in order to inform 
future debates on cannabis regulation. Therefore, it is not only crucial to monitor these three areas 
closely when introducing new regulations in the context of the pilot trials or future legislation, but also 
conduct research on the point of departure. 
 
4.3 Protection of minors 
Another issue which has to be prioritized in the Swiss context is certainly the impact on the protection 
of minors. First, there is relatively little scientific evidence from international studies. A recent article on 
cannabis legalization in Canada concludes: "It is far too soon to know how increased access to cannabis 
for non-medical use will impact Canadian youth, and data from jurisdictions in the United States that 
have legalized cannabis remain unclear" (Watson et al. 2019: 473). Second, recent figures on cannabis 
use among youth in Switzerland show that consumption is widespread. An international comparative 
study by the World Health Organization (WHO), which used surveys, concludes that nowhere are 
schoolchildren in Europe more likely to use cannabis than in Switzerland: 27 percent of 15-year-old boys 
say they have already used cannabis. At 17 percent, use among girls is also in the upper middle range 
(Carli 2020). Third, the protection of minors seems to be a central dimension in public and political 
debates about the regulation of Cannabis in Switzerland.  
 
For an effective protection of minors with regard to drug use, the approach in Switzerland is founded 
on different pillars7:   
 
• Legal regulation to protect minors (“Gesetzlicher Jugendschutz"): Here the question of efficient 
youth protection is at the center stage. With regard to legal aspects, a minimum age of 18 has 
already been defined for the pilot trials. Similarly, it is illegal to sell cannabis products to minors 
in other countries that have already legalized cannabis (although with different minimum ages). 
In addition, access restrictions, price regulations such as taxing or minimum prices for certain 
products, or restrictions on promotion might be in place.  
 
• Promotion of youth and prevention (“Jugendförderung”): These measures are directed 
towards all minors and contain adequate information as well as the development of important 
life and health competences such as handling stressful situations, group pressure, etc. It is often 
argued that the illegality of cannabis can act to deter young people in particular from seeking 
 
 
7 More information can be found here: https://www.bag.admin.ch/bag/de/home/gesund-leben/sucht-und-gesundheit/regulierungen-
suchtbereich/jugendschutz.html 
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comprehensive information about the harms and effects of cannabis use. In contrast, it is feared 
that non-prohibitionist approaches would lead to a trivialization and thus create wrong signals 
or conflicting prevention messages. Therefore, the question arises to what extent different 
regulatory options affect the perception of risks and the health competences of young people. 
 
• Youth support (“Jugendhilfe”): If young people are at-risk or already show problematic 
consumption behavior, recognizing these problems and intervening early is a crucial. In case 
negative consequences (school, job, family, etc.) are already noticeable, assistance and provision 
of services such as therapeutic offers need to be provided. The prohibited and criminal status 
of cannabis use might discourage youth from seeking out professional help. The pivotal 
question is to what extent (problematic) youth consumption and negative consequences for 
young people with addictive behavior can be reduced.  
 
An analysis of the different structures and framework conditions related to the various cannabis 
regulation approaches is important in order to contrast the different effects as well as barriers and 
advantages they have with regard to the three listed areas. 
 
4.4 Effective and equitable governance 
This last area encompasses different social as well as economic aspects. Before introducing a new legal 
framework, knowledge about the current state of cannabis production and consumption and its 
inherent structures and processes is crucial in order to develop the adequate incentives for users and 
producers. Therefore, the long-term objectives of prosperity, social justice and equity refers to the 
demand as well as the supply side. 
 
Legalizing access to cannabis should not only strip criminals from profits, but also offers an opportunity 
for a new industry. Within the Swiss political debate it was mentioned that if cannabis was to be 
legalized, it must be organic and grown in Switzerland. Profits for Swiss farmers have been presented 
as an argument for legalization or decriminalization in the public discourse (see also section 6.1).  
 
In addition to a commercial model of cannabis production, small-scale decriminalization approaches 
are also a priority for research. The different effects of the middle-ground option, ranging from 
decriminalized self-cultivation over state monopoly to a strictly regulated market, need to be contrasted 
in order to gain more knowledge about the advantages and disadvantages. For instance, Uruguay has 
legalized and Australia has decriminalized home-growing. A potential future regulation could concern 
the regulation of a seed market that allows home-growers to use cannabis varieties.  
 
Another aspect that would need to be explored in future studies concerns social justice and equity. From 
international experience we learned that this issue has been often neglected. The non-legalized 
cultivation, possession and consumption of cannabis leads to the criminalization and stigmatization of 
sections of the population, especially among the younger and socioeconomically disadvantaged 
(Fischer et al. 2020a: 187; Todd 2018). Experts describe the handling of cannabis by the authorities as 
extremely inconsistent in Switzerland as well as in other countries (Schoop 2019). Depending on the 
canton, misdemeanors are punished differently, sometimes resulting in serious consequences for those 
affected. Different interpretations of unclear regulations and unclear powers of law enforcement can 
cause legal arbitrariness and injustice (Herzig et al. 2019).  
 
Following Shover and Humphreys (2019: 700) on policy lessons relevant to cannabis legalization and 
the reviewed literature, the following priority areas can be formulated: 
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• Effective and equitable governance: The pivotal question here is how to establish regulatory 
oversight of the whole or parts of the supply chain in an efficient, accountable and transparent 
manner (best practices and guidelines, licensing and control system, tracking, etc.). The 
different effects of models from decriminalized self-cultivation over state monopoly to a strictly 
regulated market need to be contrasted in order to gain more knowledge about the advantages 
and disadvantages in minimizing health and social harms. The economic potential of a legal 
cannabis market for Swiss producers and retailers is another important field of investigation, 
which includes how to create a diverse, equitable, and inclusive industry (big corporations vs. 
Swiss farmers). The restriction of corporate influence and the protection of science and 
regulation is crucial. Lastly, it would be necessary to find suitable policy implementation 
solutions for the Swiss context (capacity and infrastructure, oversight, federalism, multi-level 
governance, etc.). This also includes adequate communication with the public as well as the 
funding for research and surveillance (see also chapter 7). 
 
• Supply Chain: Regulatory decisions on production, distribution, retail and consumption not 
only have clear implications for businesses hoping to enter the cannabis market, but also for the 
different long-term objectives. Therefore, on each level the different options (restrictions on 
access and promotion, product range, standards and quality controls, limitations and caps, etc.) 
and their consequences need to be analyzed. This also includes the question of pricing and 
taxing in a way that makes it possible for a legal market to compete with the illicit market while 
not encouraging increased consumption. Developing an adequate pricing scheme should be a 
priority as research has shown that drug use is responsive to price (Shover and Humphreys 
2019). In this area it would be especially helpful to see to what extent we can learn form other 
fields such as alcohol and tobacco regulation research.  
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5 Pilot trials 
In this chapter, we first discuss the legal framework for conducting scientific pilot trials with narcotic 
drugs of the effect type cannabis in Switzerland with the goal of an evidence-based support for future 
legislation/ regulation. Second, we present some preliminary insights on ongoing reflections about 
potential pilot trials. Subsequently, we discuss considerations on which research questions can be 
investigated within the framework of pilot trials and where these pilot trials reach their limits. 
Possibilities for complementary research will be introduced in the following chapter. 
 
5.1 Legal framework 
The Ordinance on Pilot Trials under the Narcotics Act (BetmPV) adopted by the Federal Council at the 
end of March 2021 provides the legal framework. Article 2 sets out the basic objectives for pilot trials. 
According to Article 2, paragraph 1, only those pilot trials may be carried out that serve to gain scientific 
knowledge about the effects of measures, instruments or procedures, namely distribution systems, 
concerning the handling of drugs of the effect type cannabis for non-medical purposes. 
 
Furthermore, according to Art. 2 Abs. 2 BetmPV the projects should deliver insights about:  
a. physical and mental health of consumers and their performance; 
b. consumption behavior; 
c. socio-economic aspects; 
d. the drug market in a specific area; 
e. the protection of minors;  
f. public order and safety. 
 
There are exceptions for the pilot trials for some provisions of the NarcA. These include the prohibition 
of placing narcotics of the cannabis effect type on the market, the obligation for physicians to dispense 
cannabis only in accordance with the recognized rules of medical science, and for pharmacies to 
dispense cannabis only on medical prescription (Art. 3). Pilot trials are limited to one or a few 
municipalities and to a maximum of five years with the possibility of a one-time extension by two years 
(Art. 5). Furthermore, the number of participants may not exceed 5000 (Art. 6). Only adult individuals 
who can prove that they already use narcotics of the cannabis effect type are eligible to participate (Art. 
14). This means that the effects of regulatory changes cannot be investigated. In addition, there are 
requirements regarding the origin of the cannabis, product quality, packaging and product information, 
points of sale, and monitoring of the health status of the participants. The FOPH is responsible for 
approving project applications, for which applicants must fulfill various conditions that will not be 
discussed further here (see Articles 21 to 26 BetmPV). In addition, there is an obligation to provide 
information and reporting to the FOPH, which also performs a supervisory and control function. Thus, 
for the implementation of pilot trials, extensive requirements must be met, which can be explained by 
the preceding political process.  
 
5.2 Preliminary insights and ongoing reflections by researchers 
For the preparation of this report, we were in contact with various researchers and experts who have 
reflected on possible research designs for future pilot trials in Swiss cities. We are aware of six research 
teams involved in the process of elaborating research designs for pilot trials in some of Switzerland's 
largest cities: Bern, Basel, Geneva, Lausanne, St. Gallen and Zurich. At least two of these research teams 
are also considering to extend their investigation to partner cities. While there are common themes, each 
project sets different accents. There are thoughts about coordination or alignment of research among 
the research teams. The core tool might be a common questionnaire used to survey individual cannabis 
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users enrolled in the projects. The Cannabis Use Disorder Identification Test (CUDIT), which is 
considered a generally accepted tool for early detection of problematic cannabis use (Adamson and 
Sellman 2003), might be used by several research teams.  
 
Insights from exchanges with research teams currently reflecting on research designs for pilot trials 
show that one of the central questions from the parliamentary debate, regarding the effects of different 
retail models or systems, is reflected in discussions on the general orientation of future research. There 
are research teams with an interest in analyzing the effects of different retail models in a single 
investigation, meaning that there will be no restriction to specific retail outlets such as pharmacies or 
cannabis social clubs. Instead, potential dispensaries might be pharmacies, kiosks or vape stores. Other 
research teams think about restricting retail models to a single form, e.g. urban pharmacies or cannabis 
social clubs. International research indicates that state-run outlets are a promising alternative to 
commercial models and seem to be best suited for public health-oriented cannabis regulation (Kirst et 
al. 2015). With regard to regulation in other subject areas such as tobacco or alcohol, it can be seen that 
commercial models correspond most closely to the Swiss political culture and are also preferred in the 
political debate. Provided that the legal framework would allow to operate with state dispensaries, it 
might make sense to incorporate this type of dispensary in research designs for pilot trials as well, or at 
least explore the question of what role the state must play in dispensing cannabis to ensure public health 
objectives. 
 
The preliminary conceptual considerations of the research teams are mostly aimed at gaining insights 
into the effects of legal dispensing of cannabis for recreational use on study participants' consumption 
behaviors and patterns (amount and type of use, use of other substances, and proportion of cannabis 
acquisition in the illegal market), and the associated health effects. These topics were also at the forefront 
of the political debate and are therefore seen as key priorities. Some research teams are also interested 
in gaining additional insights on socioeconomic aspects (e.g. work absenteeism), on the performance of 
consumers, on their social environment, and the drug market in a specific area, the protection of minors 
and the public order and safety. Another aspect raised during the exchanges with the research teams 
and very likely to be explored in future pilot trials is the impacts of different forms of regulation (e.g. 
price regulation or restrictions on product types) on the legal and illegal market.  
 
Variation also exists in terms of which methods are expected to be used. The majority of research teams 
might work with quantitative online surveys to collect the relevant information from the participants. 
Some research teams are planning a more qualitative focus. Methodological approaches discussed were 
open, non-standardized in-depth interviews, focus groups or ethnographic observation phases. Some 
preliminary research designs also state that qualitative interviews should be conducted with youth 
workers, police, or residents in the vicinity of dispensaries, which might be a way to gain insights on 
the effects for public order and safety. Evidence on co-consumption of other substances such as alcohol 
or tobacco and the judicial handling of offenses and charges might also be obtained via online surveys. 
Another intention is to cover a comparatively large product range. Not only cannabis for smoking, but 
also as a vaping product might be distributed, as well as cannabis with different THC and CBD 
concentrations. There are also differences in terms of which groups are expected to be primary 
participants, i.e. the groups of cannabis users for which additional scientific findings are to be obtained 
(problem users/ heavy users, average users, etc.). Another adjusting screw is the tasks and functioning 
of the dispensaries, such as pharmacies. Dispensaries can take a rather passive role during the trials and 
primarily dispense cannabis according to the respective guidelines set out in the BetmPV. Alternatively, 
they might be entrusted with various responsibilities such as recruiting participants, purchasing and 
selling cannabis, as well as designing and implementing preventive measures. 
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5.3 Additional potential research topics and questions for pilot trials 
This section discusses potential research questions and topics that could be explored as part of pilot 
trials. Primarily, these are topics and questions that have not yet been raised by research teams as part 
of ongoing reflections on potential pilot trials. One issue seems to be online sales. Scientific evidence 
on Switzerland would be needed on this particular sales channel as well. Recent experience from other 
countries shows that this channel has become more important, especially in the current pandemic. 
Before anything else, details whether the distribution of cannabis via an online channel is legally 
permitted at all would need to be examined. Art. 13 BetmPV stipulates that cannabis products may only 
be made available through sales outlets that have expertise and appropriately trained staff, as well as 
an adequate infrastructure, and ensure safe storage of the products.  
 
In order to investigate the effects on the drug market or public safety and order, sophisticated research 
designs incorporating complex statistical methods are needed to identify causal effects. It would be 
conceivable to compare two cities or municipalities that are very similar in terms of potential 
confounding factors, preferably differing only in that treatment is provided in one city (legal dispensing 
of cannabis for recreational use to certain individuals) and not in the other. When all confounding 
factors are removed, the causal effect of the intervention could be estimated. A similar approach is the 
synthetic control method, which has been applied in an investigation to estimate the consequences of a 
policy intervention, more specifically a new tobacco legislation in California (Abadie et al. 2010). In the 
context of the impact on the drug market in a given area or on public safety and order, involvement of 
the local population might also be a way to gain additional insights. For example, residents in a 
municipality participating in pilot trials could be invited to assess the regulations being tested, and their 
consequences, by means of a survey. 
 
With regard to international cannabis research, it seems particularly important to keep an eye on 
possible changes in alcohol consumption and co-use of other substances among participants of the pilot 
trials. Questions about co-consumption of alcohol and cannabis or changes in alcohol use, if not already 
included, can in our view be implemented into existing research designs/ questionnaires and might 
provide insights into the extent to which there are public health benefits or harms and how the illegal 
market is affected (see also Hall et al. 2019). 
Additional information on specific consumption behavior could also be collected and analyzed in pilot 
trials, e.g. by means of additional items in a planned survey. The focus here is on the questions of which 
regulatory measures can be used to promote low-risk consumption and which measures are effective in 
increasing the consumption competence of consumers. 
 
The question of the consequences of a legalization of cannabis on youth use and the protection of 
minors more generally might not be conclusively assessed with pilot trials under a strict prohibition of 
sales to minors. Some lessons may be drawn from the insights of non-minor consumption of cannabis, 
but whether they actually hold in reality is an open question. Insights on youth protection could 
possibly be gained by explicitly selecting study participants who live in the same household with 
adolescents (e.g., parents). Adolescents might even be interviewed or surveyed to gain insights on 
potential effects of legally dispensing cannabis for the social environment. 
 
Further questions that can in principle be investigated within the framework of pilot trials are situated 
in the thematic block processing and distribution of our logic model. Additional insights on adequate 
and credible packaging and branding of cannabis products (see e.g. Hall et al. 2019) might be collected. 
First, this involves ensuring the quality of the product, i.e. the packaging must be designed in such a 
way that it guarantees a long-lasting high quality. Second, the packaging should contain warnings, THC 
levels and information on correct and reasonable consumption. Third, the presentation of the packaging 
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should not be particularly aimed at young people and thus thwart the protection of minors. These 
different elements can have a very concrete impact on consumers' choice of products. We would 
welcome experimental research (e.g. discrete choice experiments) in this area that looks at the impact of 
different product features on purchases by consumers of different age groups (Shi et al. 2019). Certain 
aspects could be included in surveys for the future pilot trials. An experimental research design for a 
pilot trial is also conceivable, in which different types of information and packaging are given to 
respective groups of participants. Since consumer preference is strongly dependent on the respective 
context or culture, insights from previous studies (e.g. Hammond 2019) in other countries can only be 
transferred to Switzerland to a limited extent. Different product forms and variations and how they 
affect the health of users are a topic that might also be incorporated in research designs for future pilot 
studies. Insights into the effects of different products can help to better advice consumers in the future 
and guide their consumption toward less harmful products. 
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6 Research questions for supplementary research 
As described in the previous chapter, the framework for the pilot trials seem to be adequate to study 
issues surrounding consumption behavior and individual health. The trials have some limits because 
they primarily provide individual level data and are restricted in time and place. Some generalizations 
might however be made to the general population or specific target groups. Issues that pilot trials can 
only address to a very limited extent include the production, processing and distribution of cannabis 
products, public safety and public order, the protection of minors, and the use of revenues and taxes. 
These are broad potential topics for complementary research, outside of the framework of, but related 
to the pilot trials. The aim of this section is to outline the important topics and questions for 
complementary research. 
 
6.1 Ongoing research supported by the FOPH 
Before we begin, it is useful to briefly discuss ongoing research mandates commissioned or financially 
supported by the Federal Office of Public Health (FOPH) focusing on a variety of contextual aspects 
related to the pilot trials. Indeed, the FOPH has already mandated different research organizations with 
investigations as a complement to the pilot trials in Swiss cities. Table 5 shows ongoing projects, as well 
as the core questions investigated by them.  
The commissioned projects thus cover certain research areas that cannot be investigated in the pilot 
trials. The survey conducted by Sotomo is directed towards the general population eligible to vote. It 
will generate knowledge on the general acceptance of regulatory options and attitudes towards 
legalization. This includes questions regarding who is allowed to produce and sell cannabis with 
substantial THC for recreational use, at what age cannabis can be consumed, where cannabis can be 
consumed, what quality standards apply, how cannabis can be advertised and taxed, what regulations 
apply to the taxation, and what accompanying measures would be important in the event of legalization. 
 
The aim of the mandate given by the FOPH to Sucht Schweiz is to compile a literature review on the 
consequences of the legalization of cannabis in other countries. More specifically, the question is which 
regulatory measures concerning the recreational use of cannabis have already been evaluated in other 
contexts and what the findings are in terms of health, economic and societal consequences of the 
regulation (Schmidhauser and Zobel 2021). This mandate can be seen as a continuation and 
supplementation of the work of an earlier report on regulatory approaches and measures in countries 
that have already gained experience with the legalization of cannabis for recreational use (Zobel and 
Marthaler 2016). In general, it is noted that one must be extremely cautious in drawing conclusions 
based on past experience in other countries. A few findings are regarded as certain. Legalization 
contributes to a diversification of the product range, which also leads to an increase in cannabis-related 
intoxications due to a lack of consumption indications. The number of arrests decreases post-
legalization. A legal market also seems to take over parts of the illegal market, but without causing it to 
disappear. Other potential impacts of legalization are categorized as either merely probable, or 
uncertain (Schmidhauser and Zobel 2021). 
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Table 5: Ongoing or recently completed projects and insights 





Sotomo General population 
survey on cannabis 
- What is the general attitude towards a new 
regulation for cannabis? 
- What regulatory options (e.g. age restrictions, 
restrictions of use in public, etc.) are accepted by 
the general Swiss population? 




on cannabis in 
different countries 
- In which countries is cannabis for recreational use 
legal and which regulations have been introduced?  
- Which policies concerning the regulation of 
cannabis for recreational use have already been 
evaluated? 
- What are the results of the evaluations in terms of 
health, social and economic consequences of 
regulation? 
University of 
Geneva & Rütter 
Soceco 
Cannabis and the 
Swiss economy: 
social costs and 
economic effects 
- What are the overall direct and indirect economic 
effects of different regulatory models?  
- Will there be a substantial increase of tax income 
following legalization of cannabis? 
- What is the economic potential of a legal cannabis 
market for Swiss producers and retailers? 
- Could prevention and health protection measures 







IRM Basel8 Report THC-
thresholds in road 
traffic. A literature 
analysis 
- What are possible scenarios to adapt road 
regulations in case of legalization / 
decriminalization of cannabis consumption? 
ZHAW9 Comparison 
between the Good 
Agricultural and 
Collection Practices 
(GACP) of the EMA 
and the Canadian 
Good production 
practices guide for 
cannabis10 
- Which cultivation and product standards best 
protect consumers? 
- Which existing standards from other jurisdictions 
are suitable for Switzerland? 
 
The study by the University of Geneva and Rütter Soceco (sozioökonomische Forschung + Beratung)11 
on direct and indirect economic impacts can primarily generate knowledge in the thematic block of 
socioeconomic outcomes. More specifically, the economic impact of different regulatory models will be 
calculated and insights into respective impact mechanisms are expected. The research team is expected 
 
 
8 The full report can be found under: https://www.bag.admin.ch/dam/bag/de/dokumente/npp/forschungsberichte/forschungsberichte-
cannabis/bericht_thc-grenzwerte_strassenverkehr.pdf.download.pdf/Bericht_THC-Grenzwerte_Strassenverkehr.pdf  
9 This mandate resulted in two publications. The first one can be found under: 
https://www.bag.admin.ch/dam/bag/en/dokumente/npp/cannabis/betm-pv-entwurf/bericht_vergleich_gacp-
cppc.pdf.download.pdf/bericht_vergleich_gacp-cppc.pdf.  




11 Contracting authorities are the FOPH, the Canton of Geneva, the Canton of Basel-Stadt, the cities of Zurich and Bern. 
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to calculate costs based on different regulatory scenarios. The study of IRM Basel on THC limits in road 
traffic can be located as research in the area of public order and safety. The results of the literature 
analysis, which have been available since the end of 2020, also provide insights into the negative public 
health consequences of the simultaneous consumption of alcohol and cannabis (co-consumption). Three 
variants for possible THC limits in whole blood for road traffic are proposed (Bucher et al. 2020). The 
ZHAW mandate on cultivation and product standards provides insights for the thematic block 
production.12 In this mandate, the cultivation regulations of the European Medicines Agency and those 
in Canada are compared in order to derive recommendations that factor in the legal framework in 
Switzerland. It is recommended that the good agricultural and collection practices (GACP) be followed, 
a standard recognized by the authorities in Europe for the cultivation of plant material to be used as 
resource for pharmaceuticals or herbal health products. The GACP’s primary objective is to ensure 
consumer safety by ensuring adequate and consistent quality of the plant material. The second part of 
the ZHAW mandate is to investigate how product quality is ensured with regard to active ingredient 
control and tolerances for active ingredient fluctuations, and how pesticide residues and other 
contaminants are regulated (Lardos 2021).  
These projects are complementary to the cannabis pilot trials in that they focus on topics that cannot be 
investigated in the pilot trials. They nevertheless provide crucial evidence on relevant areas of the logic 
model (see section 3.2.4).  
 
6.2 Additional research needs 
Overall, the planned pilot trials and the mandates already commissioned or supported by the FOPH 
cover a significant portion of the issues and thematic blocks visualized in our logic model (see section 
3.2.4). However, comparing this logic model and the research agenda covered by the pilot trials 
themselves as well as by the complementary mandates commissioned by the FOPH, it appears that 
additional research is needed mainly in the following areas: processing/distribution of cannabis 
products, use of revenues and taxes, consequences for public order and safety, and the protection of 
minors. In addition, research is needed on other specific topics such as the appropriate control structure, 
consumption behavior, or the status quo of cannabis policy. In the following, we will specify relevant 
research questions for each topic area in which additional research seems to be necessary. We conclude 
by discussing questions that go beyond our model and those that cover multiple subject areas within it. 
 
In the thematic block processing and distribution potential insights on the impact of different product 
features on consumer choice can be gained through the implementation of respective survey items in 
surveys for pilot trials, as already discussed in section 5.3. However, it is also possible to investigate 
aspects related to product or packaging characteristics, acceptance of possible warnings, declarations 
and information detached from pilot trials and without actually dispensing cannabis products. 
Investigations can be short-term oriented. The advantage of investigating these questions outside the 
framework of pilot trials is that research teams would be less restricted, i.e. the requirements regarding 
packaging and product information (see BetmPV Art. 11) would not apply. This could possibly lead to 
a stronger focus on actually effective regulations of packaging and product information under more 
realistic circumstances. 
 
The use of revenues and taxes seems to be a field in which additional research is needed. The use of the 
resources is, of course, highly dependent on pricing. The price level should ensure a certain 
competitiveness with the illegal market, without encouraging consumption due to the low price. In 
states where cannabis has been legalized in recent years, there are different approaches to using the 
 
 
12 For an international perspective on production and regulation regarding cultivation, see e.g. Kilmer et al. (2013). 
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revenues and taxes. A substantial portion of the revenue often goes to the implementation of regulatory 
measures or to the regulatory authorities themselves. However, it is also possible to establish a specific 
distribution key for tax revenues from the outset. Resources can be made available for prevention and 
education campaigns, for research projects on cannabis, or they can flow into certain policy areas, e.g. 
the education, health, or police system (Transform Drug Policy Foundation 2016: 252ff.). The research 
questions to be examined in this thematic block must take appropriate account of Switzerland's federal 
structure.  
 
• What pricing model makes sense (minimum price, taxation regarding THC level or weight, etc.)? 
• How should cannabis tax revenues be used?  
• Could prevention and health protection measures be financed by the additional tax revenues?  
• Which distribution key makes the most sense for Switzerland?  
 
The question of how the money will be used naturally presupposes that cannabis products will be taxed, 
and that the state will be able to generate revenue as a result. Numerous associated questions about the 
amount of the sales price or taxation are also still open at this point. The mandate by the University of 
Geneva and the consulting company Rütter Soceco will not be able to provide in-depth answers in this 
regard. Additional research on the tax consequences of a possible legalization should be carried out (e.g. 
Irvine and Light 2020). 
 
In the thematic block public order and safety, there are many research questions that need to be 
investigated by complementary studies. Respective studies would have to be designed for the long term. 
A first potential issue for a more in-depth investigation in this thematic block could be the consequences 
of legalization for the illegal market. Can the illegal market be replaced through legalization of cannabis? 
These consequences cannot be assessed conclusively due to the comparatively short time research 
projects are usually covering and the long process before a stable market equilibrium is reached. In 
addition, researching the illegal market presents a methodological challenge making it difficult to obtain 
reliable numbers (see also Zobel et al. 2020). Pilot trials on the controlled delivery of cannabis can hardly 
make far-reaching statements about the effects on the illegal market in Switzerland. The group of users 
who are part of the investigations (a maximum of 5000 participants) might be too small to influence the 
market equilibrium nationally. A long time horizon and a larger number of participants would be a 
prerequisite for obtaining sound findings on the impact on public order and safety. Economic 
simulations based on findings restricted to the local level, or insights from other contexts or policy fields, 
could help to advance knowledge under current conditions.  It seems certain that legalization will 
incrementally erode the illegal market (Schmidhauser and Zobel 2021). In this context, future research 
should also address the question of which factors have an effect on the speed with which a legal market 
can replace an illegal market in the future.  
A second point refers to potentially problematic consequences of cannabis use in public space. An 
effective regulation on cannabis must determine to which extent cannabis consumption in public space 
is appropriate for a minimization of social and health costs. It is important to consider that eventually, 
there might be a substantial range of cannabis products available (e.g. vaping products, candies, oils, 
drinks, etc.). A public health oriented regulation of cannabis consumption in public space must take this 
product variety adequately into account, thereby guaranteeing that existing regulations cannot be 
bypassed by product innovations. In the case of indoor consumption, air quality and passive smoking 
can endanger health, while public consumption outdoors contributes to normalization and trivialization 
of cannabis consumption. Both arguments need to be considered. In this context, risk perception of 
cannabis seems to be of central importance. The public presence of cannabis and cannabis users shapes 
what is regarded as problematic use via the risk perception of the population. Therefore, additional 
research on risk perception of cannabis in the general population is needed. 
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The protection of minors is another thematic block on which further research is needed. Since the 
distribution of cannabis to minors is generally prohibited in the context of the planned pilot trials and 
scientific findings can therefore only be expected at the margins, other research designs and methods 
must be chosen. We see online surveys as a promising method for gaining insights. Applying quasi-
experimental online surveys under realistic conditions to investigate how different product 
characteristics (e.g., price, potency, warning labels) affect adolescents' choice of cannabis products (see 
Shi et al. 2019 for a similar attempt) might be a viable option. In order to be able to ensure adequate 
protection of minors, prevention work must also start early, before profit-oriented companies enter the 
scene and try to influence the legislation to suit their commercial goals (see also Rosenbaum 2016). In 
the context of programs aiming to prevent underage cannabis use and educate young people on 
cannabis, the question of funding is particularly important. In many jurisdictions, additional resources 
flow into prevention campaigns following legalization (Pardo 2014). However, evidence from Colorado 
indicates that appropriate action should be taken prior to legalization from a public health perspective 
and should not be dependent on post-legalization revenue/taxes (Subritzky et al. 2019). Reflection is 
also needed on how any regulatory interventions in the area of youth prevention can adequately 
address parents, family structures, and trusted caregivers who have a strong influence on adolescent 
users (Faggiano et al. 2014). As outlined in section 3.2.1, scientific evidence suggests that peer-group or 
family-based prevention is more effective than large-scale public campaigns. There is a need for research 
on the extent to which prevention campaigns targeting young people via social media are a more 
promising alternative (see also Boumparis et al. 2019). In addition, research is needed on how 
restrictions of advertisement and promotion can be designed. The effects of advertising cannot be 
investigated within the framework of the pilot trials, as there is a strict ban on advertising (see BetmPV 
Art. 12). However, quasi-experimental designs would be conceivable in order to investigate how 
different advertising messages and channels affect potential use (see also Moreno et al. 2018). 
Advertising messages for different product forms could also be taken into account (e.g. flowers, edibles, 
etc.). 
 
Another central aspect, which should be investigated further in complementary investigations, crosses 
several thematic blocks in the logic model outlined before (see 3.2.3). More specifically, it concerns the 
topic of appropriate state control, control bodies and control measures. A central question is how a 
regulatory authority responsible for the supervision of regulatory measures can and should be designed 
in order to match the specific characteristics of the Swiss context. Which types of actors should be 
involved in regulation must also be clarified. This could include, for example, actors from the field of 
public health, but also economic actors acting on behalf of the state. In Uruguay for example, a rather 
strong new public agency, the Institute for regulation and control of cannabis, was founded and given 
the responsibility to effect the regulation (van Kempen and Fedorova 2019: 189). The appropriate 
requirements for licenses for the cultivation, production, processing, or sale, of cannabis must be 
determined such that they best protect public health. Furthermore, it must be clarified whether a 
concentration of power in the hand of a few actors can be prevented by the interdiction to 
simultaneously be a producer, supplier and retailer (see also Zobel and Marthaler 2016). 
 
With regard to consumption behavior, there is great research potential in the area of regulatory 
measures to support consumers in pursuing a non-problematic consumption behavior and 
integrating consumption into their everyday lives without negative consequences. Which structural 
measures contribute to an informed behavioral choice and which specifications provisions regarding 
safe consumption (e.g. “safer use guidelines” and their specific design) are appropriate? To our 
knowledge, there is so far no known suitable instrument on how to adequately capture risk knowledge, 
low-risk consumption knowledge and consumption competence. Various measures regarding 
education, sensitization and product information have to be implemented in the pilot trials (see 
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BetmPV). However, it can be assumed that the effects of these measures on consumer behavior can only 
be studied marginally during the pilot trials. 
 
Research on the status quo is needed to accompany the pilot phase but also with a view to possible 
future regulatory changes. Reliable data on the current situation is a prerequisite for any evidence-based 
statements about the effects of policy changes and interventions. This point applies to most of the 
thematic blocks discussed in this report. Experience from other countries also indicates that data 
collection must begin at an early stage and continue over time (Jesseman 2019; Dills et al. 2021). In 
particular, early data collection and a long-term perspective might be warranted to answer the questions 
of whether legalization or decriminalization lead to an increase in the number of invalidity (IV) cases 
and hospitalizations, as well as to an increase of physical and mental illnesses. For this purpose, the 
status quo must also be researched.  
 
The consequences of legalization for public health, safety, and also social equity, are highly dependent 
on the specific implementation of the policies, on which actors are involved and on how they use their 
discretionary power in the implementation phase (see also Kilmer 2019). There is a significant 
discrepancy between formal cannabis policies and how they are actually implemented (Loo et al. 2003). 
Policy implementation research from a political science and/or a public administration perspective is 
therefore important and should closely accompany any future policy changes. It might indeed be 
valuable to research the implementation of certain measures already in pilot trials (e.g. how do different 
dispensaries implement the specifications of the project leader?). One of the research questions could 
be how the various public, private or non-profit actors coordinate most effectively in the context of 
cannabis governance, also across multiple federal levels. Surveys and interviews of people involved in 
the implementation of current and future cannabis policies (e.g. judges, police officers, etc.) might 
provide new insights in this regard. 
 
There is, lastly, a need to examine and start reflections on the question of what happens to previous 
criminal sentences related to the cultivation, use, or sale of cannabis before legalization (see also Herzig 
et al. 2019). Even if no legal changes are expected in this regard during the ten-year experimentation 
phase, the issue should be addressed early in order to be ready at the time of potential future legislative 
changes. The concrete details of the regulation are crucial in this case. Are criminal records 
automatically expunged, or must an application for record suspension be filed? What are the costs 
involved and what is the bureaucratic process required to do so? Various approaches have been taken 
in other countries, and it is at this stage not possible to determine which are the most promising. Looking 
at Canada, some authors argue that non-automated record suspension creates inequities because some 
individuals cannot afford to apply for expungement due to the cost, lack of resources, or the complicated 
bureaucratic process (McAleese 2019).13 In this context, it is also important to point out that experience 
from other jurisdictions underlines the importance of issues of equity. They need to be reflected upon 
in advance in the context of the handling of earlier sentences, but also in the implementation of other 
regulatory measures. It should be anticipated that not all segments of the population will be affected by 
regulatory measures to the same extent and that adverse effects may arise in some cases. 
To identify further research needs specifically adapted to the Swiss context, it could be useful to seek 
an exchange with consumers, their relatives or family members in the future. This was not included in 
the framework of our mandate. Participatory involvement of directly affected population groups in the 
elaboration of future research priorities might be a promising way and could contribute to an evidence-




13 The Canadian Government opted for a non-automated record suspension instead of a full expungement of minor cannabis-related 
offenses (see McAleese 2019). 
Research coordination and funding A Research Agenda for the Regulation of Non-Medical Cannabis Use in Switzerland 
Page 87 
7 Research coordination and funding 
In the previous sections, we identified a range of topics and questions for research that should be 
investigated in the context of the cannabis pilot trials as they unfold, and that are needed for an 
evidence-based choice of policy options for future cannabis regulation in Switzerland. In this chapter of 
the report, we discuss options of research coordination and funding and formulate some 
recommendations.  
 
7.1 Models of research funding and coordination 
In general, three different models of research funding and coordination can be distinguished (Braun 
1998), in the sense of ideal-typical funding schemes that differ in terms of their influence on what is 
investigated and by whom (see also Frey and Kübler 2011). 
1. Political funding schemes: these immediately serve the interests of a ministry and are obliged to 
respond to precise, pressing problems raised by government. In order to find practical and 
applicable solutions in a given policy field, these funding schemes are aimed at creating 
research communities involving established, but also upcoming and unconventional scientists 
from various disciplines.  
2. Science-based funding schemes: they serve the interest of all disciplines of science and aim to foster 
the most promising scientific agendas for knowledge advancement judged according to criteria 
proper to the various scientific disciplines. Science-based funding schemes tend to result in a 
strong disciplinary orientation, promote mainstream research, and bear the risk of disjointed 
and incoherent research efforts, where various scientists tackle a problem completely 
independently from each other. Investigation or discussion of policy-related questions or issues 
may occur, but are not a priority. 
3. Strategic funding schemes: they promote research in a particular problem area, and have the 
mission of promoting all promising research paths in the respective domain, as well as 
responding to problems raised by the scientific community, the public, or politicians. Strategic 
funding schemes promote both disciplinary research and the development of strategies to apply 
basic research results. They often foster a fruitful combination of both reputed scientists and 
more unconventional investigators. 
 
7.2 Political research funding: looking back on a past example in Swiss substance research 
The legal basis for the cannabis pilot trials precludes direct funding by the federal government. Hence, 
a political funding scheme is clearly ruled out on the national level.  
Nevertheless, it is instructive to look back on an example of a political funding scheme for research and 
coordination in the field of substance research in Switzerland, namely the projects for the medical 
prescription of heroin (Heroingestützte Behandlung – HeGeBe) in the 1990ies (Uchtenhagen et al. 2000). It 
is still widely regarded as an instance of a successful and internationally renowned project for evidence-
based policy-making in the field of illegal drugs and addiction (Uchtenhagen 2010: 29ff.). In response 
to worsening conditions of a rising number of heroin addicts in Swiss cities, medical prescription of 
heroin to heavily addicted users was introduced by the Swiss federal government in the form of 
scientific trials in 1992 (Bundesrat 1992). While cantons, municipalities and private organizations were 
responsible for the implementation of the trials, the federal government provided the financial resources 
for their scientific evaluation. All trials had to be approved and supervised by the Federal Office of 
Public Health FOPH. The FOPH also awarded the mandates for the scientific evaluation and supervised 
the research activity. Subsequently, the “Swiss Program for a Medical Prescription of Narcotics 
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(PROVE)” started in 1994, and continued until 1999 (HeGeBe 2002). The treatment proved to be 
successful in improving patients’ mental and physical health as well as their living situation, and in 
significantly reducing drug-related crime. Given its success, heroin-based treatment became a routine 
medical procedure covered by mandatory health insurance (Uchtenhagen 2010: 34). The trials and the 
numerous publications based on the research related to them drew worldwide attention with 
researchers and policy makers alike.  
PROVE was a rather centralized program in terms of research organization. As stipulated in the federal 
government’s 1992 decision, a research group under the leadership of Professor Ambros Uchtenhagen 
from the Zurich-based Swiss Research Institute for Addiction (nowadays Swiss Research Institute for 
Public Health and Addiction) was mandated to define and implement the overall integrated research 
plan. PROVE was designed as a cohort study in 17 treatment facilities located across several Swiss cities 
and included 1’146 patients (Gschwend 2004: 9ff.). Data was gathered using a range of standardized 
research instruments according to the research protocol. All data was collected in standardized format 
and centrally stored. Educational events prior to the start of the trials ensured that the treatment facility 
staff were familiar with the research goals and the use of the research instruments. 
Coordination of the PROVE trials worked rather smoothly. Initial reluctance of doctors and clinics to 
participate in research and data collection could be overcome as all trials needed the FOPH’s approval, 
which was only given for trials that included participation in data collection using a common 
standardized questionnaire for patients. This patient questionnaire was the main common data-
gathering tool throughout all trials. It was based on the international state of the art on the surveying of 
heroin users, recommended by the World Health Organization WHO. The same questionnaire had been 
previously used in methadone-based substitution programs and in abstinence therapy, and was 
therefore well established in the field. Regular conferences and meetings of the involved researchers to 
discuss new developments and questions further facilitated coordination. The high number of 
publications resulting from PROVE is an indicator for its high integration both in terms of its substantial 
agenda and the resulting researcher network.  
Three main factors account for the success of research coordination in the case of PROVE. First, 
comprehensive funding by the FOPH. Second, a pre-existing integrated research community whose 
members already shared a consensus on the central questions, processes and tools. Third, the leading 
investigators were very well known and undisputed experts in the field of addiction research.  
 
7.3 The scenario emerging: decentralized research funding and self-coordination 
Given the legal basis of the cannabis pilot trials and the conditions stipulated there for funding of 
scientific research and coordination, the scenario that emerges is one characterized by a high degree of 
decentralization. The role of the federal government is limited to passing legislation on experimental 
research on cannabis and authorizing research institutions to fund and undertake such research with 
other partner organizations or institutions. The federal government evaluates and approves research 
projects and bundles research results, but does not play an active role in their production. Individual 
researchers therefore carry the responsibility to find funding for their projects and to coordinate with 
other researchers. Within the boundaries of the trial legislation, they are free in their choice of research 
questions, research scope, method, and operationalization, including data-gathering tools. In contrast 
to the PROVE example discussed above, where funding and coordination of research was centralized 
and strongly steered by the FOPH, the emerging scenario for the cannabis pilot trials is one where 
funding and coordination of research is organized by researchers involved in the individual projects 
themselves – in other words: a science-based funding scheme. 
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A science-based funding scheme is, in principle, open to any researcher interested in getting involved in 
the cannabis pilot projects, under the condition that they are able to organize the funding for this 
endeavor. In Switzerland, there are several potential donors for science-based funding.  
The Swiss National Science Foundation (SNSF) is the most important independent research funding 
agency in Switzerland. The SNSF features many different funding instruments, which are open to 
researchers seeking to investigate a research topic of their choice – and which are, hence, potentially 
suitable for funding research related to cannabis regulation in general, or cannabis pilot trials in 
particular. Indeed, the SNSF, in 2017, approved the SCRIPT-project by the University of Bern, aiming to 
investigate the implications of dispensing cannabis for non-medical purposes to pharmacies (the project 
was, however, not approved by the FOPH at that time). Besides the possibility to submit proposals for 
individual research projects in all disciplines, further thematically open funding instruments include 
programs such as the National Centres of Competence in Research (aimed at established researchers 
who wish to pursue a long term research program on a theme of strategic importance), Sinergia 
(promoting interdisciplinary collaboration of two to four research groups that propose breakthrough 
research), several funding schemes intended to foster international collaboration of research groups, as 
well as career funding schemes focused on projects proposed by individual researchers. They are all 
characterized by a science-based rationale: topics are defined by individual researchers, aims are mainly 
scientific in nature, and requests for funding are systematically submitted to international peer-review. 
High competition in these funding schemes generally ensures high scientific quality of the research 
funded. However, due to low acceptance rates, researchers are cautious in their decisions to invest time 
and energy into submitting proposals to these funding schemes. 
Besides the SNSF, a large number of other independent foundations play a role in funding scientific 
research in Switzerland. Funding schemes by independent foundations are generally open to proposals 
from individual researchers or research institutions. While individual foundations usually focus on 
specific themes or research fields, together, they provide a wide range of topics on which research can 
be funded. However, it is as yet unclear to what extent such foundation-based funding schemes would 
be suitable to research related to cannabis regulation or, more specifically, the cannabis pilot trials. 
In the field of substance use and addiction, important science-based funding instruments are related to 
the Tobacco Control Fund (Tabakpräventionsfonds), as well as the Alcohol Prevention Fund 
(Alkoholpräventionsfonds), to which researchers can submit requests for funding of projects that 
investigate the prevention of use, or at risk use. While it is unclear whether research focusing on 
questions related to cannabis regulation or the cannabis pilot trials could be submitted to these funds, 
they are of interest regarding their organizational and financial setup. Indeed, both funds are alimented 
through federal sales taxes: the Tobacco Control Fund is alimented mainly by a tax on cigarettes (0.026 
CHF per cigarette packet sold), the Alcohol Prevention Fund is alimented by the revenue of the federal 
alcohol tax. As stipulated by the Federal Act on Tobacco Taxation (Tabaksteuergesetz) and the Swiss 
Alcohol Act (Alkoholgesetz), these taxes are collected by the federal government, who is also responsible 
for the redistribution of the funds and, hence, for the approval of research proposals submitted for 
funding. For this task it involves independent and permanent commissions of experts who issue 
recommendations. It is important to note that, while producers and retailers of tobacco and alcohol 
products are involved in collecting the tax perceived by the federal government, the legal and 
organizational setup of both the Tobacco Control Fund and the Alcohol Prevention Fund ban producers 
and retailers from involvement in the definition of research agendas or the approval of research projects. 
These precautions have been taken to prevent conflicts of interests between production and retail on 
the one hand, and research funding and researchers on the other hand. Indeed, in the field of substance 
use and addiction, such conflicts of interests are a particularly sensitive issue. While this issue is well-
known in the field of legal drugs, it has only recently emerged with respect to cannabis. The 
decriminalization of production and sale of cannabis, even under relatively strict conditions, has turned 
cannabis producers and retailers into stakeholders who can now legally claim and pursue their interests. 
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It is, however, understood that cooperation with and/or funding by industry partners creates a high 
potential for conflicts of interest and carries a significant reputational risks for scientists – as is well-
known from the fields of tobacco and alcohol. A clear assertion of independence is paramount, all the 
more since public and media scrutiny for the cannabis trial and research can be expected to be intense. 
Conflicts of interests therefore bear serious risks of credibility of research results in this field. Hence, it 
is important to design the organizational set-up of funding research related to cannabis in a way that 
precludes conflicts of interests (see also box).  
 
Box: Avoiding conflict of interests in cannabis-related research funding 
The following principles may serve as guidance for avoiding conflicts of interest:  
- Full transparency on research funding must be given at all times. 
- Submission of proposals and funding decisions on cannabis-related research must be fully 
independent from cannabis producers or retailers, or their representatives. 
- Direct funding of cannabis-related research by producers or retailers must be avoided. 
- Indirect funding (e.g. through levies on cannabis products) should be collected nationwide, 
ideally as a governmental tax.  
- Data ownership of cannabis-related research must lie with researchers. 
- Researchers involved in cannabis-related research must be free to publish their results. 
- Cannabis-related research must have received ethical clearance, and researchers must comply 
with relevant research ethics guidelines. 
 
 
Research in science-based funding schemes is researcher-driven, and so is research coordination. Efforts 
of coordination and integration of research, as well as exchange of data and research results therefore 
typically follows researchers’ needs, as well as rules and practice established in their field or discipline. 
The principles of so-called Open Science emphasize the transparency of the research process, public 
availability of data, as well as dissemination of results. The open science movement has been gaining 
momentum in Switzerland in recent years, especially in the science, technology, engineering and 
mathematics disciplines. The emerging scenario of a science-based funding of the cannabis pilot trials 
will also entail substantial and continued efforts of researcher self-coordination, notably with respect to 
the research instruments used to collect data on trial participants and their behavior. This can be 
expected to ensure standardization of data collection across the trials, which is important to the 
comparability of results and findings.  
In sum, the emerging scenario suggests that, in scientific terms, a favorable outcome is likely. This 
mainly depends on an integrated, generally renowned research community jointly using standardized 
and validated research instruments, and avoiding conflict of interest with the cannabis industry. 
7.4 Looking ahead: decentralized funding and strong coordination 
Let us now sketch a scenario characterized by decentralized funding and strong coordination. This 
scenario tries to minimize the challenges and risks of the previous one. In this scenario, research teams 
develop and conduct individual projects in a variety of locations, while also coordinating intensely. 
Such coordination can vary in form and degree, and range from a joint research platform or a project 
alliance to a unified multi-site or multi-centered study. 
We see realistic potential for stronger coordination in mainly three areas. First, a basic condition for 
measurement comparability is the determination of a standard cannabis unit size. Cannabis products 
used in the trials should be produced and their potency clearly labeled using this common measure, in 
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addition to the declaration mandated by the government ordinance (BetmPV Art. 11) (see also Hindocha 
et al. 2018; Prince et al. 2020). Second, a common core questionnaire for study participants to be used 
in all trials would not only make sense to allow comparability of results across trials (see also Geissler 
et al. 2020), but also to coordinate research agendas across the different trials. While some trials might 
not primarily focus on individual consumers, they are still founded on administering cannabis to 
individuals. The more participants are included and evaluated, the more data is generated, and the 
better the reliability and validity of research results will be. Any chance to survey study participants 
should therefore be used. Third, a common platform for data pooling and sharing, relying on a high 
quality, user friendly and safe database would facilitate exchange and cooperation between different 
research teams and enhance the global significance of the results. Such a database will make raw data 
and unpublished study results available to all research teams involved in cannabis trials, while at the 
same time ensuring the protection of participants’ data. Such data should encompass both questionnaire 
answers and measurement results obtained in the individual projects. 
Development and use of all three methodological and coordination tools rely on a well-connected 
research community. Regular meetings of the principal investigators and their core teams facilitate such 
connections. We do not see potential for a fully-fledged multi-site or multi-center study at the current 
stage, as some planned pilot trials are already advanced in their development and pursue a variety of 
research questions. This variety is indeed valuable to enable broad insights. However, such a multi-site 
or multi-center study might be developed at a later stage based on the projects currently under 
preparation, and additional future studies. A multi-site study offers several advantages over single-site 
studies, including the use of synergies, greater generalizability of results also due to sufficient statistical 
power, or the possibility of quasi-experimental comparisons. While these three elements of coordination 
might emerge as a result of researcher-driven self-coordination, we think that both setting up and 
strength of coordination would benefit substantially from support by the FOPH. Indeed, the FOPH 
could provide funding for the development and use of these coordination tools as well as for regular 
meetings, workshops and conferences to facilitate communication and strengthen exchange across 
research groups. It is to be noted that support by the FOPH for research coordination does not 
jeopardize and is therefore compatible with the science-based funding strategy currently pursued by 
research groups involved in the cannabis pilot trials.  
Given the FOPH’s limited resources and legal discretion for funding and coordinating research in the 
field of cannabis, the overall integration of the research agenda would strongly benefit from additional 
means and resources, as would the likeliness that the topics defined in the agenda be comprehensively 
covered. This would require, however, turning towards the third type of funding schemes, namely a 
strategic funding scheme, explicitly geared towards promoting research in the field of cannabis. The 
obvious instrument for such a strategic funding-scheme exists in the form of the SNSF’s National 
Research Programs (NRPs). These are programs that “embrace research projects that contribute to 
solving the key problems of today”. 14  Federal offices, research organizations, research groups or 
individuals can propose topics to the State Secretariat for Education, Research and Innovation (SERI). 
After final selection of topics by the Federal Council, these are then referred to the SNSF and 
investigated with an NRP. NRPs are a strategic funding scheme precisely in that they explicitly promote 
research in a specific problem area the government considers as politically relevant. At the same time, 
disciplinary openness, systematic peer review and high competition ensure that research implemented 
within NRPs is usually of high quality and contributes to the advancement of knowledge in the field. 
An NRP would obviously be an appropriate funding scheme to further high quality and integrated 
scientific research in the field. If expedient, the focus of such a NRP might be expanded to issues 
surrounding the use of other substances and addiction more generally.  
 
 
14 See www.snf.ch. 
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8 Conclusion 
The guiding question in this report was which regulatory conditions can effectively minimize the social 
and health costs of cannabis consumption, as the public health perspective is at the forefront of debates 
on cannabis regulation in Switzerland. The three most important research fields were derived based on 
this overarching purpose, namely the minimization of health and social harms of use, the improvement 
of public safety and order and the establishment of governance over a safe and responsible supply chain. 
Reflections fed into the development of a comprehensive logic model of cannabis regulation validated 
by the FOPH and an advisory group. In this model, the broad range of possible regulatory options is 
pointed out and related to the key desired impacts. 
 
Prioritization of the research questions, derived from international discourse, was based on objective 
criteria such as the current political debate in Switzerland and the interests, values and concerns 
represented therein by different stakeholders as well as evidence from research abroad. Nevertheless, 
priority order still lies in the eye of the beholder at least to some extent. The four priority fields 
correspond to the impact dimensions from the logic model. In light of the ongoing planning of different 
pilot trials with cannabis, it is important to learn from research evidence and experience about the 
legalization of cannabis for non-medical use and its health, social, economic and public safety impacts. 
Taking the time and making a proactive investments is necessary for a strong and comprehensive 
regulatory framework. 
 
The first of the priority areas identified is the promotion of individual and public health. The national 
addiction strategy with its four-pillar model enjoys large support along the entire political spectrum. 
Derived from the overarching goals of the National Strategy on Addiction and the corresponding 
legislative foundations, and in conjunction with findings from international research, various research 
priorities in the field of public health have been derived in four different areas. These areas are the 
prevention of addictive disorders including the question of how low-risk consumption can be facilitated, 
providing addicted individuals with the necessary help and treatment, mitigating social harms and 
damage to health, and reducing the negative impacts on society. An analysis of how the various 
regulation options affect not only the individual person and his or her behavior, but also the overarching 
social, economic, and cultural framework seems to be crucial in order to gain additional knowledge 
about how to create a favorable legislation. 
 
The second priority research area is the promotion of public order and the reduction of criminality. 
Although this is not the main driver for possible legislative changes in Switzerland, this goal is 
repeatedly referred to in the political debate. Legalization is expected to increase security and reduce 
the illegal market. As the international workshop showed, there is only little reliable evidence to draw 
on here, as well. Long-term and large-scale studies on the functioning of illegal markets or the behavior 
of criminal groups or organizations would be necessary. Additional insights on criminal activities 
including effects on the illegal market, public order and policing, police organization and law 
enforcement, including the cooperation of different stakeholders also in the implementation phase, are 
of particular importance for Switzerland. 
 
The third priority area is the protection of minors. At the moment, the findings of international research 
are still rather modest and existing data remains unclear in this area. However, cannabis use among 
Swiss adolescents is comparatively high and this is also a frequently recurring topic in the political 
debate. Not only would a blueprint for an ideal education and prevention campaign need to be 
developed, but also the possibilities would have to be explored as to which age limits for acquisition 
and consumption prevent young people from being pushed into the uncontrolled illegal market. It also 
seems important to ask to what extent the legalization of cannabis contributes to a trivialization of its 
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use among young people and whether there is a shift away from alcohol use (substitution) or a joint use 
of both substances, which would very likely be associated with additional negative effects on public 
health. The existing pillars for an effective protection of minors with regard to drug use, namely the 
legal regulation to protect minors (“Gesetzlicher Jugendschutz”), promotion of youth and prevention 
(“Jugendförderung”) and youth support (“Jugendhilfe”) must be adequately taken into account. 
 
The fourth priority area is defined as the increase of prosperity, social justice and equality. Legalizing 
access to cannabis should not only take profits away from criminals, but also offers an opportunity for 
a new industry. Since the boom of cannabis with low THC and high CBD content in Switzerland, if not 
already before, profit-oriented players have become influential in the cannabis market. A strong 
position of profit-oriented players in the cannabis market is hardly compatible with public health-
oriented regulation. Therefore, there is a compelling need for research that addresses the question of 
how an effective economic governance over the supply chain can be established and what the 
consequences of regulatory decisions regarding production, distribution and consumption actually are. 
The pivotal question seems to be how regulatory oversight of the whole or parts of the supply chain can 
be established in an efficient, accountable and transparent way. In addition, international debates on 
cannabis legalization point out that it is important not to lose sight of the consequences of various 
regulations in terms of social justice and equity. 
 
Various relevant insights can be gained through future pilot trials. The legal framework for pilot trials 
is set out in the Ordinance on Pilot Trials under the Narcotics Act (BetmPV) of 2021. Several research 
teams are currently elaborating research designs for future pilot trials. There are considerations about 
research coordination in the context of developing a common questionnaire for the participants. 
Research teams intend to work with different types of dispensaries. Considerations of the research 
teams so far are predominantly related to health aspects and consumption behavior. However, 
socioeconomic aspects and possible effects on public safety in the vicinity of dispensaries are also being 
addressed in some cases. Additionally, there are aspirations to investigate pricing, effects of different 
products and co-consumption of other substances. Potential research priorities for future pilot trials are 
the following. One priority is to study the drug market in a given area or the impact on public order 
and safety. This could be done via a comparison of similar cities with the support of statistical methods 
allowing the estimation of causal effects. Questions about co-use of other substances should be 
considered in interviews or surveys of participants. The protection of minors could be investigated by 
explicitly selecting study participants who live together with minors and interview them as well. It can 
also be investigated to what extent different product formats and variations have an impact on the 
health of the study participants, which product features particularly appeal to them, which regulatory 
measures can promote lower risk consumption and what the effects of an online sales channel are, if 
actually legally permitted. 
 
The planned pilot trials and the mandates already commissioned or supported by the FOPH cover a 
significant portion of the issues and thematic blocks visualized in our logic model. Additional research 
needs are identified in the following areas: processing/distribution of cannabis products, use of 
revenues and taxes, consequences for public order and safety, and protection of minors. Research is also 
needed on other specific issues such as the appropriate control structure and approaches to support 
consumers in pursuing a non-problematic consumption behavior. In addition, research across several 
areas on the status quo is necessary in order to be able to assess the effects of various regulations in the 
future. Research is furthermore needed in the area of policy implementation, as there is often a relatively 
large discrepancy between formal policies and their implementation. Comparative research is also 
needed on the advantages and disadvantages of the various regulatory options in the middle ground 
between decriminalization and legalization.  
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For the cannabis pilot trials, the scenario of decentralized research funding and self-coordination is 
emerging as a realistic viable path. The federal government evaluates and approves research projects 
and collects the results, but plays no active role in production or funding. There are several possible 
donors in Switzerland for the financing of such a science-based funding scheme. The SNSF is certainly 
the most important independent agency for research funding. Besides the possibility to submit 
individual applications for single projects, there are National Centres of Competence in Research for 
established researchers with long-term research programs, Sinergia for interdisciplinary research of 
several research teams and various instruments to enable international research collaborations. Several 
independent foundations also provide financial support for scientific projects. In addition, funds are 
known from the tobacco and alcohol sector that also support research. The potential of conflicts of 
interest is a known problem in this area. Independence from possible industrial interests and preventing 
conflicts of interest is thus central for future cannabis research funding and can be strengthened by 
following some central principles. It is also conceivable that researcher-driven research coordination be 
inspired by Open Science principles. 
 
We currently see a realistic chance for stronger coordination mainly in three areas: the determination of 
a standard cannabis unit size, the development of a common core questionnaire for the participants, 
and the creation of a common platform for data pooling and sharing, in which results and raw data are 
made accessible. Coordination is strongly dependent on a well-connected research community and 
currently we do not see a multi-site or multi-center study as a realistic option. Stronger support from 
the FOPH including funding for research coordination could be helpful. The obvious instrument for a 
more strategically oriented funding scheme would be the SNSF’s National Research Programs (NRPs). 
NRPs are a strategic funding scheme precisely in that they explicitly promote research in a specific 
problem area the government considers politically relevant. While a focus on cannabis might seem 
narrow, an NRP on the topic of substance use and addiction more generally could provide for an 
appropriate coverage of the relevant questions of the cannabis-research agenda. 
 
Finally, it is important to point out some limitations of this report. Obtaining an adequate overview of 
the current state of research in cannabis regulation in a relatively short period of time was challenging. 
By limiting the review to current English-language literature reviews and meta-analyses complemented 
with selected additional publications, a pragmatic strategy was pursued. By doing so, we might have 
missed further potentially relevant older or other-language literature. Furthermore, a pragmatic 
approach had to be taken in the composition of the advisory board, i.e. not all relevant perspectives 
were represented. The absence of toxicologists and health economists who could have contributed their 
expertise should be noted, for instance. Similarly, no provision was made for the participation of 
cannabis users and their relatives in the development of the research agenda. They, being directly 
affected, could in particular provide relevant inputs on the problems of the current legislation.15 These 
limitations need to be adequately addressed in the further process.  
 
 
15 A team of researchers at the University of St. Gallen is currently working on a research agenda for cannabis research in Switzerland 
that takes greater account of consumers and their embeddedness in a social environment.  
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9 Recommendations on coordination and funding of research 
Based on the considerations discussed in the previous chapters regarding the existing research gaps in 
cannabis research, the planned pilot trials in Swiss cities, experiences with the regulation of other 
substances, and the current political debate on cannabis in Switzerland, recommendations concerning 
methodology, coordination and funding of research are derived in the following. In the first section, our 
recommendations focus on the development of a research methodology across projects, the second 
section concerns the coordination of research projects (pilot studies) and the third section then relates 
to the funding of future cannabis research. 
 
9.1 Development of a cross-project research methodology 
1. In international research, a standardized core questionnaire is sometimes used, to which modules can 
optionally be added to address the specific conditions in the relevant country or region. By analogy, we 
recommend the development of a core questionnaire for Switzerland with supplementary modules that 
take greater account of the situation of the drug market in a particular area, for instance. 
 
2. While some pilot trials appear to be using similar questions and items, a common set of questions 
with core items does not exist so far. We recommend that the FOPH contributes to a cross-project 
research methodology by supporting researchers’ endeavors towards a common questionnaire or some 
agreed-upon core questions. 
 
3. We recommend the determination of a standard cannabis unit size, a common core questionnaire for 
study participants and a common platform for data pooling and sharing as steps towards a cross-project 
research methodology.  
 
9.2 Coordination of research projects (pilot trials) 
4. Public and media scrutiny for the cannabis pilot trials and research can be expected to be intense. We 
therefore recommend that researchers coordinate in developing a sound public and political 
communication strategy. 
 
5. Besides the commonly-discussed alternatives, prohibition and the standard commercial model, 
theoretically there are many middle-ground options of cannabis regulation, which are rarely 
implemented in practice. We therefore recommend that more research be conducted in Switzerland on 
these middle ground options, which are still little researched internationally. These seem to have the 
potential to significantly reduce health and social costs. 
 
6. Within the framework of the pilot trials, the FOPH performs various functions and is first and 
foremost an authorization and control body. Conflicts of interest are inevitable, and we therefore 
recommend a clarification of the FOPH's role in order to better support pilot trials in the future. 
 
9.3 Research funding 
7. A science-based funding scheme or a strategic funding scheme via SNSF grants might be viable 
options for research funding, while the legal basis precludes direct funding by the federal government. 
In order to increase the chances of funding applications, we recommend greater cooperation with 
international experts to identify relevant research gaps and ensure international relevance. 
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8. The Alcohol and Tobacco Prevention Funds, with their organizational and financial setups, represent 
interesting funding vehicles to which stakeholders interested in evidence-based research for the 
purpose of policy making should look. 
 
9. To ensure the independence of research and its credibility and to prevent undue industry influence 
on research activities, researchers should adhere to some guiding principles for avoiding conflicts of 
interest in cannabis-related research funding (e.g. no industry influence on funding decisions, freedom 
to publish research results). 
 
10. Independent foundations could play a critical role in funding pilot studies, provided the 
foundation's purpose is met. Coordination in this area (e.g. a central consulting office for the funding of 
cannabis research) could support the various research teams in seeking financial contributions from 
foundations and other actors. 
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Appendix 
Agenda of the advisory board meeting 
     Institut für Politikwissenschaft
      
Universität Zürich  
Institut für Politikwissenschaft  





Treffen Begleitgruppe «Forschungskonzept Cannabisregulierung»  
 
Datum 21.12.2020 von 15h30 bis 18h00  
 
Virtuell durchgeführtes Zoom-Meeting:  
https://uzh.zoom.us/j/8485613532?pwd=S3FWMnBWNjdBYXdwelJ1WFEyRmlXZz09  
Meeting-ID: 848 561 3532; Kenncode: 896160  
 
Hintergrund und Ziel  
Das Institut für Politikwissenschaft der Universität Zürich (IPZ) wurde vom Bundesamt für Gesundheit 
(BAG) mit der Erarbeitung eines Forschungskonzepts über die gesetzliche Regulierung von 
Cannabiskonsum zu nicht-medizinischen Zwecken beauftragt. Vor dem Hintergrund der sich 
intensivierenden politischen Debatte ist es wichtig, wissenschaftliche Entscheidungsgrundlagen für die 
Weiterentwicklung der Cannabisregulierung zu entwickeln. Ziel des Projekts ist die Erarbeitung einer 
übergeordneten Agenda zur Erforschung möglicher gesundheitlicher und sozialer Auswirkungen 
verschiedener Massnahmen zur Regulierung von Cannabis. Wichtig ist dabei auch, die in 
verschiedenen Schweizer Städten aktuell geplanten Pilotversuche zu integrieren und in Bezug zur 
übergeordneten Forschungsagenda zu setzen.  
 
In Absprache mit dem BAG wurde eine Begleitgruppe für dieses Projekt zusammengestellt. Ziel des 
virtuellen Treffens vom 21.12.2020 ist es, eine Übersicht zum aktuellen Stand der geplanten 
Pilotversuche zu erlangen, erste Überlegungen zur Struktur des Forschungskonzepts zu diskutieren, 




15:30 Begrüssung und kurze Vorstellungsrunde  
 
15:40 Geplante Pilotversuche: Zielgruppe, Fragestellung, Methode, Stand der aktuellen Planung: 
Basel: GW, Bern: RA, Lausanne: FZ, Zürich: CN, Genf: DZ, St. Gallen: FE (5 min. 
Präsentation, 3 Min. Q&A)  
 
16:30 kurze Pause 
 
16:40 Vorstellung Forschungskonzept: IPZ  
 
17:00 Feedback und Diskussion: alle -Priorisierung der Forschungsthemen und –fragen-Einordnung 
der Pilotversuche-Koordinationsbedarf 
 
17:50 Nächste Schritte: IPZ  
 
18:00 Schluss des virtuellen Treffens  
 
 
Sprachen für Präsentationen und Diskussionen: Deutsch, Französisch oder Englisch  
 
 
Mitglieder der Begleitgruppe  
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Prof. Dr. Daniele Zullino (HUG): DZ  
Frank Zobel (Addiction Suisse): FZ  
Prof. Dr. Gerhard Wiesbeck (UPK Basel): GW  
Dr. Carlos Nordt (PUK): CN  
Prof. Dr. Reto Auer (UniBe): RA  
Prof. Dr. Sandro Cattacin (UniGE): SC  
Dr. Florian Elliker (UniSG): FE  
Julia Joos (Stadt Bern): JJ  
Dr. Barbara Broers (UniGE): BB  
Dr. Christian Schneider (Kantonspolizei ZH): CS  
Prof. Irene Abderhalden (FHNW): IA  
Dr. Céline Mavrot (UniBE): CM  
Prof. Dr. Jean-François Etter (UniGE): JFE  
Prof. Dr. Michael Schaub (UniZH): MS  




Prof. Dr. Daniel Kübler (IPZ): DK (Daniel.Kuebler@ipz.uzh.ch)  
Dr. Roman Zwicky (IPZ): RZ  (Roman.Zwicky@zda.uzh.ch)  
Palmo Brunner (IPZ): PB  (Brunner@ipz.uzh.ch)  
Flavia Caroni (IPZ): FC   (Caroni@ipz.uzh.ch)   
 
Kontaktperson BAG:  
Adrian Gschwend (BA): AG 
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Agenda of the international workshop 
Cannabis research in times of legalization: what’s on the agenda? 
 
International workshop organized by  
 
Daniel Kübler, Department of Political Science, University of Zurich 
Rebecca Jesseman, Canadian Centre on Substance Use and Addiction 
 
Monday, 8th of February 2021 
15:00 hrs to 19:00 hrs (CET) 
9 am to 1 pm (EST) 
Online workshop held via Zoom 
 
Context and aim of the workshop 
After decades of political inaction and firm legal prohibition, in recent years cannabis policies have 
begun to change. Some countries have eased the enforcement of prohibition, others have opted for – 
de jure or de facto – decriminalization of cannabis use for non-medical purposes. And some 
governments, such as Uruguay (in 2013), Canada (in 2018), as well as many subnational territories in 
the United States (starting in 2012), have recently legalized and regulated the use of cannabis for 
recreational purposes. 
 
As the experiences with legalized Cannabis unfold, they draw worldwide attention from decision-
makers and policy advocates alike. However, regulatory choices for legal recreational cannabis use 
vary widely, and there are still many open questions about the impact of cannabis legalization, not 
only on individuals, but also on communities and the wider society. There is a need for scientific 
evidence about the consequences of different policy options.  
 
Against this background, this workshop brings together prominent international experts to discuss 
open questions and current issues related to the production of scientific evidence about the 
consequences of cannabis legalization. The aim of the workshop is to identify a research agenda that 
will produce the scientific evidence required to make informed policy choices on regulations for legal 
cannabis use. This initiative has been commissioned by the Swiss government in view of its planned 
trials with regulating non-medical cannabis use, and a particular focus will be on the potential 
contribution of these trials to advancing scientific knowledge in the field. 
 
Products and follow up 
The two co-conveners will produce a workshop report, to be published online after the workshop. 





1) Welcome and introduction (10’) 
 
2) Current policy changes and questions in different countries ( 40’) 
• USA (Beau Kilmer, Rand Drug Policy Research Center) 
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• Uruguay (Rosario Queireilo, Universidad catòlica del Uruguay) 
• Canada (Rebecca Jessemann, Canadian Centre on Substance Use and Addiction) 
• Netherlands (Margriet van Laar, Trimbos Instituut) 
• Switzerland (Adrian Gschwend, Swiss Federal Office of Public Health) 
 
3) Theme A: retail models (40’) 
 
4) Theme B: product supply chain – production, distribution and quality control (40’) 
 
5) Theme C: public health (40’) 
 
6) Theme D: public safety – including illegal market impact (40’) 
 
7) Conclusion and wrap up (10’) 
Note that breaks will be provided between themes. 
To facilitate meaningful discussion over zoom, each theme session will be structured as follows: 
• Short introduction to the theme (based on pre-meeting questionnaires) 
• Focus 1: which foundations for a public health-oriented regulation already exist? 
• Focus 2: which research questions still need to be clarified? 
• Focus 3: What initiatives and collaborations could respond to these questions? 
Please note that the meeting will be recorded to facilitate minute-taking. Recordings will not be published.  
Contact information: 
Rebecca Jesseman     Prof. Daniel Kübler  
Director of Policy     Department of Political Science  
Canadian Centre on Substance    University of Zurich  
Use and Addiction     Affolternstrasse 56  
500-75 Albert St.     8050 Zürich  
Ottawa, Ontario     Switzerland  
Canada K1P 5E7     Ph: +41 44 634 38 86  
Ph: +1 343-803-7754     Email: Daniel.Kuebler@ipz.uzh.ch 
Email: RJesseman@ccsa.ca  
Logistics support: Flavia Caroni  
   Department of Political Science  
   University of Zurich  
   Email: Caroni@ipz.uzh.ch 
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Participating international experts* 
NAME AFFILIATION ROLE COUNTRY 
Dr. Nadine Berndt Ministry of Health Head of National Focal Point Luxembourg 
Dana Bruce Health Canada, Controlled Drugs and Substances 
Branch 
Regulatory Development Canada 
Dr. Nina Cluny Canadian Institutes of Health Research, Institute 
of Neurosciences, Mental Health and Addiction 
Team Lead Canada 
Prof. Tom Decorte Ghent University Professor Belgium 
Dr. Julia Dilley University of Washington Senior Research Scientist USA 
Adrian Gschwend Federal Office of Public Health Deputy Head, Policies and Implementation  Switzerland 
Prof. David Hammond University of Waterloo Professor Canada 
Prof. Caitlin Hughes Flinders University & ISSDP Associate Professor (Flinders); Vice-President 
(ISSDP) 
Australia 
Brendan Hughes European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) 
Principal Scientist, Drug Legislation Portugal 
Dr. Beau Kilmer Rand Drug Policy Research Center Director USA 
Ivana Obradovic Observatoire français des drogues et des 
toxicomanies 
Deputy Director France 
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Prof. Rosalie Liccardo 
Pacula 
University of Southern California, Sol Price School 
of Public Policy 
Elizabeth Garrett Chair in Health Policy, 
Economics, and Law, and Professor 
USA 
Prof. Rosario Queirolo Universidad Católica del Uruguay Professor Uruguay 
Dr. Margriet van Laar Trimbos Instituut Head, Drug Monitoring and Policy / Reitox Focal 
Point 
Netherlands 
Frank Zobel Addiction Suisse / Sucht Schweiz Associate Director and Deputy Director of 
Research 
Switzerland 
 
